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GENERAL INTRODUCTION
The prevalence of childhood asthma and atopic disease have increased dramatically 
during the end of the last century, especially in Western countries.1 Presently, asthma is 
the most frequent chronic disorder in childhood, with a high burden in terms of morbid-
ity, health care costs, absenteeism from school, and reduced quality of life, despite 
the availability of effective and safe treatment.2 Two major challenges in the fi eld of 
childhood asthma, have still been insuffi ciently addressed. In this thesis we focused on 
both these issues.
The fi rst challenge is the search for new ways to prevent asthma development in 
children using interventions early in life. Understanding which factors are responsible 
for the rising prevalence in asthma and allergies is essential to fi nd targets for future 
prevention. The sudden increase in prevalence of childhood asthma and atopic disease 
during the end of the last century suggests, that environmental factors play an impor-
tant role in the development of allergic disease.3 Previous research has shown evidence 
that a crucial window for the effect of environmental factors may exist in prenatal and 
early postnatal life.4 Events occurring during fetal and early postnatal life may impair 
lung development in later life, and lead to development of respiratory disorders in-
cluding asthma.5 This is supported by the fi nding that lung function measured directly 
after birth is a strong indicator of lung function in adolescence.6 In part I of this thesis 
we investigated the association between several perinatal factors and the longitudinal 
development of asthma symptoms during childhood, to assess which perinatal factors 
may be promising targets for preventive interventions early in life.
A second challenge will be the clinical problem of early identifi cation of children who 
will develop asthma, and those that have only transient symptoms at a young age. It 
should be realized that even if successful prevention programs are developed, asthma 
symptoms such as wheeze and cough will remain highly prevalent in children, especially 
at preschool age. Data from the PIAMA study have shown that up to a quarter of all 
children in the Netherlands will experience wheezing symptoms in the fi rst year of life.7 
Consequently, clinicians are very often confronted with preschool children with asthma 
symptoms, and only a minority of those children will actually develop asthma.8 Early 
identifi cation of children with persistent symptoms remains one of the most diffi cult 
clinical problems.9 Therefore, in part II of this thesis, we evaluated which combination 
of perinatal factors, clinical symptoms and additional tests may be useful in clinical 
practice to predict which children with asthma symptoms at preschool age are most 
likely to develop chronic asthma.
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ASTHMA AND WHEEZING DISORDERS IN CHILDREN
Asthma
Asthma is a lung disease characterized by recurrent periods of wheezing, shortness of 
breath, and coughing.10 There is a strong association with chronic and mainly eosino-
philic infl ammation of the airways, and bronchial hyperresponsiveness. In response to 
specifi c stimuli (e.g. allergens) and nonspecifi c stimuli (e.g. infections, exercise) the 
infl amed airways can be triggered, leading to episodes with variable airfl ow obstruction 
and thereby the clinical symptoms of wheeze, shortness of breath and cough. The 
airfl ow obstruction is often reversible, either spontaneously or with specifi c treatment. 
There are three mechanisms that can cause variable airfl ow obstruction in asthmatics. 
First the airway smooth muscles contract in response to stimuli, leading to broncho-
constriction. Second, swelling of the mucosa lining the airway wall can lead to further 
airway narrowing. Third, an increase in mucus production can result in mucus plug 
formation and thereby airway obstruction. Apart from these mechanisms leading to 
a variable airfl ow limitation, irreversible changes in the airway anatomy may occur in 
some asthmatics, which is referred to as airway remodeling.11 Possibly, a chronic state 
of infl ammation is responsible for structural alterations of the airways, causing more 
chronic symptoms and irreversible loss of lung function.11 The clinical symptoms of 
asthma are well known: recurrent attacks of wheezing, shortness of breath/ dyspnea 
and coughing at night, in response to a number of triggers.12 However, the presentation 
may be heterogeneous and change rapidly over time, especially in children. Therefore 
a clear and generally accepted defi nition of asthma does not exist.13 Objective tests 
to support an asthma diagnosis include spirometry, to assess airway obstruction and 
reversibility; bronchoprovocation, to assess airway responsiveness; and sputum induc-
tion to measure airway infl ammation. These tests are diffi cult to perform in children 
under the age of 6 years, since active cooperation is necessary.14 In epidemiologic 
studies ‘asthma’ is often defi ned as a parental report of doctors’ diagnosed asthma, 
but also parental reports of asthma symptoms, especially wheezing, or the use of 
specifi c asthma medication are sometimes used as a proxy for asthma.15 The use of 
parental reports of wheeze will introduce some uncertainty, as it is less accurate than 
physician-confi rmed wheeze.16
Wheezing phenotypes in children
Wheezing is the most important symptom of asthma and highly prevalent in children, es-
pecially in the fi rst years of life. However, only a minority of these wheezing children will 
develop persistent asthma. There is also a proportion of children who do not experience 
wheeze in the fi rst years of life, but develops symptoms at later ages.8 The concept that 
‘childhood asthma’ is not a single disease entity, but comprises several heterogeneous 
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wheezing subtypes may be a possible explanation for contradictory fi ndings in previous 
studies on asthma risk factors.17 Therefore much effort has been put in the identifi cation 
of different temporal wheezing phenotypes. Martinez et al introduced 4 longitudinal 
patterns of wheezing based on reported symptoms at the age of 3 and 6 years: ‘never’, 
‘early transient’, ‘persistent’ and ‘late onset’ wheeze.18 This classifi cation has served 
as a useful model in the past decade, but may give an incomplete description of all 
wheezing illnesses during childhood. More recently Henderson et al used longitudinal 
latent class analysis to identify different wheezing phenotypes in the Avon Longitudinal 
Study of Parents And Children (ALSPAC), where wheeze was reported repeatedly from 
birth until 8 years of age.19 Many different longitudinal patterns of wheeze are possible, 
but some patterns will occur more often than others. Latent class models can be used 
to identify children with similar patterns of wheeze over time. These latent classes 
represent different longitudinal wheezing phenotypes. The analysis was repeated in 
the PIAMA study, where 5 wheezing phenotypes with similar characteristics as in the 
ALSPAC study were found, supporting their validity.20 Figure 1.1 depicts the probability 
of wheeze at every age in these 5 wheezing phenotypes identifi ed in the PIAMA study. 
The prevalence of the phenotypes are shown next to the phenotypes in the legend.
Age (years)
1 2 3 4 5 6 7 8
P
ro
ba
bi
lit
y 
of
 w
he
ez
e
0
0.1
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0.7
0.8
0.9
1.0
Never/Infrequent wheeze (75.0%)
Transient early wheeze (16.7%)
Intermediate onset wheeze (3.1%)
Persistent wheeze (3.5%)
Late onset wheeze (1.7%)
Figure 1.1. Probability of wheeze at each time point from birth to age 8 years for each wheezing 
phenotype in PIAMA (N = 2,810)
Adapted from Savenije & Granell et al.20
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PREVENTION OF CHILDHOOD ASTHMA
Understanding the factors associated with mechanisms of asthma development is 
essential in order to fi nd targets for primary prevention of specifi c wheezing illnesses 
during childhood. In spite of many cross-sectional studies, there are very few preven-
tive measures of which a benefi cial effect on asthma and allergy has been documented. 
The maximal possible benefi t on public health of an intervention on a specifi c risk factor 
will depend on several aspects. First it is important to realize that only modifi able risk 
factors can be used in prevention programs. Second, the strength of the association 
between a risk factor and later asthma will to a large extent determine the possible 
benefi t of an intervention. Third, also the prevalence of a risk factor in the population 
and the ability of an intervention to eliminate this factor from the population should be 
taken into account.
Perinatal factors as candidates for prevention
It has been suggested that some important risk factors for asthma development already 
operate during pregnancy and early in life.4 The most consistent early risk factors for 
childhood asthma are probably a family history of asthma/allergies and male gender, 
but these factors are not modifi able and hence no candidates for interventions.21 Previ-
ous analyses of data from the PIAMA study have identifi ed modifi able risk factors for 
the development of respiratory symptoms in prenatal and early life. These risk factors 
included maternal nutrition during pregnancy,22 breastfeeding,23 air polution,24 and ma-
ternal overweight.25 A modifi able factor that has received much attention for its possible 
protective effect on later asthma development is the exposure to infections early in 
life. A protective effect of early infections has been suggested based on the ‘hygiene 
hypothesis’, which was fi rst introduced by Strachan.26 He found that the risk to develop 
hay fever was reduced in children with more older siblings, and proposed the associa-
tion may be explained by the increased exposure to microorganisms in children with 
older siblings. Another factor that increases the risk of early infections and would be 
more easily modifi ed is daycare attendance. However, conclusive evidence that daycare 
is indeed associated with a reduction in asthma/allergy on the long term is lacking.27-31 
In line with the ‘hygiene hypothesis’ some studies have found an increased risk of 
asthma development in children born by a caesarean section, possibly due the delayed 
microbial colonization, and this was supported by PIAMA data.32
Another hypothesis on the association between early life events and the development 
of diseases later in life was postulated by Barker et al, who found that children with a 
low birth weight were more likely to suffer from cardiovascular disease in adulthood.33 
They proposed that fetal malnutrition could lead to disproportionate fetal growth, result-
ing in chronic diseases in later life, especially cardiovascular diseases.34 The association 
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between reduced fetal growth and childhood asthma remains much less clear.35-37 
Nevertheless a range of prenatal risk factors have been suggested to increase the risk 
of later asthma and allergies, such as reduced prenatal growth,35,37 premature birth,38 
increased head circumference39 and prenatal tobacco smoke exposure.40
DIAGNOSIS AND PREDICTION OF CHILDHOOD ASTHMA
Given the heterogeneous character of the disease it is diffi cult to diagnose asthma, 
especially in young children.41 There are no standard lung function tests available for 
preschool children, and a diagnosis is solely based on clinical symptoms. Despite 
these diffi culties an early asthma diagnosis is important to enable adequate treatment 
with bronchodilators and anti-infl ammatory drugs like inhaled corticosteroids (ICS) or 
leukotriene receptor antagonists. On the other hand, as the majority of symptomatic 
preschool children will outgrow their symptoms during childhood, chronic use of ICS in 
all wheezing young children may lead to considerable overtreatment. Previous studies 
have shown that undertreatment as well as overtreatment of asthma may indeed be 
common in children,42-44 but data in preschool children are scarce.45
Clinical prediction tools may help clinicians to better assess individual prognosis 
in preschool children and thereby contribute to the better management of childhood 
asthma. Most research on early life risk factors has focused on the etiological relation 
with asthma, rather than the predictive value for symptom persistence. Several birth 
cohorts investigated which clinical questions can be used to distinguish preschool 
children with persistent symptoms from those with transient symptoms.46-48 Prediction 
rules developed in birth cohorts from the United States of America, the United Kingdom 
and Germany included clinical questions about wheezing frequency, eczema, allergic 
rhinitis, parental asthma, recurrent infections and gender.46-48 Importantly, these rules 
were developed using information up to a fi xed age (often 3 years) irrespective of the 
age of symptom onset. Therefore it may not be appropriate to implement the rules 
when they are most useful in clinical practice: at the age a child presents with symp-
toms for the fi rst time. Secondly, all studies included blood tests in their algorithm.46-50 
Consequently, the derived prediction rules cannot be used to instantly calculate an 
individual risk profi le in children presenting with symptoms, as the lab results should 
be awaited fi rst. Currently no generally accepted asthma prediction tools are available 
for use in clinical practice.
Objective tests to diagnose asthma in preschool children
After the initial risk assessment on the basis of clinical symptoms it would be worth-
while to have additional objective tests to further improve the diagnostic and prognostic 
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accuracy. Standard tests to support an asthma diagnosis include spirometry and bron-
choprovocation, but these tests cannot be used under the age of 5-6 years.14 There are 
some objective tests available at preschool age that may help to assess the prognosis 
in symptomatic children. 
Specifi c immunoglobulin E (IgE) to inhalant allergens is a well known marker for atopy 
and is strongly associated with both doctors’ diagnosed asthma and asthma symptoms. 
Prospective studies have consistently shown that children with specifi c IgE are more 
likely to develop persistent asthma later in life.48-51 Specifi c IgE should therefore be 
tested in children suspected of asthma, and the test should be taken into account when 
assessing the additional value of other objective tests. Two objective tests that can 
be easily performed in young children and may further improve the prediction of later 
symptoms are the measurement of eosinophilic airway infl ammation using fractional 
exhaled nitric oxide (FeNO), and the measurement of airway resistance by the inter-
rupter technique (Rint).
Measurement of airway infl ammation using the fraction of exhaled nitric oxide
Chronic airway infl ammation is a key feature of adult asthma, and reduction of the 
infl ammation with anti-infl ammatory agents is the cornerstone of asthma treatment.10 
Since the association between clinical symptoms and airway infl ammation is weak at 
best, there may be clinical benefi t in accurate monitoring of the infl ammation.52 The gold 
standard to assess airway infl ammation is broncho-alveolar lavage or airway mucosal 
biopsy performed during bronchoscopy, in children usually under general anesthesia. 
Clearly these procedures are not suitable for routine clinical use in young children. In-
directly, airway infl ammation can be measured counting infl ammatory cells in induced 
sputum,53 but this is diffi cult to perform in preschool children and the analyses are 
time consuming. Measurement of the fraction of nitric oxide in exhaled air (FeNO) is 
possible at all ages, and has been shown to strongly correlate with eosinophilic airway 
infl ammation.54,55 This implied that FeNO might be useful as a non-invasive test for 
airway infl ammation, especially in young children.
In the airways, nitric oxide is produced by the oxidation of the amino acid L-arginine by 
NO-synthases (NOS).56 At least three isoforms of NOS have been described; constitu-
tive NOS (cNOS), neuronal NOS (nNOS) and inducible NOS (iNOS).57 The inducible form 
iNOS has been mainly localized in the airways, alveolar epithelium, alveolar macro-
phages and the vascular endothelium.56,58 Expression of iNOS can be up-regulated in 
infl ammatory states by several cytokines (i.e. IFN, TNF, interleukin 1), which can lead to 
a manifold rise in NO levels.59 (Figure 1.2)
NO is an important mediator with diverse functions, such as the regulation of airway 
and blood vessel diameter, through smooth muscle contraction or dilatation.60
Daan BW 7.indd   14 28-10-10   13:05
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Nitric oxide levels in exhaled air can be measured either ‘online’ or ‘offl ine’. In the 
online method subjects exhale directly into the NO analyzer.61 The single breath online 
measurement at a constant fl ow of 50 ml/sec is now regarded the ‘gold standard’ 
FeNO measurement.62 In order to compare FeNO values it is important to use standard-
ized exhalation fl ows, since FeNO levels are highly fl ow-dependent.63 Unfortunately this 
standard method is diffi cult to perform in young children.62 In the offl ine measurement 
exhaled air is fi rst collected in a NO impermeable, inert balloon, the collected gas 
can be analyzed afterwards.64 Since the FeNO concentration strongly depends on the 
exhalation fl ow, a dynamic fl ow restrictor facilitates a constant fl ow and can be used 
in children aged 4 years or older. This method has a good correlation with the ‘gold 
standard’.64 In the PIAMA study FeNO was measured at the age of 4 years using the 
offl ine method with dynamic fl ow restrictor at a 50ml/sec exhalation fl ow. (Figure 1.3a) 
At the age of 8 years FeNO was measured using the standard online method. (Figure 
1.3b) In both methods a charcoal NO scrubber was used to wash out all ambient NO 
from the air inhaled through the mouthpiece.
Previous studies have shown that exhaled nitric oxide levels are elevated in children 
with asthma, wheeze and atopy.65-69 Most of these studies used a cross-sectional 
design comparing confi rmed asthma cases with selected healthy controls, possibly 
overestimating the discriminative capacity of FeNO. Large scale epidemiological stud-
ies from the general population are scarce, especially for pre-school children.70,71 Using 
data from the PIAMA study at the age of 4 years, Brussee et al found no signifi cant 
difference in FeNO between early wheezing phenotypes, and only a small difference 
between asthmatics and non-asthmatics.67 Prospective data collected until the age of 8 
cNOS iNOS
L-arginine
L-citrulline
NO
Physiological
stimuli
Endotoxins
cytokines
Peroxynitrite Nitrite S -nithrosothiols
Figure 1.2. Synthesis of nitric oxide (NO) from L-arginine
cNOS, constitutive NO sythase; iNOS, inducible NO synthase. Reprinted from Pijnenburg et al,55 
with permission.
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years in the PIAMA study allowed us to investigate, whether a FeNO measurement in 
preschool children with asthma symptoms can improve prediction of the risk of asthma 
symptoms at older ages. A test can only be of clinical benefi t when it offers additional 
information over the readily available clinical history or allergy tests. The added value 
of FeNO over other clinical parameters has not been investigated previously, and was 
part of our analyses.
Measurement of airway resistance by the interrupter technique
The interrupter technique (Rint) was fi rst described by von Neergaard and Wirz in 1927.72 
It is a measure of airway resistance, calculated as the ratio of alveolar pressure and 
airfl ow at the mouth during tidal breathing. The airfl ow can easily be measured at the 
mouth, but the alveolar pressure cannot be directly assessed in a non-invasive manner. 
In the Rint measurement alveolar pressure is derived from the pressure measured at 
the mouth during a brief interruption of the airfl ow. The airfl ow is interrupted by briefl y 
closing off the airways using a valve in the mouth piece. During the interruption alveolar 
pressure will rapidly equilibrate with the pressure at the mouth. Alveolar pressure just 
before airfl ow interruption can be estimated by back-extrapolating the pressure-time-
curve measured in the oral cavity to the moment the valve was shut. The estimated 
 
Figure 1.3. Measurement of nitric oxide fraction in exhaled air at 4 and 8 years
(a). Offl ine measurement in a 4-yr-old boy. 1: NO scrubber, 2: dynamic fl ow restrictor (50 mL/s), 3: 
manometer, 4: mylar balloon. (b). Online measurement of the nitric oxide fraction in exhaled air in 
an 8-yr-old girl. 1: computer animation gives visual feedback to maintain constant expiratory fl ow 
(50 mL/s), 2: online nitric oxide analyzer with built-in NO scrubber and dynamic fl ow restrictor.
1
1
2 2
3
4
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alveolar pressure is then divided by the airfl ow measured immediately prior to the 
airfl ow interruption, to calculate the Rint value.73-75
During the Rint measurement a subject needs to sit upright and breath quietly through 
the measurement device, while wearing a nose clip. To reduce upper airway compli-
ance, which is an important component of the total compliance of the respiratory 
system and co-determines Rint, the cheeks and chin are fi rmly supported by the inves-
tigator.75 (Figure 1.4) Previous studies have shown that the measurement can be easily 
performed in preschool children.76 Rint measurements correlate well with conventional 
methods for airway resistance, such as whole body plethysmography (Raw),73,76,77 and 
have an acceptable short- and long term reproducibility within subjects,78,79 and good 
interobserver agreement.76 Cross-sectional studies have reported higher Rint in asth-
matics compared to controls, although there was considerable overlap.80-82 Previous 
analysis of PIAMA data at age 4 showed that Rint in persistent wheezers was higher 
than in children who never or transiently wheezed.83 It is however not known whether 
Rint measurements can be used prospectively in preschool children, to predict the 
likelihood of symptom persistence at a later age.
Figure 1.4. Measurement of interrupter resistance in a 4-year-old girl
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PREVENTION AND INCIDENCE OF ASTHMA AND MITE ALLERGY STUDY
In this thesis data from the ‘Prevention and Incidence of Asthma and Mite Allergy’ 
(PIAMA) study are analyzed. The PIAMA study is a prospective birth cohort study 
among children recruited from the general population. The study originally consisted of 
two parts: 1) the Intervention Study (IS, designed to investigate the effect of house dust 
mite impermeable mattress covers on the incidence of asthma); 2) the Natural History 
Study (NHS, designed to study the natural course of asthma, allergy and respiratory 
symptoms).84 (Figure 1.5) Potential participants were recruited via antenatal clinics in 
the northern, middle and south-western regions of the Netherlands from May 1996-July 
1997. A validated screening questionnaire on maternal allergy/asthma was developed 
and used to categorize a total of 10,232 pregnant women into ‘allergic’ mothers 
(mothers with self-reported asthma and/or inhalant allergic disease) and ‘non-allergic’ 
mothers.85 Based on the screening 7,862 women (2,779 allergic and 5,083 non-allergic) 
were invited to participate in the study, approximately 50% (n = 4,146) agreed and gave 
informed consent (1,327 allergic and 2,819 non-allergic). Their children were defi ned as 
high-risk and low-risk children respectively. High-risk children were allocated to either 
the IS (one third in the intervention group, one third in the placebo group) or to the NHS 
(one third). All low-risk children were allocated to the NHS. In all chapters of this thesis 
the complete PIAMA population (IS+NHS) was included in our analyses. As previously 
published, the intervention with mattress covers had only a limited effect on the actual 
concentration of house dust mite on the child’s mattress, and it had no effect on the 
incidence of allergy, respiratory symptoms, or asthma.86,87 The proportion of children 
with an allergic mother (31%) in the total PIAMA study (IS+NHS) was very similar to 
the proportion in the population of pregnant mothers from which participants were 
recruited (n = 10,232). Of the 4,146 participants with informed consent, 183 were lost 
to follow-up before any data on the child had been obtained, so that the study started 
with 3,963 newborn children. Attrition rate was relatively low and at age 8 years, 88% 
of these children were still participating in the study.
The total study population was invited to complete postal questionnaires on prenatal 
risk factors such as maternal smoking, diet, medication use, exposure to pets and 
allergen avoidance measures. Parents were also invited to complete a postal question-
naire 3 months after the child was born, and annually starting when the child was 
1 year of age. These questionnaires contain data on: respiratory health of the child, 
siblings (adapted protocol of the International Study of Asthma and Allergy in Childhood 
(ISAAC))88 and parents (ECRHS protocol),89 perinatal characteristics of the child, general 
health of the child, type of feeding, housing characteristics, environmental factors, 
social contacts, development of height and weight, dietary habits and possible changes 
in many of these characteristics throughout childhood. 
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At age 4 and 8 years a subgroup consisting of almost all high-risk children and a 
random subsample of the low-risk children was invited for a medical examination and 
collection of biological data. At 4 years 1,808 children were invited. Their medical exami-
nation included the measurement of height, weight, interrupter resistance, nitric oxide 
fraction in exhaled air, peak fl ow, and the collection of blood samples. At 8 years of age 
Phase I: screening  10,232 pregnant women  
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 Baseline study population 
(n=4,146) 
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Study* (n=855) 
 Natural History 
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 Intensive follow-up 
(n=855) 
 Intensive follow-up 
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Figure 1.5. Flow chart with observation scheme at different ages in the PIAMA study
At baseline the study population consisted of n = 3,963 newborn children. *: The intervention 
measures were applied in 810 subjects; 416 subjects received active mattress covers and 394 
subjects received placebo mattress covers.
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1,554 children were invited for a hospital-based medical examination. This examina-
tion included the measurement of height, weight, interrupter resistance, nitric oxide 
fraction in exhaled and nasal air, lung function (Forced Expiratory Volume in 1 second; 
FEV1 and Forced Vital Capacity; FVC), bronchial hyperresponsiveness (methacholine 
provocation test) and atopy (serum immunoglobulin E and skin prick test to common 
inhalant allergens). Additionally at 8 years, 1,964 of the remaining low-risk children were 
also invited for a short community-based medical examination or house visit, in which 
height and weight were measured and blood samples were collected for analysis of 
specifi c immunoglobulin E to food and inhalant allergens.
AIMS OF THE STUDY
In the current thesis we aimed to investigate the following aspects of childhood asthma:
  · Which (combinations of) pre- and perinatal factors are associated with the develop-
ment of asthma, allergy and/or respiratory symptoms in the fi rst 8 years of life?
  · Which of the modifi able pre- and perinatal factors are the most promising targets for 
prevention in terms of their capacity to reduce later respiratory morbidity?
  · What is the proportion of undertreatment and overtreatment of asthma symptoms 
in children until the age of 8 years?
  · When a young child presents with wheezing, is it possible to predict the risk of 
persistent asthma symptoms until the age of 8 years, using only the information 
from a simple clinical history?
  · Are FeNO, Rint and/or specifi c IgE in children with asthma symptoms at the age of 
4 years of added value in the prediction of symptom persistence until the age of 8 
years, after taking the clinical history into account?
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OUTLINE OF THIS THESIS
Part I examines perinatal factors as possible etiologic risk factors for the development 
of childhood asthma. Chapter 2 describes the association between birth weight in 
children born at term and the risk of developing asthma or asthma symptoms in fi rst 
seven years of life. Furthermore, it describes the effects of parental smoking on the 
association between birth weight and asthma symptoms. Using a similar longitudinal 
analysis chapter 3 presents the association of early daycare attendance and the pres-
ence of older siblings, two important determinants of respiratory infections in early life, 
with the development of asthma symptoms and allergy until the age of 8 years. Chapter 
4 gives an overview of a wide range of perinatal factors and their relation with the de-
velopment of different longitudinal wheezing phenotypes. These longitudinal wheezing 
phenotypes were previously defi ned using longitudinal latent class analysis. In chapter 
5 we compare the fraction of nitric oxide in exhaled air, a marker for eosinophilic airway 
infl ammation, between the different longitudinal wheezing phenotypes at the ages of 
4 and 8 years. Part II focuses on the early diagnosis of asthma in symptomatic children 
and their clinical prognosis. Chapter 6 explores the agreement between prescribed 
asthma medication on the one hand, and asthma symptoms and doctors’ diagnosis of 
asthma on the other hand. Chapter 7 presents a clinical prediction rule to predict the 
probability that preschool children with asthma symptoms will still experience asthma 
symptoms at the age of 8 years, using only information from a simple clinical history. 
In chapter 8 we investigate whether the objective tests Rint, fraction of exhaled nitric 
oxide (FeNO) and specifi c IgE could improve the prediction of later symptoms after 
the clinical history was taken into account. In chapter 9 we discuss the fi ndings of this 
thesis in the context of other studies and evaluate their implications for clinical practice.
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ABSTRACT
Rationale
The relation between birth weight and respiratory symptoms and asthma in children 
remains unclear. Previous studies focused on a relation at separate ages. A longitudinal 
analysis may lead to a better understanding.
Objective
To estimate the effect of birth weight on the development and course of respiratory 
symptoms and asthma in the fi rst seven years of life.
Methods
In a prospective birth cohort study, 3,628 children with a gestational age 37 weeks or 
more were monitored for 7 years. Parental questionnaires were used to assess respira-
tory health yearly. Associations of birth weight with respiratory symptoms (wheezing, 
cough, respiratory infections) and doctor’s diagnosis of asthma were assessed in a 
repeated-event analysis.
Main results
Lower birth weight was associated with more respiratory symptoms (adjusted odds 
ratio [aOR] per kg decrease in birth weight, 1.21; 95% confi dence interval [CI95%]: 1.09-
1.34). The effect of birth weight increased from age 1 to 5, but decreased thereafter 
and was no longer signifi cant at the age of 7. The effect of birth weight on respiratory 
symptoms was signifi cantly greater among children exposed to tobacco smoke in their 
home (aOR at 5 yr: 1.52; CI95%: 1.23-1.87) than among non-exposed children (aOR at 5 yr: 
1.21; CI95%: 1.02-1.44). Birth weight and doctor’s diagnosis of asthma were not related 
(aOR: 1.06; CI95%: 0.82-1.37).
Conclusions
A lower birth weight in children born at term is associated with a transiently increased 
risk of respiratory symptoms. This effect is enhanced by environmental tobacco smoke 
exposure.
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INTRODUCTION 
Respiratory symptoms, such as wheezing, cough, and respiratory infections, are 
common in young children and put a serious burden on the affected children,1 their 
parents, and the healthcare system. In early childhood, these symptoms are related 
to a predisposition to asthma only in a minority of children.2 In the majority of children, 
symptoms will be transient and disappear during school age. Because the prevalence of 
these different phenotypes of symptoms changes rapidly during childhood, risk factors 
should be investigated using longitudinal data and analyses.
Size and maturity are major factors in the development of the lung. In children with 
diminished prenatal growth, and consequently low birth weight, a disturbed lung 
development is associated with a relatively small airway calibre.3 This might cause a 
decreased lung function and more respiratory symptoms later in life.2-4 Several studies 
have shown that prematurity is associated with lower lung function at birth and later, 
and a higher prevalence of respiratory symptoms in childhood.5-9 However, pathways 
leading to compromised lung development in premature and term infants are almost 
certainly not the same. The question remains whether the development of respiratory 
symptoms is infl uenced by birth weight in infants born at term.
The association between birth weight and asthma has been extensively studied, 
and the results are inconsistent. This may in large part be due to different periods of 
follow-up and to different defi nitions of asthma and (low) birth weight. In addition, 
not all studies took pregnancy duration into account in the analysis, thereby studying 
the combined effect of prematurity and birth weight.5 It has been postulated that the 
inverse association between birth weight and asthma as found in some studies might 
be explained by misclassifi cation of transient respiratory symptoms as asthma.10 
The aim of this study was to investigate birth weight as a predictor of respiratory 
symptoms and doctor’s diagnosis of current asthma longitudinally in children born at 
term. The prospective Prevention and Incidence of Asthma and Mite Allergy (PIAMA) 
birth cohort data gave us the opportunity to investigate the effect of birth weight on the 
development and course of respiratory symptoms in children 1 to 7 years. We hypoth-
esized that reduced intrauterine growth could lead to more respiratory symptoms as a 
result of smaller airways, which improve with increase in body size during childhood. 
We also investigated other factors that could possibly modify the effect of birth weight, 
such as gender, parental smoking, and allergic predisposition. 
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METHODS
Study population
The study population consisted of 3,628 children who participated in the PIAMA birth 
cohort study. Details of this study have been published earlier and are described in 
the data supplement.11 Briefl y, recruitment took place by means of a validated screen-
ing questionnaire,12 distributed to 10,232 pregnant women visiting one of 52 prenatal 
clinics in the Netherlands. On the basis of this screening 8,033 woman were invited 
to participate in the study; approximately 50% (n = 4,146) agreed and gave informed 
consent. Their children were monitored for 8 years. Standardized questionnaires for 
self-completion (according to the ISAAC [International Study of Asthma and Allergies 
in Childhood] guidelines)13 were sent to participating parents at the 3rd trimester of 
pregnancy, at the ages of 3 months and 1 year, and yearly thereafter. The present study 
analyzes the data up to the age of 7 years. We excluded all children with a gestational 
age of less than 37 weeks to avoid possible confounding effects of prematurity. In our 
fi nal analyses 3,628 children were included (88%).
Defi nition of variables
Birth weight was obtained from the child’s delivery chart, and reported in the 3-month 
questionnaire. Birth weight was considered as a continuous variable. 
We defi ned the following 6 (dichotomous) outcomes, each of which were obtained at 
the ages of 1 to 7 years, and which pertain to the previous 12 months:
1. Wheezing: at least one episode of wheezing
2. Frequent wheezing: 4 or more episodes of wheezing (subgroup of ‘wheezing’)
3. Cough: at least one episode of cough at night, not associated with a cold
4. Lower respiratory tract infection (LRTI): parental report of a doctor’s diagnosis of 
pneumonia, bronchitis or pertussis
5. Respiratory symptoms: a compound score with at least one positive score on the 
outcomes ‘wheezing’, ‘cough’, or ‘LRTI’. If medication was prescribed for asthma 
this score is considered positive, because symptoms may have been suppressed
6. Doctor’s diagnosis of current asthma: parental report of asthma ever diagnosed by 
a doctor in combination with symptoms of asthma in previous 12 months
Using questionnaire data, the following potential confounders were defi ned and in-
vestigated: gender, gestational age, parental education, parental history of allergies, 
multiparity, caesarean section, age of mother, region of birth, breastfeeding, maternal 
smoking during pregnancy (at least 4 weeks after onset of pregnancy), and body mass 
index of mother (before pregnancy). The latter two potential confounders had missing 
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values of 4.9% and 10.1%, respectively; in these variables, a separate category ‘miss-
ing’ was created. As a potential effect modifi er, we also looked at exposure to tobacco 
smoke in the child’s home 3 months after birth (not exclusively by mother). It was 
defi ned as a linear term with 3 values (never, < once a day, > once a day).
Statistical Analysis
Locally-weighted regression (LOESS) smoothing curves14 of the crude relationship be-
tween birth weight and the different outcomes were created using S-Plus 6.0 software 
(Insightfull, Seattle, WA) (See Figure E2.3 (data supplement) for the outcome ‘wheeze’). 
We compared smoothed curves with linear fi ts by testing for a difference between the 
linear fi t and the smooth fi t that includes both linear and smooth terms. Because no 
signifi cant difference was found between linear and smooth fi t (except at the age of 3 
years), linearity of the association between birth weight and the logit of the outcome 
were assumed in all subsequent analyses. 
Further analyses were performed with SAS 9.1.3 statistical software (SAS Institute, 
Inc., Cary, NC). Analyses of crude birth weight effect on all outcomes were fi rst per-
formed by logistic regression at every age separately (cross-sectional). Variables that 
meaningfully changed the univariate point estimate on one or more of the outcomes 
were included in the longitudinal models. Generalized estimating equations (GEEs) 
were used to investigate the longitudinal effects of birth weight on all 6 outcomes from 
age 1 to 7 years, taking into account the serial relations between repeated measure-
ments in the same individual. To test for effect modifi cation, we calculated terms for 
interactions between birth weight and the variables age (time trend), parental smoking, 
gender, and maternal allergy in the GEE model. 
RESULTS
Participants
From the 4,146 included women, 187 (4.5%) dropped out before returning the fi rst 
postnatal questionnaire due to various reasons (e.g., perinatal death, language bar-
rier, not interested, moved). The children who dropped out were more likely to have 
an allergic mother (50% vs. 31% based on screening questionnaire). Of the 3,959 
remaining children, those without a recorded birth weight (n = 45) or gestational age 
(n = 9), those with no data on the specifi ed outcomes at any of the 7 years (n = 82), 
and those with missing data on multiparity (n = 9) were excluded from analysis. These 
excluded children (n = 145) were more likely than the children with complete data (n = 
3,814) to have an allergic mother (51% vs. 30%), to have both parents with a low level 
of education (32% vs. 13%), to have a mother who smoked during pregnancy (27% vs. 
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17%) and to have been exposed to environmental tobacco smoke (ETS) at 3 months 
(43% vs. 28%). After exclusion of all children who were born prematurely (n = 186), 
3,628 children remained in the fi nal analyses.
General characteristics
Birth weights were normally distributed, even after adjustment for gestational age. 
Table 2.1 shows the general characteristics of the study population. Male gender, higher 
gestational age at birth, overweight of the mother and presence of older siblings were 
Table 2.1. General Characteristics of Study Population (n = 3,628)
Characteristic Mean ± SD or %
Birth weight  (range) 3.56 ± 0.49 (1.76-5.71)
Duration of pregnancy, weeks* 40.1 ± 1.2 
Age mother, years† 30.4 ± 3.9
Male gender* 51.7
Body mass index mother*
< 25 kg/m2 71.9
≥ 25 kg/m2 17.9
Missing 10.1
Older sibling present* 51.5
Breastfeeding ever given† 81.7
Allergic mother 30.1
Allergic father 30.8
Born by caesarian section‡ 8.0
Smoking mother during pregnancy*
No 81.6
Yes, < 10 cigarettes/day 8.9
Yes, ≥ 10 cigarettes/day 4.5
Missing 4.9
Smoking indoors at 3 months*
Seldom or never 56.3
Yes, but < once/week 15.4
Yes, ≥ once/week 28.3
Low education of both parents† 12.7
Region Netherlands†
North 31.3
Central 41.0
Southwest 27.8
Study population (n = 3,628). The signifi cance of the associations between birth weight and 
the other characteristics was tested using unpaired t test and analysis of variance (categorical 
variables), or Pearson’s correlation coeffi cient (continuous variables). Body Mass Index of mother 
was calculated from self reported weight and height before pregnancy. Smoking during pregnancy 
was considered positive only if mother reported smoking at least 4 weeks after estimated date of 
conception. *:p < 0.0001, †:p < 0.01, ‡:p < 0.05.
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strongly related with a higher birth weight. Maternal smoking during pregnancy was 
clearly associated with a reduced birth weight. A considerable proportion of children 
were exposed to tobacco smoke in utero (13.5%) and/or after birth (28.3%). 
Prevalence of respiratory symptoms and asthma
Wheezing at least once was the most frequently reported symptom in the fi rst year 
(21%), but showed a steep linear decline with increasing age. Frequent wheezing 
showed the same decline and accounted for 25 to 30% of all reported wheeze. (Figure 
2.1) The symptom ‘cough’ was more stable over the years, with the highest reported 
prevalence at the age of 5 (23.2%) and the lowest at age 7 (14.9%). After the age of 
2 years, cough was the most frequently reported symptom and, between the ages 
of 4 and 7, about 70% of the cases with ‘respiratory symptoms’ reported cough. The 
prevalence of LRTIs declined from 16.4% in the fi rst year to 4.4% in the seventh year. 
During the full 7-year follow-up, 38.9% of the study population had at least 1 wheezing 
episode, 51.7% reported cough at night, and 37.3% had a LRTI at any point. The com-
pound outcome respiratory symptoms showed that the overall burden of respiratory 
morbidity declined from 36.8% at 1 to 20.4% at 7 years. Overall, 70% of the cohort had 
reported at least one of the respiratory symptoms at some point in the fi rst 7 years of 
life. The prevalence of reported doctor-diagnosed current asthma showed a decline with 
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Figure 2.1. Prevalence of wheeze (of available cases) at different ages
Bars show infrequent (1-3 times, light grey) and frequent (4 or more, dark grey) wheezing episodes 
per year. Total height of each bar is prevalence of wheezing at least once. Number in each bar is the 
absolute number of children who reported infrequent wheezing or frequent wheezing.
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increasing age from 5.8% in the fi rst year to 2.7% at age 7. (Figure 2.2) In total 13.6% 
of the children were diagnosed with asthma by a doctor at any point. Table E2.1 in the 
data supplement shows the annual prevalence of all outcomes.
Association of birth weight with respiratory symptoms and asthma
In crude analyses performed cross-sectionally, birth weight showed an inverse asso-
ciation with wheezing, frequent wheezing, cough, and LRTIs, especially between the 
ages of 2 to 5. Of the variables tested for confounding, the following fi ve meaningfully 
changed the univariate point estimate: gender, gestational age at birth, body mass index 
of mother, smoking during pregnancy, and the presence of older siblings (multiparity). 
These variables had a comparable confounding effect on all specifi ed outcomes, and 
were controlled for in the longitudinal models.
To account for the serial correlations among outcomes of the same individual, we 
used GEE models to perform longitudinal analyses on all outcomes. For crude esti-
mates on all outcomes, see Table E2.2-7 of the data supplement. Figure 2.3 shows the 
adjusted odds ratios (aORs) from the longitudinal multivariate analysis for all outcomes. 
The overall effect of birth weight over 7 years was calculated, but the effect at every age 
separately from models with interaction term (age) is also presented. After multivariate 
adjustment, a lower birth weight remained signifi cantly associated with more wheezing 
(aOR 1.17 per kg decrease in birth weight, CI95%: 1.01-1.35), cough (aOR 1.21; CI95%: 
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Figure 2.2. Prevalence of self-reported doctor’s diagnosis of current asthma at different ages
Total height of each bar represents the prevalence; the number in each bar represents the absolute 
number of children with doctor’s diagnosis of current asthma.
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1.07-1.36), and respiratory infections (aOR 1.20; CI95%: 1.05-1.38) overall. In addition, the 
association with the compound score for respiratory symptoms was signifi cant over 
the whole 7-year period (aOR 1.21; CI95%: 1.09-1.34). We investigated the aORs of birth 
weight at different ages, by allowing interaction of the effect with age. The inverse 
relation between birth weight and wheezing remained signifi cant at the ages 2 to 5 
(c) Coughing at night
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Figure 2.3. Odds ratios (ORs) and confi dence intervals per kilogram decrease in birth weight for all 
outcomes, from longitudinal GEE model
ORs given for the overall effect and (allowing for a time trend) for each year of age separately. 
Estimates adjusted for gender, multiparity, body mass index of mother, smoking of mother during 
pregnancy, and gestational age at birth. The following outcomes are depicted: (a). Wheezing at 
least once; (b). Lower respiratory tract infections (LRTI), including pneumonia, bronchitis and 
pertussis; (c). Cough in absence of a cold; (d). Compound score ‘respiratory symptoms’; (e). 
Doctors’ diagnosis of current asthma.
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years, with the highest aOR at age 4 (aOR 1.36; CI95%: 1.08-1.71). For the outcome LRTI, 
the aOR was also highest at the age of 4 (aOR 1.45; CI95%: 1.13-1.86). The aOR increased 
from age 1 to 4, and decreased to zero by the age of 7. Tests for this interaction between 
birth weight and age (time trend) in the GEE model reached signifi cance for wheez-
ing and LRTI (p = 0.03 and 0.05, respectively). The association between birth weight 
and wheezing could not be explained by the relation between birth weight and LRTI. 
The aOR of birth weight on cough was more stable over the years, ranging between 
1.34; CI95%: 1.10-1.62 and 1.13; CI95%: 0.92-1.39. The compound score for respiratory 
symptoms was signifi cantly associated with birth weight at the ages of 2 to 6 years. 
To assess the relative impact of children with an extreme birth weight, we performed a 
sensitivity analysis by excluding the 2% of the lightest and 2% of the heaviest children. 
ORs of the different outcomes became somewhat smaller at certain ages, but the 
overall pattern of the associations remained the same.
There was no signifi cant association between birth weight and doctor’s diagnosis 
of current asthma over all ages. (Figure 2.3e) Inspecting the effect at different ages 
showed a borderline signifi cant association only at the age of 5 year (aOR 1.43 per kg 
decrease; CI95%:0.99-2.07).
Interaction with gender, maternal allergy and ETS exposure on respiratory 
symptoms
Modifi cation of the effect of birth weight on respiratory symptoms by gender, atopic 
constitution, gestational age (wks) at birth and ETS was investigated. The effect did not 
differ between boys and girls, between children with and without an allergic mother, or 
between children with a lower and children with a higher gestational age range at birth. 
Separate analysis of the results of the participants who were exposed and who were 
not exposed to ETS in their house after birth, revealed a greater effect of birth weight 
in the exposed group. In the GEE model, interaction with ETS exposure at 3 months 
reached signifi cance for the outcomes wheezing (p = 0.03) and respiratory symptoms 
(p = 0.04). In Figure 2.4, the predicted probabilities of respiratory symptoms for children 
with different birth weights (2.5, 3.5 and 4.5 kg) are shown in presence and absence 
of ETS exposure, to visualize the effect of birth weight in children of smoking and 
nonsmoking parents. Probabilities were calculated with given values for all confound-
ers, as specifi ed in the fi gure legend. A comparison of Figure 2.4a with 2.4b reveals 
the interaction effect of ETS exposure at 3 months in children who were not exposed 
prenatally. The difference between Figures 2.4a and 2.4c could be interpreted as the 
combined effect of pre- and postnatal ETS exposure. In the presence of ETS exposure 
(Figure 2.4b), a child with a birth weight of 2.5 kg has an approximately 45% chance 
each year of having respiratory symptoms between the ages 1 and 5 years, compared 
with 25% in a child with a birth weight of 4.5 kg. In absence of ETS exposure (Figure 
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2.4a), the difference in prevalence of respiratory symptoms between a 2.5- and a 4.5-kg 
newborn child is much smaller, about 6 percentage points. As can also be seen from 
Figure 2.4, a child of low birth weight (2.5 kg) has an additional 6% chance of respiratory 
symptoms if exposed to ETS postnatally. When exposed to ETS both pre- and postna-
tally the additional risk of symptoms mounts to 12%. Figure 2.5 shows the predicted 
probabilities of the outcome wheezing for children from both smoking and nonsmoking 
parents. Clearly, the effect of birth weight is larger in the children exposed to ETS, 
especially in the fi rst year of life. The isolated effect of postnatal exposure appears 
limited after adjustment for prenatal smoking; however, 87.2% of the children exposed 
to tobacco smoke during pregnancy were also exposed at three months after birth. Of 
the children exposed to cigarette smoke in their home more than once a week, about 
half (48%) had a mother who smoked at least 4 weeks during pregnancy.
(c) Smoking during pregnancy and ETS exposure
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Figure 2.4. Predicted probabilities of any respiratory symptom (wheezing, cough or LRTI) for a 
child of male gender, 40 weeks gestational age at birth, with a non-overweight mother, and with 
older sibling(s)
Probabilities are predicted for a child with a birth weight of 2,500 g, 3,500 g, and 4,500 g. (a). For 
children of whom the mother did not smoke during pregnancy, and who were not exposed to 
environmental tobacco smoke at 3 months. (67.3% of study population); (b). For children of whom 
the mother did not smoke during pregnancy, but who were exposed to environmental tobacco 
smoke (≥ once/week) at 3 months (14.4% of study population); (c). For children of whom the 
mother did smoke during pregnancy, and who were exposed to environmental tobacco smoke (≥ 
once/week) at 3 months (11.9% of study population).
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DISCUSSION
This prospective birth cohort study shows that a low birth weight at term is signifi -
cantly associated with more respiratory symptoms, including wheezing, cough, and 
respiratory infections in early childhood. The effect of low birth weight was amplifi ed by 
exposure to ETS, and declined after the age of 5. 
The effect of birth weight on respiratory symptoms has been examined in several 
other birth cohorts. Our fi ndings are in concordance with results from a large birth 
cohort that showed an association between birth weight and wheezing at 3 years, 
but not at 6 months.15 Another study in term infants did report an association in the 
fi rst year of life.16 A separate analysis on the same cohort at the age of 6 years no 
longer showed a signifi cant association,17 in line with our fi ndings. Some other studies 
reported no association between birth weight and respiratory symptoms.18,19 The dis-
(b) No smoking during pregnancy, with ETS exposure
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(c) Smoking during pregnancy and ETS exposure
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Figure 2.5. Predicted probabilities of wheeze for a male child, 40 weeks gestational age at birth, 
with a non-overweight mother, and with older sibling(s)
Probabilities are predicted for a child with a birth weight of 2,500 g, 3,500 g, and 4,500 g. (a). For 
children of whom the mother did not smoke during pregnancy, and who were not exposed to 
environmental tobacco smoke at 3 months (67.3% of study population); (b). For children of whom 
the mother did not smoke during pregnancy, but who were exposed to environmental tobacco 
smoke (≥ once/week) at 3 months (14.4% of study population); (c). For children of whom the 
mother did smoke during pregnancy, and who were exposed to environmental tobacco smoke (≥ 
once/week) at 3 months (11.9% of study population).
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crepancy might be explained by the fact that symptoms in these studies were assessed 
only after the age of 5. Our yearly longitudinal analysis over a period of 7 years extends 
our knowledge on the time trend of the association. We found an increase of the odds 
ratio until the age of 5 and a decrease thereafter, suggesting an association between 
birth weight and transient symptoms in preschool- and early elementary school-aged 
children. It is clear from previous publications that prematurity is associated with a 
decreased lung function and more asthmalike symptoms.6-9 Unlike previous studies 
investigating the effect of birth weight on respiratory symptoms,5,18-20 we excluded all 
premature infants from our analyses. This enabled us to separate the effect of a low 
birth weight in children born at term from the sequelae of prematurity, and to investi-
gate the independent effect of birth weight. The association between birth length and 
respiratory symptoms was investigated, but was not signifi cant after adjustment for 
birth weight. The increased risk of symptoms in term children of a lower birth weight 
can be due to small airways relative to lung size (dysanapsis),3 as a result of diminished 
prenatal growth.2 Although the impact of impaired fetal growth surely is related to its 
timing, we have no data on the timing of any possible adverse prenatal conditions. As 
the airways grow in absolute size with age, such children may become less apt to have 
symptoms, which would explain the transient nature of the increased risk. Lung func-
tion in the low-birth-weight children might remain suboptimal, even after these children 
become asymptomatic, as was found in children who wheezed between the ages of 1 
and 6 years.2 This is important because it has been speculated that these children may 
be at increased risk of respiratory morbidity when lung function decreases in later life.21 
One could also argue that disorders of fetal growth affect the immune function, thereby 
leading to a higher rate of respiratory symptoms.
This study does not support an effect of birth weight on the risk of a doctor’s diagno-
sis of current asthma in children born at term. Because objective tests, including lung 
function, bronchial hyperresponsiveness, or allergy tests, are either diffi cult to perform 
in young children or not informative, a diagnosis of asthma in children younger than 5 
is mainly based on respiratory symptoms.22,23 As the diagnosis becomes more reliable 
with increasing age, one would expect less misclassifi cation at later ages. This would 
lead to less dilution bias and more precise estimates of the association between birth 
weight and an asthma diagnosis. Our results show a decrease of the association at 
ages 6 and 7 years. Previous studies on the association between birth weight and 
asthma in children have shown contradictory results, with some reporting a positive 
association,24-26 some a negative association5,27-30 and some no association.8,17,18 Only 
few of these studies excluded premature children.17,24 The increased risk of asthma in 
low-birth-weight children reported by some studies might therefore be confounded by 
the effect of prematurity and/or bronchopulmonary dysplasia. Further inconsistencies 
in the results might appear because varying defi nitions of asthma were used in the 
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different studies. Our longitudinal data suggest a negative association between asthma 
and birth weight only at the ages 4 and 5. Possibly this association is caused by mis-
diagnosis of transient wheezing syndromes.10 This is supported by the fact our study 
showed a strong association between birth weight and (transient) wheezing, especially 
at the ages 4 and 5 years.
This study reports for the fi rst time an interaction between birth weight and ETS 
exposure in infancy on respiratory symptoms. To assess ETS exposure we used re-
ported smoking in the child’s home, as this is the most important single location for 
exposure in children. We observed a stronger effect of low birth weight in the group 
with ETS exposure at 3 months. The interaction with ETS could not be explained by the 
correlation of ETS with the level of education of the parents, which we used as a proxy 
of socio-economic status. Both in groups with high and low socio-economic status, 
the interaction between ETS and birth weight remains present. On the basis of our 
longitudinal models, we estimated that, in the presence of ETS exposure, a child with 
a birth weight of 2.5 kg suffers a nearly doubled risk of having respiratory symptoms 
compared with a 4.5-kg child until the age of 5 years. In a 2.5-kg child we estimated that 
ETS exposure pre- and postnatally is associated with a 12% increase in prevalence of 
wheezing and respiratory symptoms. Although several other factors, such as prematu-
rity, other environmental pollutants, and a history of allergy, were previously reported 
to possibly infl uence the susceptibility for the effects of ETS,31 a low birth weight was 
not. A possible explanation for our fi nding is that the lungs of a child with lower birth 
weight are more vulnerable to the irritating effects of ETS. Many epidemiologic stud-
ies have demonstrated that children are more sensitive to the respiratory effects of 
ETS exposure than adults.32 In low-birth-weight children, a disturbed lung development 
could lead to immature lungs and therefore a higher susceptibility to the effects of ETS. 
We investigated interaction with ETS exposure established at the age of 3 months, 
because this variable had no missing values and it prevents bias caused by a change 
of parental smoking behavior due to their child’s later symptoms. Tests for interaction 
between birth weight and ETS exposure at later ages showed similar results as ETS 
exposure at 3 months. This fi nding might suggest that ETS exposure is especially harm-
ful for children of low birth weight, regardless of the child’s age. However, another 
explanation is that ETS exposure at young ages has a long-lasting harmful effect in 
low-birth-weight children and that tracking of parental smoking behavior is responsible 
for the association with ETS exposure at later ages.
There are some limitations of this study that should be considered in the interpreta-
tion of the results. First, the presence of respiratory symptoms was based on parental 
reporting, which may lead to misclassifi cation. We assume that this misclassifi cation 
is nondifferential (independent of a child’s birth weight) which may lead to dilution of 
the effect estimate. Especially at age 1 to 2 years this could have caused some under-
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estimation, because the ISAAC questionnaires that were used are originally designed 
and validated for the age category of 6 to 7 years. Misclassifi cation of parental reports 
of ETS exposure is less likely because previous analyses showed that ETS exposure 
correlated well with nicotine concentrations measured in living-room air.33 Second, in 
our analyses, we adjusted for the confounding effects of smoking during pregnancy. 
The mechanisms by which smoking leads to more respiratory symptoms include a 
lower birth weight,2 which would imply that smoking is an antecedent rather than a 
confounder. Hence, adding prenatal smoking to our models might have caused some 
overadjustment and conservative estimates of the effect. Third, a problem encountered 
by many investigators studying the independent effect of in utero and household expo-
sure to ETS is the strong correlation between the two factors.34 Although in our study 
we were able to adjust these factors for each other without the problem of colinearity, 
it remains diffi cult to prove that the interaction with birth weight found in this study is 
attributable to either in utero or postnatal exposure. Our data does suggest (especially 
for the compound score of respiratory symptoms) that the household ETS exposure 
is the actual effect modifi er, but we base our conclusion largely on pathophysiologic 
reasoning. 
Our study shows that low birth weight is an important risk factor for development 
and persistence of respiratory symptoms during preschool and early elementary school 
age. The effect of birth weight was greater in children exposed to ETS. Hence, it seems 
that the increased risk of symptoms in a low-birth-weight child might be considerably 
reduced by prevention of postnatal ETS exposure. In recent years passive smoking has 
been reported in numerous studies to have harmful effects on a child’s health.32 Our 
fi ndings contribute to the knowledge that exposure to tobacco smoke is a public health 
problem with a substantial impact on respiratory health in children, especially those 
with a low birth weight. Despite growing public awareness the prevalence of smoking 
during pregnancy and frequent ETS exposure in the fi rst years of life has remained 
high.35 An active policy to reduce in utero and ETS exposure on infants is desirable for 
all new parents. Our study suggests that signifi cant extra health benefi t can be gained 
by focusing on parents of newborns with a low birth weight. 
CONCLUSION
We conclude that a low birth weight is an important risk factor for respiratory symp-
toms in young children born at term, independent of other characteristics at birth. This 
association showed a time trend with the strongest effect at 4 years and no effect 
after the age of 6. We also demonstrated potentiation of the effect of birth weight by 
exposure to ETS. All parents should be strongly encouraged to stop smoking because it 
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has clear health benefi ts for their offspring. Our data suggest that focusing on parents 
of low-birth-weight children is of specifi c interest, because their children may be espe-
cially vulnerable to the effects of ETS.
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METHODS
Recruitment of participants 
Participating children were part of the Prevention and Incidence of Asthma and Mite 
Allergy (PIAMA) birth cohort study. This is a multi center study conducted in 3 different 
regions of The Netherlands: north (Groningen and surroundings), central (Bilthoven, 
Wageningen and surroundings) and southwest (Rotterdam and surroundings). Recruit-
ment took place between March 1996 and May 1997 by means of a validated screening 
questionnaire,E1 distributed by midwifes to 10,232 pregnant woman visiting one of 3 
prenatal clinics. According to the results of this screening the women were divided 
in an allergic and a non allergic group. Women with any of the following self-reported 
symptoms were defi ned as allergic: asthma, hay fever, house dust allergy, house dust 
mite allergy or pet allergy. Children of allergic women were defi ned as ‘high-risk’. All 
allergic women (n = 2,949) and a random sub-sample of the non-allergic women (n = 
5,084) were invited to participate in the study, approximately 50% (n = 4,146) agreed 
and gave informed consent. The PIAMA cohort includes an ‘intervention part’, studying 
the effect of impermeable mattress covers, and a ‘natural history part’. Figure E2.1 
shows the fl ow diagram for recruitment of the intervention and the natural history arm. 
For the present study on the effect of birth weight, data on all 4,146 children was used. 
Any confounding or interaction of the birth weight effect with the intervention was 
investigated. None of the outcomes in this study changed meaningfully after adjust-
 
Phase I: Screening 
 
 
 
 
 
Phase II: Recruitement 
Invited to participate 
 
Agreed to participate 
 
 
Random allocation into intervention 
and natural history cohorts 
 
 
Random allocation within  
Intervention and natural history cohorts 
 
 
10,232 pregnant women 
2,949 atopic 
pregnant women 
7,283 non-atopic 
pregnant women 
2,779 atopic 
pregnant women 
5,083 non-atopic 
pregnant women 
1,327 atopic 
pregnant women 
2,819 non-atopic 
pregnant women 
855 
high-risk children 
Intervention Study 
50% high-risk 
placebo group 
472 
high-risk children 
Natural History Study 
2,819 
low-risk children 
Natural History Study 
50% high-risk 
intervention group 
472 high-risk 
control group 
625 low-risk 
with home visit 
2,194 low-risk 
questionnaire only 
Figure E2.1. The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) recruitment 
scheme
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ment for the intervention and there was no signifi cant interaction. The PIAMA study 
was approved by the Medical Ethical Committees of the participating institutions.
Data collection
For the present study data from standardized questionnaires (according to the ISAAC 
guidelines)E2 were used. The questionnaires were sent to participating parents for 
self-completion at the 3rd trimester of pregnancy, 3 months after birth, at the age of 
1 and yearly thereafter. The fi nal questionnaire was sent at the age of 8, when also a 
physical examination was conducted. Information was collected on birth characteristics 
(e.g. birth weight, pregnancy duration, length and head circumference, season of birth), 
indoor environmental factors (e.g. smoking in the house, pets, housing characteristics), 
socioeconomic characteristics (e.g. parental education and employment status), life-
style factors (e.g. feeding, child care), demographic factors (e.g. siblings, parental age/ 
bmi) and on the child’s health (e.g. allergies, eczema, respiratory symptoms, doctors’ 
diagnosis and medication use).
Statistical Analysis
LOESS-curves of the crude relationship between birth weight and the outcome ‘wheez-
ing at least once’ were created.E3 (Figure E2.2) The logarithm of the odds of having 
wheeze at least once a year is plotted against birth weight for every age separately. 
Considering the negative monotonous relation at all ages it was decided to investigate 
birth weight as a continuous variable. Goodness of fi t was later tested by adding the 
variable of birth weight-squared to the fi nal models. This variable was not signifi cant for 
any of the 6 specifi ed outcomes.
Multiple logistic regression was used to asses a relationship between birth weight 
and respiratory outcomes at every age. A longitudinal analyses was then performed, 
combining information on the outcomes at every age in one model. In this analysis 
we have to take account for the fact that the repeated measurements in the same 
individual are correlated, in order to calculate correct standard errors and p-values of our 
estimates. A Generalized Estimation Equations (GEE) model was used. As correlations 
between repeated measurements can be expected to depend on the time lag between 
2 measurements, a 6-dependent correlation matrix was modeled. This complex correla-
tion matrix was specifi ed, to make the model more robust against outcomes missing 
at random and to gain effi ciency.E4 In the models interaction with age was signifi cant 
only for the effect of birth weight and multiparity. We allowed for these interactions in 
our fi nal models. 
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RESULTS
Prevalence of all 6 outcomes at the ages 1 to 7 are shown in Table E2.1. The crude and 
adjusted odds ratios on all outcomes per kilogram decrease in birth weight are shown 
in Tables E2.2-7. Multivariate models are presented both with and without adjustment 
for pregnancy duration. Though birth weight and pregnancy duration were highly cor-
related, the problem of co-linearity did not occur in the multivariate models, as can be 
concluded from the stable confi dence intervals.
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Figure E2.2. LOESS-curves of the crude effect of birth weight on wheezing (at least once) at every age
Log-transformed odds on wheezing in relation to birth weight. Considering the negative 
monotonous relation at all ages it was decided to investigate birth weight as a continuous variable 
in further analyses. * p_lin: p-value for linear association, † p_nlin: p-value for nonlinear associasion.
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Table E2.2. Associations between birth weight and wheezing at least once
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 0.96 (0.81-1.14) 1.11 (0.93-1.33) 1.06 (0.88-1.27)
2 1.14 (0.95-1.36) 1.30 (1.09-1.56)|| 1.24 (1.03-1.49)¶
3 1.15 (0.94-1.39) 1.29 (1.06-1.57)¶ 1.23 (1.00-1.50)¶
4 1.29 (1.03-1.62)¶ 1.43 (1.14-1.79)|| 1.36 (1.08-1.71)||
5 1.28 (1.02-1.62)¶ 1.39 (1.10-1.76)|| 1.32 (1.04-1.68)¶
6 1.20 (0.93-1.54) 1.28 (0.98-.65) 1.21 (0.93-1.57)
7 0.98 (0.74-1.30) 1.03 (0.77-1.37) 0.98 (0.73-1.31)
Overall§ 1.08 (0.95-1.23) 1.23 (1.07-1.40)|| 1.17 (1.01-1.35)¶
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05. ||:p < 0.01.
Table E2.3. Associations between birth weight and frequent wheezing
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 0.91 (0.70-1.19) 1.08 (0.82-1.41) 1.00 (0.75-1.33)
2 1.13 (0.84-1.52) 1.31 (0.97-1.77) 1.21 (0.88-1.66)
3 1.35 (0.92-2.00) 1.55 (1.05-2.27)¶ 1.43 (0.96-2.12)
4 1.11 (0.73-1.67) 1.24 (0.82-1.87) 1.14 (0.75-1.75)
5 1.81 (1.22-2.68)|| 1.99 (1.33-2.97)** 1.83 (1.22-2.77)||
6 1.00 (0.63-1.60) 1.09 (0.68-1.74) 1.01 (0.63-1.61)
7 0.99 (0.58-1.68) 1.06 (0.61-1.83) 0.98 (0.57-1.69)
Overall§ 1.10 (0.89-1.35) 1.26 (1.02-1.56)¶ 1.16 (0.92-1.47)
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §:Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05. ||:p < 0.01. **:p < 0.001.
Table E2.1. Prevalence of outcomes at age 1 to 7 years
Age (yrs) Wheezing ≥ 
once, % (n)
Frequent 
wheezing, 
% (n)
Coughing at 
night, 
% (n)
LRTI†, % (n) Any respiratory 
symptoms, 
% (n)
Doctors’ 
diagnosis current 
asthma, % (n)
1 21.4 (770) 6.9 (249) 17.0 (592) 16.4 (572) 36.8 (1,275) 5.8 (210)
2 17.3 (618) 5.6 (200) 15.4 (535) 13.5 (465) 32.0 (1,106) 4.6 (163)
3 15.1 (534) 3.6 (127) 19.9 (688) 11.1 (383) 33.8 (1,160) 4.1 (146)
4 11.5 (395) 3.1 (105) 21.9 (734) 8.9 (294) 32.0 (1,066) 4.0 (138)
5 9.3 (315) 2.9 (97) 23.2 (767) 10.3 (332) 32.7 (1,059) 3.8 (129)
6 7.4 (247) 2.1 (68) 18.0 (585) 7.2 (230) 25.1 (806) 3.7 (123)
7 5.8 (183) 1.4 (45) 14.9 (473) 4.4 (136) 20.4 (634) 2.7 (87)
Ever 
positive*
39 (1,411) 15 (549) 52 (1,875) 37 (1,352) 70 (2,547) 14 (492)
Absolute numbers of children with symptoms given in brackets. *: A positive score on this 
outcome at least once during 7 year follow-up. †: Lower respiratory tract infections, including 
doctors’ diagnosed pneumonia, bronchitis, and/or pertussis.
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Table E2.4. Associations between birth weight and coughing
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 1.09 (0.92-1.30) 1.16 (0.97-.39) 1.15 (0.95-1.38)
2 1.16 (0.96-1.40) 1.22 (1.01-1.47)¶ 1.20 (0.99-1.46)
3 1.23 (1.04-1.46)¶ 1.27 (1.07-1.52)|| 1.25 (1.04-1.51)¶
4 1.19 (1.00-1.40)¶ 1.20 (1.02-1.43)¶ 1.19 (1.00-1.42)
5 1.24 (1.05-1.46)|| 1.24 (1.05-1.47)|| 1.22 (1.03-1.45)¶
6 1.38 (1.15-1.65)** 1.36 (1.13-1.63)|| 1.34 (1.10-1.62)||
7 1.19 (0.98-1.44) 1.15 (0.94-1.40) 1.13 (0.92-1.39)
Overall§ 1.20 (1.08-1.34)** 1.23 (1.10-1.37)** 1.21 (1.07-1.36)||
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05. ||:p < 0.01. 
**:p < 0.001.
Table E2.5. Associations between birth weight and LRTI**
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 0.93 (0.77-1.13) 1.07 (0.88-1.29) 1.05 (0.86-1.28)
2 1.23 (1.01-1.50)¶ 1.37 (1.12-1.68)|| 1.35 (1.10-1.66)||
3 1.24 (0.99-1.56) 1.34 (1.06-1.69)¶ 1.32 (1.04-1.67)¶
4 1.40 (1.10-1.79)|| 1.47 (1.15-1.88)|| 1.45 (1.13-1.86)||
5 1.15 (0.91-1.45) 1.18 (0.93-1.49) 1.16 (0.91-1.47)
6 1.24 (0.95-1.62) 1.23 (0.94-1.61) 1.21 (0.92-1.59)
7 1.04 (0.74-1.47) 1.01 (0.71-1.43) 0.99 (0.70-1.41)
Overall§ 1.13 (1.00-1.28) 1.22 (1.07-1.39)|| 1.20 (1.05-1.38)||
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05. ||:p < 0.01. **LRTI: Lower respiratory tract infections, including 
doctors’ diagnosed pneumonia, bronchitis, and/or pertussis.
Table E2.6. Associations between birth weight and ‘Any respiratory symptoms’
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 1.00 (0.86-1.15) 1.10 (0.95-1.28) 1.10 (0.94-1.28)
2 1.17 (1.01-1.36)¶ 1.27 (1.10-1.48)|| 1.27 (1.09-1.48)||
3 1.13 (0.98-1.31) 1.21 (1.04-1.40)¶ 1.20 (1.03-1.40)¶
4 1.22 (1.05-1.42)|| 1.28 (1.10-1.49)|| 1.27 (1.09-1.49)||
5 1.30 (1.12-1.50)** 1.33 (1.14-1.54)** 1.32 (1.13-1.54)**
6 1.31 (1.11-1.54)|| 1.31 (1.11-1.55)|| 1.31 (1.10-1.55)||
7 1.10 (0.93-1.31) 1.08 (0.91-1.29) 1.08 (0.90-1.29)
Overall§ 1.15 (1.05-1.27)|| 1.21 (1.10-1.34)** 1.21 (1.09-1.34)**
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05. ||:p < 0.01. **:p < 0.001.
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Table E2.7. Associations between birth weight and doctors’ diagnosis of current asthma
Age OR’s (CI95%)* OR’s (CI95%)
† OR’s (CI95%)
‡
1 0.77 (0.58-1.02) 0.97 (0.72-1.31) 0.90 (0.66-1.22)
2 0.99 (0.70-1.40) 1.23 (0.87-1.75) 1.13 (0.79-1.63)
3 0.85 (0.62-1.18) 1.04 (0.75-1.44) 0.95 (0.68-1.34)
4 1.23 (0.85-1.80) 1.48 (1.00-2.18)¶ 1.36 (0.91-2.02)
5 1.33 (0.95-1.88) 1.56 (1.09-2.23)¶ 1.43 (0.99-2.07)
6 1.07 (0.75-1.55) 1.24 (0.85-1.81) 1.14 (0.77-1.67)
7 1.11 (0.72-1.74) 1.26 (0.79-1.99) 1.15 (0.72-1.84)
Overall§ 0.95 (0.75-1.19) 1.16 (0.91-1.47) 1.06 (0.82-1.37)
GEE-models, odds ratios per kilogram decrease in birth weight. *: Crude analysis. †: Adjusted 
for gender, body mass index of mother, smoking of mother during pregnancy and multiparity. ‡: 
Adjusted for previous confounders and gestational age at birth. §:Overall effect at age 1-7 years (no 
interaction term with age). ¶:p < 0.05.
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ABSTRACT
Rationale
Daycare exposes young children to more infections early in life and may thereby prevent 
the development of asthma and allergy.
Objective
To prospectively study the effect of daycare on the development of asthma and allergic 
sensitization during the fi rst 8 years of life.
Methods
In the Prevention and Incidence of Asthma and Mite Allergy birth cohort 3,963 newborn 
children were followed prospectively for 8 years. Daycare use and respiratory health 
were assessed yearly by questionnaires. At 8 years, sensitization to airborne allergens 
and airway responsiveness were measured. Daycare was defi ned as early (aged 0-2 
yr), late (aged 2-4 yr) or none (no daycare before age 4 yr). Associations of daycare and/
or older siblings with asthma symptoms (wheezing, shortness of breath, and inhaled 
steroids taken in the last year), airway responsiveness and allergic sensitization were 
assessed in a longitudinal repeated-event analysis.
Results
Children with early daycare had more wheezing in the fi rst years of life, but less 
wheezing and steroid use between 4 and 8 years of age. At the age of 8 years, early 
daycare was not protective for asthma symptoms (adjusted odds ratio [aOR], 0.99; 95% 
confi dence interval [CI95%], 0.74-1.32), allergic sensitization (aOR 0.86; CI95%: 0.63-1.18) 
or airway hyperresponsiveness (aOR 0.80; CI95%: 0.57-1.14). The transient reduction in 
airway symptoms between age 4 and 8 years was only observed in children without 
older siblings.
Conclusion
Early daycare is associated with an increase in airway symptoms until the age of 4 
years, and fewer symptoms between the ages of 4 and 8 years. We found no protection 
against asthma symptoms, hyperresponsiveness or allergic sensitization at the age of 
8 years.
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INTRODUCTION
Will parents who send their children to daycare thereby prevent the development of 
asthma and allergies, at the cost of more airway infections in infancy? Previous studies 
have not been able to give a conclusive answer to this important dilemma.
A preventive effect of daycare attendance on the development of asthma has been 
suggested, based on the hypothesis that infections early in life may reduce the later 
development of allergic diseases.1 Daycare has been consistently associated with 
increased prevalence of infections in early life.2-5 Because daycare is a modifi able factor 
it could be important for asthma prevention programs. However, convincing evidence 
that daycare is indeed associated with a reduction in asthma/allergy on the long term is 
lacking.6-10 The fact that multiple studies reported an increased risk of asthma in children 
with infections in early childhood further adds to the controversy.10-15 
In the Prevention and Incidence of Asthma and Mite Allergy birth cohort, daycare and 
the development of asthma and allergy were assessed prospectively in 3,963 children 
up to 8 years. At 8 years airway hyperresponsiveness and specifi c IgE in serum were 
measured. This enabled us to examine age-specifi c associations between daycare and 
the presence of older siblings on the one hand, and asthma symptoms and allergic sen-
sitization on the other. Some of the results of this study have been previously reported 
in the form of an abstract.16 
METHODS
Study population
Recruitment took place in the years 1996 to 1997. After birth the baseline study popula-
tion consisted of 3,963 children. Questionnaires for parental completion, based on the 
ISAAC core questionnaires17 were sent to the parents during pregnancy, at the child’s 
ages of 3 and 12 months, and yearly thereafter up to the age of 8 years. At 8 years 3,518 
children were invited for venipuncture to assess specifi c IgE for common allergens. 
Also, all children with an allergic mother (n = 988) and a random subset of children 
with a non-allergic mother (n = 566) were invited for a medical examination including 
spirometry and measurement of airway responsiveness by means of a methacholine 
challenge.18 See Figure 3.1 for a population fl ow chart. Details of the Prevention and 
Incidence of Asthma and Mite Allergy study design have been published previously.19 
The study included an intervention part: 416 children (with allergic mother) were given 
house dust mite-impermeable mattress covers. This intervention had no effect on the 
incidence of allergy or respiratory symptoms at 4 or 8 years of age, nor was it associ-
ated with daycare attendance.20 Therefore, we decided to include these children in the 
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present analysis. The study protocol was approved by the medical ethics committees 
of the participating hospitals.
Outcome variables
Parents reported their child’s airway symptoms annually at age 1 to 8 years. Data on 
shortness of breath and prescription of inhaled steroids were collected yearly after the 
age of 2 years. We defi ned the following (dichotomous) outcomes, pertaining to the 
past 12 months:
 Screenings questionnaire in pregnant women (n=10,232)  
    
 Invited pregnant women (n=7,862)  
    
 Agreed with informed consent (n=4,146*)  
    
 Children in study after birth (n=3,963)  
    
 n=3963  
 
  
 
n=3,963 n=3,963 n=3,963 
Questionnaire sent at 8 yrs 
(n=3,653)  
Invited for AHR 
measurement at 8 yrs 
(n=1,554†) 
 
Invited for specific IgE 
measurement at 8 yrs 
(n=3,518) 
      
Questionnaire returned 
(n=3,269)  Participated (n=1,133)  Participated (n=2,214) 
      
Asthma data available 
(n=3,251)  
AHR data available 
(n=938)  
IgE data available 
(n=1,713) 
Non-allergic mother 
Allergic mother 
n=2,238 
n=876 
 Non-allergic mother 
Allergic mother 
n=325 
n=613 
Non-allergic mother 
Allergic mothers 
n=1,060 
n=653 
       
Multiple imputation 
(n=3,963)  
Multiple imputation 
(n=1,554)  
Multiple imputation 
(n=3,518) 
 
Figure 3.1. Population fl ow chart
All 3,963 eligible children could enter each of the 3 arms of fl owchart. *: A total of 1,327 allergic 
mothers (32%) and 2,819 non-allergic mothers (68%) were included, which is a good refl ection 
of the general Dutch population. †: Invited for the hospital-based medical examination, including 
airway hyperresponsiveness (AHR) were all children of allergic mothers (n = 988) and a random 
sample (22%, n = 566) of the children of nonallergic mothers who were still in the study at 8 years 
of age. 
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  · Wheezing: at least one attack of wheezing
  · Inhaled steroid prescription by a medical doctor (after age of 2 yr)
  · Asthma symptoms: at least one attack of wheeze and/or at least one attack of short-
ness of breath and/or a prescription of inhaled steroids (after age of 2 yr)
  · Allergic asthma: asthma symptoms + sensitization to at least 1 airborne allergen (at 
age of 8 yr)
Sensitization to airborne allergens at 8 years was defi ned as specifi c IgE of 0.70 IU/
mL or greater for at least one of the following: house dust mite (Dermatophagoides 
pteronyssinus), cats, dogs, grass pollen (Dactylis glomerata), birch, Alternaria alternata. 
The cutoff was chosen because this was previously shown to be associated with clini-
cal symptoms.21 Frequent respiratory tract infections were defi ned as parental report of 
3 or more serious infections in the past year. Airway responsiveness was determined 
according to the protocol of the European Community Respiratory Health Survey18 and 
airway hyperresponsiveness (AHR) was defi ned as a 20% or greater decrease of FEV1 
at a cumulative dose 0.61 mg methacholine bromide or less. 
Exposures and confounders
Daycare use was assessed yearly and in our fi nal analyses children were divided in 3 
groups: early daycare (fi rst attendance between 0-2 yr), late daycare (fi rst attendance 
between 2-4 yr), and no daycare. Daycare was defi ned as at least 4 hours a week 
in a professional daycare institution, where children were exposed to other children 
under the age of 12 years. The average group size in professional daycare centers in the 
Netherlands is 10 children.22 The presence of siblings was defi ned as having an older 
sibling at time of birth (dichotomous). As potential confounders we defi ned: gender, 
gestational age, birth weight, parental education, ethnicity, mother’s age, maternal al-
lergies/asthma, breastfeeding, smoking during pregnancy, tobacco smoke exposure at 
home, urbanization, presence of pets and single parenthood.
Statistical analyses
Associations of daycare or older siblings with the outcomes at 8 years were analyzed 
by logistic regression. Generalized estimating equations (GEE) were used to study as-
sociations with respiratory outcomes longitudinally, taking into account the correlation 
between repeated measurements in the same individual. Interaction of exposures and 
confounders with age was included in the GEE model when signifi cant, allowing associa-
tions to vary with age. The analyses were stratifi ed for maternal allergy and gender be-
cause these variables were potential effect modifi ers. Also interaction between daycare 
attendance and siblings was tested. Besides a complete case analysis, missing data were 
multiple times imputed to avoid bias, which may result from complete case analysis.23,24 
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The Multivariate Imputation by Chained Equations procedure in the statistical program R 
version 2.6.2 was used.25,26 The 10 imputed datasets were analyzed and results combined 
using PROC MIANALYZE in SAS 9.1 (SAS Institute, Inc., Cary, NC). Data on sensitization 
and AHR were assessed in a subgroup. Therefore separate multiple imputation proce-
dures were performed for these data, creating multiple imputed datasets for reported 
airway symptoms (n = 3,963), specifi c IgE (n = 3,518), and AHR (n = 1,554).
Table 3.1. General characteristics of study population
Characteristic
Baseline population with 
complete data
(n=3,643)
Population with 
early daycare
(n=1,112)
Population without 
early daycare
(n=2,531)
% n % %
Female gender 48.3 1,760 47.3 48.8
Born by caesarean section† 8.5 305 9.5 8.0
Older siblings present* 50.2 1,828 60.2 45.3
Maternal smoking in pregnancy* 16.8 604 14.3 17.9
Smoking in house after birth 
(≥ once per week)*†
27.4 998 23.0 29.3
Breastfeeding ever given*† 82.7 3,013 87.3 80.7
Allergic mother 29.9 1,089 30.0 29.8
Allergic father 30.7 1,119 32.6 29.9
Single parenthood*† 1.1 42 1.9 0.8
Pets present at birth* 53.4 1,937 49.7 55.0
Maternal education level*†
Low 22.7 825 11.4 27.6
Intermediate 41.9 1,528 36.6 44.3
High 35.4 1,290 52.0 28.1
Daycare attendance‡
Early daycare (age 0-2 years) 30.5 1,112 100 -
Late daycare (age 2-4years) 46.9 1,709 - 67.5
No daycare before age 4 22.6 822 - 32.5
Urbanization (address/km2)*†
<1000 33.0 1,202 25.9 36.1
1000-1500 23.3 847 20.1 24.6
>1500 43.7 1,594 54.0 39.3
mean SD mean mean
Maternal age (years)*† 30.4 3.8 31.3 30.0
Duration of pregnancy (weeks)† 39.8 1.7 39.8 39.8
Birth weight child (grams)† 3,517 544 3,502 3,515
Signifi cance of associations between characteristics and exposure variables (daycare/siblings) was 
tested using Chi-square test (categorical variables) or analysis of variance (continuous variables). 
Smoking during pregnancy was considered positive only if mother reported smoking at least 4 
weeks after estimated date of conception. *: Signifi cant association with daycare (p < 0.05). †: 
Signifi cant association with older siblings (p < 0.05). ‡: Defi ned as at least 4 hours per week in a 
daycare centre with other children (under 12 yr of age) present. 
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RESULTS
Study population
Complete data on exposures and confounders was available in 3,643 of the 3,963 chil-
dren (92%). Table 3.1 shows baseline characteristics of this group and their association 
with daycare and older siblings. After 8 years, 92% of the children were still in the 
study. In 1,445 children (36%) a questionnaire-based outcome was missing for at least 
one year. These children were more likely than children with complete data (n = 2,518) 
to have an atopic mother (39 vs. 27%) or a mother with a low level of education (31 vs. 
20%), but less likely to attend daycare before the age of 5 (73 vs. 79%). Data on IgE 
were obtained in 1,713 children (response rate 49%) and data on airway responsive-
ness in 938 children (response rate 60%). The response rates were not associated with 
daycare. To avoid bias resulting from complete case analysis, reported results pertain to 
the multiple imputed datasets. 
Wheezing*
Age, years
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> 4 times/year
Shortness of Breath†
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Figure 3.2. Annual prevalences of wheezing, shortness of breath, inhaled steroid prescriptions, 
and asthma symptoms up to the age of 8 years (n = 3,963)
*: Bars show infrequent (1-3 times, light grey) and frequent (4 or more, dark grey) wheezing 
episodes per year. †: At least one attack of shortness of breath in the past year ‡: Defi ned as at 
least one attack of wheeze, one attack of shortness of breath, or a prescription of inhaled steroids 
in the past year.
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Prevalence of airway symptoms and asthma
Wheezing at least once was reported by 22% at 1 year and showed a linear decline to 
8% at 7 years. (Figure 3.2) Shortness of breath showed a similar time trend, with 16% 
positive at 3 and 9% at 7 years. Prescription rates for inhaled steroids remained stable 
over time, between 8 and 9%. At 8 years, 15% of the children had at least one asthma 
symptom (wheezing, shortness of breath, or the use of inhaled steroids). (Table 3.2) Of 
the invited children, 33.6% was sensitized to 1 or more airborne allergen, and 8.9% had 
allergic asthma. Forty-six per cent with an allergic mother and 38% with a nonallergic 
mother had AHR.
Associations of daycare and siblings with airway symptoms, sensitization 
and AHR
Children with early daycare were twice as likely to experience wheezing in the fi rst year 
of life, compared with children without daycare (adjusted odds ratios [aOR] at 1 year 
1.89; CI95%: 1.50-2.39). The association changed with increasing age; at 5 years there 
was a trend for less wheezing in children with early daycare (aOR 0.83; CI95%: 0.60-1.14). 
At 8 years, early daycare was not associated with wheezing. Figure 3.3 shows the ad-
justed odds ratios of daycare for wheeze, steroid prescription, and asthma symptoms. 
The associations of early and late daycare are plotted with no daycare as reference. The 
outcome “asthma symptoms” was not available at ages 1 and 2 years, but the associa-
tions with daycare at later ages followed the same pattern as for wheeze. We found 
no protective effect from early daycare on asthma symptoms until 8 years (aOR at 8 
years 0.96; CI95%: 0.73-1.29). In the early daycare group a trend for fewer prescriptions 
of inhaled steroids was observed between the ages of 5 and 7 years, but not at 8 years. 
A sensitivity analysis in which stricter outcomes were defi ned as “frequent wheezing 
Table 3.2. Prevalence of outcomes at 8 years and associations with daycare and older siblings
Asthma symptoms§ Sensitization¶ Allergic asthma|| AHR**
Overall prevalence 14.7 %†† n = 429 ‡‡ 33.6 %†† n = 473 ‡‡ 8.9 %†† n = 147‡‡ 43.0 %†† n = 402‡‡
aOR CI95% aOR CI95% aOR CI95% aOR CI95%
aOR* Older siblings† 1.14 (0.92; 1.42) 0.89 (0.73; 1.09) 0.98 (0.69; 1.40) 1.09 (0.81; 1.45)
aOR Early daycare‡ 0.99 (0.74; 1.32) 0.86 (0.63; 1.18) 0.77 (0.53; 1.13) 0.80 (0.57; 1.14)
aOR Late daycare‡ 0.94 (0.72; 1.23) 0.83 (0.65; 1.05) 0.82 (0.60; 1.14) 1.01 (0.82; 1.45)
*: Associations are adjusted for gender, birth weight, breastfeeding, urbanization, age and 
education of mother, history of allergies in mother. †: No older siblings at birth is reference group. ‡: 
No daycare before the age of 4 is reference group. §: Defi ned as at least one attack of wheeze, one 
attack of shortness of breath or a prescription of inhaled steroids in the past year. ¶: Defi ned as a 
specifi c IgE concentration ≥ 0.70 IU/ml for at least one of the tested airborne allergens. ||: Defi ned 
as positive score on both asthma symptoms and sensitization. **Defi ned as a decrease ≥ 20% 
in FEV1 at a cumulative dose of 0.61 mg methacholine. 
††: Percentage of cases based on imputed 
datasets. ‡‡: Absolute number of cases based on complete dataset (not imputed).
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(≥4 episodes per year)” and “doctor’s diagnosis of asthma with asthma symptoms 
past year” led to similar results, without any protective effect of daycare at the age of 
8 years. The associations with late daycare were less pronounced and not statistically 
signifi cant on any outcome. We found the effect of daycare to change gradually with the 
age of fi rst attendance, without a clear window of opportunity. Also when daycare was 
(a) Wheezing at least once
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Figure 3.3. Adjusted odds ratios for longitudinal outcomes of wheezing at least once, inhaled 
steroid prescription, and asthma symptoms
Odds ratios and confi dence intervals for early daycare and late daycare (no daycare is reference) 
for all outcomes, from longitudinal generalized estimating equations model. Estimates adjusted for 
gender, birth weight, breastfeeding, urbanization, age and education of mother, history of allergies 
in mother.
Daan BW 7.indd   63 28-10-10   13:05
CHAPTER 3
64
defi ned as “very early daycare” (attendance before the age of 6 months) we found no 
protective effect on any respiratory outcome at the age of 8 years.
(a) Predicted probability frequent infections  
Age, years
1 2 3 4 5 6 7 8
0.0
0.1
0.2
0.3
0.4
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Early daycare AND siblings
Early daycare, no siblings
No daycare, no siblings
(c) Predicted probability asthma 
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(b) Predicted probability wheezing at least once
Age, years
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Early daycare, no siblings
No daycare, no siblings
Figure 3.4. Predicted probabilities for longitudinal outcomes frequent respiratory infections, 
wheezing at least once, and asthma symptoms 
Three lines represent children with: 1) early daycare and older siblings; 2) early daycare but no 
older siblings; and 3) no daycare and no older siblings. Predicted probabilities are calculated for 
children with: a male gender, a nonallergic mother, breastfeeding ever given, and average values 
for gestational age, birth weight, urbanization, age and education of mother.
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In the fi rst year of life, children with older siblings had more wheezing than fi rst-born 
children (aOR 2.15; CI95%: 1.81-2.56). The strength of the association with wheezing, 
steroid prescriptions, and asthma symptoms decreased linearly with age and disap-
peared at 8 years. The presence of older siblings was not protective for wheeze, inhaled 
steroid prescriptions, or asthma symptoms at any age.
Table 3.2 shows the adjusted associations between daycare, older siblings and the 
clinical outcomes at 8 years. Neither daycare nor the presence of older siblings was 
associated with asthma symptoms, sensitization, allergic asthma, or AHR at 8 years. 
Of the variables tested for confounding, the following changed the point estimate of 
either daycare or siblings, and were controlled for in all analyses: gender, birth weight, 
breastfeeding, urbanization, mother’s age, mother’s education and maternal allergy. We 
found the associations with airway symptoms in the imputed data to be weaker than in 
the complete case data. However, the overall pattern did not change on any outcome. 
Results on sensitization and AHR were not affected by the multiple imputation analysis.
Interactions between daycare and gender, atopy, or siblings
Stratifi ed analyses were performed to investigate effect modifi cation by gender or 
maternal atopy. The effects of daycare and siblings did not differ between boys and 
girls or between children with and without an allergic mother. We found a signifi cant 
interaction between siblings and daycare for wheeze (p < 0.001). In Figure 3.4 the oc-
currence of frequent respiratory infections, wheeze, and asthma symptoms are shown 
for children with early daycare and older siblings (n = 486), with early daycare but no 
older siblings (n = 714), and without daycare and siblings (n = 330). Children with older 
siblings and early daycare had a more than fourfold higher risk of frequent respiratory 
infections and a more than twofold higher risk of wheezing in the fi rst year compared 
with children without older siblings and daycare. After the age of 4 years children with 
early daycare and no older siblings were less likely to wheeze (signifi cant at 5 yr), to 
use inhaled steroids (signifi cant at 6 yr), and to have asthma symptoms (signifi cant at 
age 5 to 7 yr) as compared with those without daycare. At the age of 8 years these 
associations had disappeared. Importantly, children exposed to both early daycare and 
older siblings experienced most infections and symptoms in early childhood, without a 
protective effect on wheeze, inhaled steroid prescription, or asthma symptoms until the 
age of 8 years. Interaction between daycare and older siblings was also signifi cant for 
the outcomes sensitization and allergic asthma. In models allowing for this interaction, 
the associations of daycare and siblings with these outcomes remained not signifi cant 
(Table 3.3).
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DISCUSSION 
We found no evidence for a protective or harmful effect of daycare on the development 
of asthma symptoms, allergic sensitization, or airway hyperresponsiveness at the age 
of 8 years. Early daycare was associated with more airway symptoms until the age 
of 4 years and, only in children without older siblings, with a transient decrease in 
symptoms between 4 and 8 years. Children with early daycare and older siblings had 
the highest prevalence of respiratory symptoms in early childhood, but no decreased 
prevalence of asthma symptoms at any time point.
Since the postulation of the “hygiene hypothesis” by Strachan,1 many studies have 
focused on the relation between daycare and the development of asthma. Studies 
investigating the association between reported respiratory infections in early life and 
development of asthma consistently found no protective effect on asthma.5,10-15,27 
We studied the effect of daycare, which is a proxy for infections.2-5 Studying daycare 
has two important advantages compared to reported infections. Firstly, the relation 
between daycare and asthma is unlikely to be infl uenced by reverse causation. This is 
a problem with reported infections as young children with an asthmatic constitution 
may be more likely to experience symptoms during respiratory infections and to get a 
doctor’s diagnosis of infection. Second, daycare is a feasible target for prevention.
Previous studies investigating the effects of daycare on the risk of asthma were 
mostly cross-sectional and the results differed. Discrepancies can be explained by con-
sidering the results according to age. In early childhood, daycare has been consistently 
associated with more respiratory infections and wheezing.2-4,28,29 Between 3 and 5 years 
no association was found between daycare and asthma.29,30 Between the ages of 4 and 
14 years, a cross-sectional study reported less wheezing and asthma in children who 
Table 3.3. Associations of asthma symptoms and sensitization at 8 years with early daycare 
attendance, allowing interaction by presence of older siblings
Exposures* Asthma symptoms‡ Sensitization§ Allergic asthma¶
Early daycare Siblings aOR† CI95% aOR CI95% aOR CI95%
Yes Yes 1.32 (0.95; 1.83) 0.97 (0.68; 1.37) 1.06 (0.66; 1.68)
Yes No 0.83 (0.61; 1.12) 0.86 (0.66; 1.13) 0.64 (0.43; 0.96)
No Yes 0.99 (0.76; 1.29) 0.82 (0.66; 1.02) 0.81 (0.54; 1.22)
No No 1.00 p = 0.10|| 1.00 p = 0.36|| 1.00 p = 0.18||
*: No older siblings at birth in combination with no early daycare reference category. †: Odds ratios 
are adjusted for gender, birth weight, breastfeeding, urbanization, age and education of mother, 
history of allergies in mother. ‡: Defi ned as at least one attack of wheeze, one attack of shortness 
of breath or a prescription of inhaled steroids in the past year. §: Defi ned as a specifi c IgE 
concentration ≥ 0.70 IU/ml for at least one of the tested airborne allergens. ¶: Defi ned as positive 
score on both asthma symptoms and sensitization. ||: Signifi cance of F-test for combined variable 
(Siblings*Early daycare).
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attended daycare.6 A recent longitudinal study (n = 922) also reported a reduced risk 
of wheezing at 5 years in children with daycare.31 Our data cover a wide age range and 
show a pattern of an early increase in airway symptoms followed by a later reduction. 
Similar results were found in the Tucson Children’s Respiratory Study (n = 1,035) and in 
the Home Allergens and Asthma Study (n = 505).7,32 We observed a reduction in airway 
symptoms associated with early daycare only in children without older siblings, in line 
with earlier reports of interaction between daycare and siblings.3,4,6 
The relationship between daycare and asthma later in childhood is less clear. We 
found no decreased prevalence of asthma symptoms at the age of 8 years in children 
who attended daycare. Similarly, Nafstad and colleagues reported no association be-
tween daycare and asthma at the age of 10 years in the Oslo birth cohort (n = 2,540).10 
A retrospective study in adults aged 20-44 years reported an increased risk of asthma 
associated with daycare attendance.9 In contrast, the Tucson study reported a preven-
tive effect of daycare on the development of asthma lasting up to the age of 13 years.7 
In this study exposure was defi ned as daycare before the age of 6 months and informa-
tion was collected retrospectively around the age of 7 years, introducing the possibility 
of recall bias.7 Furthermore a signifi cant effect on asthma was only reported for the 
combined effects of older siblings and daycare. To our knowledge no prospective study 
has reproduced these fi ndings.
This is the fi rst prospective study to report on the relation between daycare and 
AHR. We found no signifi cant decrease in AHR in children exposed to daycare or older 
siblings in early childhood. The high prevalence of AHR could imply that the cutoff at a 
cumulative dose 0.61 mg or less of methacholine bromide was not strict enough for 
our population. However, in a separate sensitivity analysis where responsiveness was 
defi ned as the dose-response slope (% change in FEV1 in response to total methacho-
line bromide dose), a continuous variable, we found no signifi cant association with early 
daycare. AHR is a feature of asthma,33 and has strong predictive value for the long-term 
prognosis.34,35 The fi ndings that daycare was not associated with asthma symptoms at 
8 years and did not affect AHR strongly support our conclusion that early daycare does 
not prevent asthma.
The relationship between daycare attendance and atopy remains unclear despite 
earlier studies. Several studies reported a lower prevalence of sensitization in children 
with daycare, as measured by skin prick test reactivity7,14,30 or specifi c IgE.14,28 Other 
studies found no signifi cant association,9,10,36,37 or even increased sensitization, after 
daycare.31,38 These studies vary in methodology: some investigated skin tests, others 
specifi c IgE, and different allergies were assessed. Furthermore, the defi nition of day-
care and the age at which outcomes were assessed varied. We found no signifi cant 
effect of daycare or siblings on sensitization measured by the presence of specifi c IgE. 
We found a trend of less asthma with sensitization in children with early daycare, and 
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without siblings. Likewise, Krämer and colleagues reported lower rates of sensitization 
and asthma associated with early daycare in a cross-sectional study in Eastern Ger-
many, in a subgroup of children without siblings.6 Possibly children with older siblings 
are already exposed to more infections early in life, reducing any additional effects 
of daycare. However, if infections would protect, one would expect a dose-response 
relationship with the largest protection in children with the highest microbial burden at 
an early age. Our results show that children with older siblings and early daycare indeed 
experienced most infections in infancy, but did not develop less asthma or sensitiza-
tion, thus arguing against a causal relationship.
Strong points of our study are the large cohort with a prospective design, long 
follow-up with very good compliance, and collection of objective data including AHR 
and specifi c IgE. Because the study population is a fairly random representation of the 
Dutch population, our results can be generalized. However, in the population invited 
for AHR measurement there was an overrepresentation of children with an allergic 
mother. Because we found no interaction by allergy of the mother on the association 
between daycare and AHR, this does not compromise generalizability of our fi ndings. 
There is evidence that the age of entry into daycare may infl uence the natural course 
of asthma.6,31 It has been suggested that a window of opportunity exists earlier in 
life, (e.g., in the fi rst 6 months of life).7 We found no support for this in our data. Early 
daycare was defi ned as attendance before the age of 2 years, but the majority of these 
children (59%) visited daycare before the age of 6 months. Also, when the defi nition 
was limited to attendance before the age of 6 months there was no signifi cant associa-
tion with any of the studied outcomes at 8 years. 
Some limitations should be considered in the interpretation of our results. First, in 
the absence of a gold standard, the defi nition for asthma remains arbitrary. Apart from 
the sensitive defi nition “asthma symptoms” we performed sensitivity analyses with 
outcomes “frequent wheezing (≥4 times/year)” and “doctor’s diagnosis of asthma with 
asthma symptoms past year”. Early daycare was associated with a higher prevalence 
of all these outcomes in the fi rst years of life, but there was no association at the age 
of 8 years. Second, airway symptoms were based on parental reports. Especially at 
early ages this may have led to some misclassifi cation. Most likely any misclassifi ca-
tion would be independent of the exposure to daycare (i.e., nondifferential), causing 
underestimation of the effect. Because we found strong correlations especially in the 
fi rst years of life, we consider it unlikely that our results have been biased by misclas-
sifi cation of early symptoms. Parents with an atopic history may report wheeze more 
accurately and this could infl uence our results. However, we found that atopy of the 
mother had no confounding effect nor did it modify the effect of daycare on any of the 
outcomes. Furthermore it should be realized that apart from early infections, multiple 
other pathways might explain a relation between daycare and later asthma symptoms. 
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Finally, children were followed up to the age of 8 years. Strictly, we can therefore not 
exclude a protective effect of early daycare on symptoms at later ages. Our data are not 
suggestive of such an effect.
What are the practical implications of our fi ndings? We found that early daycare is 
associated with a transient decrease in wheezing after the age of 4 years, but not 
with the development of allergic sensitization, AHR, or asthma symptoms at 8 years. 
Apparently, the incidence of asthma cannot be reduced by promoting early daycare 
attendance. Early daycare merely seems to shift the burden of respiratory morbidity to 
an earlier age, where it is more troublesome than at a later age. Hence, early daycare 
should not be promoted for reasons of preventing asthma and allergy.
CONCLUSION
Early daycare is associated with an increase in airway symptoms until the age of 4 
years, and fewer symptoms between 4 and 8 years. We found no protection against 
asthma symptoms, hyperresponsiveness, or allergic sensitization at the age of 8 years.
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ABSTRACT
Rationale
A novel data-driven approach was used to identify wheezing phenotypes in preschool 
children aged 0-8 years, in the PIAMA birth cohort. Five phenotypes were identifi ed: 
never/infrequent wheeze, transient early wheeze, intermediate onset wheeze, persis-
tent wheeze, and late onset wheeze. It is unclear whether these phenotypes have 
different perinatal risk factors. 
Objectives
To assess the associations of wheezing phenotypes with perinatal factors, and to 
identify possible targets for prevention.
Methods
In the PIAMA study (n = 3,963) perinatal factors were collected at 3 months, and 
wheezing was assessed annually until the age of 8 years. Associations between the 5 
wheezing phenotypes and perinatal risk factors were assessed using weighted multi-
nomial logistic regression models. Odds ratios were adjusted for confounding variables 
and calculated with ‘never/infrequent wheeze’ as the reference category.
Results
Complete data on outcome and all confounding variables were available for 2,728 
children. Risk factors for transient early wheeze (n = 455) were male gender, maternal 
and paternal allergy, low maternal age, high maternal body mass index, short preg-
nancy duration, smoking during pregnancy, presence of older siblings, and daycare 
attendance. Risk factors for persistent wheeze (n = 83) were male gender, maternal 
and paternal allergy, and not receiving breastfeeding for at least 12 weeks. Intermediate 
onset wheeze (n = 98) was associated with a lower birth weight and late onset wheeze 
(n = 45) with maternal allergy. 
Conclusion
The association with perinatal factors varied between different wheezing phenotypes, 
which suggests different underlying pathophysiology. Some of the identifi ed risk fac-
tors are modifi able and may be important targets for prevention programs.
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INTRODUCTION
The rapid rise in asthma prevalence at the end of the last century is most likely caused 
by a change in environmental factors, affecting individuals with a genetic susceptibility 
for asthma. A crucial window for the effect of such environmental factors appears to 
exist in prenatal and early postnatal life.1 Understanding the mechanisms of asthma 
development is essential in order to fi nd targets for primary prevention. Unfortunately, 
conclusive evidence on the relevant major risk factors is still lacking. A likely explanation 
for contradictory fi ndings in previous studies is that ‘childhood asthma’ does not refer 
to a single disease entity, but comprises several distinct wheezing phenotypes, each of 
which may have different risk factors.2
Much effort has been put in identifying different wheezing phenotypes. Martinez et al 
described longitudinal patterns of ‘transient early’, ‘persistent’ and ‘late onset’ wheeze, 
based on reported symptoms between the ages of 0-3 and 3-6 years.3 Henderson et 
al more recently used longitudinal latent class analysis to identify different wheezing 
phenotypes in the Avon Longitudinal Study of Parents And Children (ALSPAC), where 
wheeze was reported repeatedly from birth until 8 yrs.4 The same analysis was ap-
plied in the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) study, and 5 
wheezing phenotypes with similar characteristics as in the ALSPAC study were found, 
supporting their validity.5 
The aim of the present study was to investigate pre- and perinatal risk factors for 
wheezing phenotypes in the PIAMA study. If specifi c wheezing illnesses are associated 
with different risk factors, this would support the hypothesis that they have a differential 
etiology and pathophysiology. Understanding of these complex associations may lead 
to the discovery of targets for primary prevention of specifi c wheezing illnesses during 
childhood.
METHODS
Study population
The PIAMA study is a prospective birth cohort study in Western, middle and Northern 
areas of the Netherlands. Recruitment took place in the years 1996 and 1997. The base-
line study population consisted of 3,963 children. Questionnaires for parental comple-
tion, based on the ISAAC core questionnaires were sent during pregnancy, at 3 months, 
and yearly after birth up to the age of 8 years. More details of the PIAMA study design 
are given in the online supplement and have been published previously.6 The study 
protocol was approved by the medical ethics committees of the participating hospitals.
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Phenotypes of wheeze
Wheeze was assessed annually with the question: “Has your child had wheezing or 
whistling in the chest in the last 12 months?” at the age of 1 to 8 years, and answered 
with yes or no. Therefore 28 = 256 different longitudinal patterns of wheeze were pos-
sible. In order to identify children with similar patterns of wheeze over time, longitudinal 
latent class analysis (LLCA) was used. With LLCA wheezing phenotypes were derived 
in the PIAMA and the ALSPAC birth cohort, and results were previously reported.4,5 The 
derived phenotypes in these independent cohorts were comparable, supporting the 
validity of the phenotypes.5 Including only children with complete data on wheezing at 
every age in the PIAMA cohort, the following fi ve phenotypes of wheeze were identi-
fi ed: never/infrequent wheeze, early wheeze, intermediate onset wheeze, persistent 
wheeze and late onset wheeze.
Perinatal factors
Candidate perinatal risk factors were selected based on previous literature and avail-
ability within our dataset, and included parental characteristics (n = 5), child character-
istics (n = 5), prenatal exposures (n = 3), and postnatal exposures (n = 6). Apart from 
exposure to fi ne particulate matter (PM2.5) and study region, all investigated risk factors 
were defi ned using questionnaire data. Maternal age, maternal body mass index (BMI), 
pregnancy duration, birth weight, and exposure to PM2.5 were included as continuous 
variables. Maternal BMI was calculated on the basis of maternal height and weight 
before pregnancy, as reported by the mother. Study region was considered a possible 
confounder and included as a variable with 4 categories. All other items were analyzed 
as dichotomous variables. High educational level was defi ned as a completed bachelor 
and/or master study. Breastfeeding was defi ned positive if the child was breastfed for at 
least 12 weeks. Individual exposure to PM2.5 was assessed as the annual average con-
centrations at the birth address, and estimated by land-use regression models. These 
models were based on four two-week measurements of PM2.5 at 40 sites throughout 
the study area, and details were previously described.7 A detailed defi nition of all peri-
natal factors is given in the online supplement.
Statistical analysis
All analyses were carried out using SAS 9.1 (SAS Institute, Inc., Cary, NC). The as-
sociation between phenotypes of wheeze and all perinatal factors was investigated 
using a weighted multinomial logistic regression model (SAS PROC CATMOD). The 
analyses were weighted for the probability that a child belonged to a certain phenotype 
(individual posterior membership probability), to minimize bias due to misclassifi cation 
of the wheezing phenotypes. All factors were inspected adjusting for gender. Secondly, 
multivariable models were built, adjusted for the following confounding variables (based 
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on literature and correlations within our dataset): gender, parental allergy, pre- and 
postnatal smoke exposure, breastfeeding, daycare, pregnancy duration, older siblings, 
birth weight, maternal age, study region, parental level of education. Finally, modifi ca-
tion of the associations between all perinatal factors and wheezing phenotypes was 
investigated for gender of the child, and maternal allergy. These factors were selected, 
because interaction of gender and maternal allergy with several other perinatal factors 
has been previously reported.8-10
Screenings questionnaire in pregnant women (n=10,232) 
  
 Invited pregnant women (n=7,862)  
Allergic mothers 
n=876 
Non-allergic mothers 
 n=2,238 
 
 
 Agreed with informed consent (n=4,146)  
   
  n=183 lost to follow-up 
before birth*   
   
 Children in study after birth (n=3,963)  
   
  Lost to follow-up†  
before age 4 yrs: n=151 
at 5 yrs: n=75 
at 6 yrs: n=39 
at 7 yrs: n=55 
at 8 yrs: n=22 
  
   
 In follow-up at 8 yrs (n=3,614)  
   
  1 questionnaires missing 
at age 1-8 yrs (n=843)   
   
 Wheezing data available at every age from 1-8 yrs (n=2,810)  
 
Figure 4.1. Population Flow Chart
*: Lost to follow-up due to various reasons; perinatal death, language barrier, not interested, 
moved, etc. †: Various reasons (e.g. moved, personal reasons, repeated non-response without 
known reason).
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RESULTS
Study population
Of the 3963 children included at baseline 3,614 were still in follow-up at 8 years and 
2,810 (71%) had complete data on wheezing at every single year. This was taken as 
the study population for the present analyses. A detailed fl owchart is presented in 
Figure 4.1. Table 4.1 shows general characteristics of the study population (n = 2,810). 
This population was comparable to the baseline population (n = 3,963) with respect 
Tables 4.1. Description of the study population
Variable n / N %
General characteristic
Female gender 1,360 / 2,810 48.4
Allergic mother 750 / 2,810 26.7
Allergic father 850 / 2,810 30.3
Maternal education (% high) 1,046 / 2,807 37.3
Paternal education (% high) 1,166 / 2,792 41.8
Study region
North 891 / 2,810 31.7
Middle 765 / 2,810 27.2
East 426 / 2,810 16.2
West 728 / 2,810 25.9
Maternal smoking during pregnancy 421 / 2,780 15.1
Premature birth (<37 wks) 131 / 2,805 4.7
Low birth weight (<2500 g) 89 / 2,805 3.1
Breastfeeding ever given 2,334 / 2,789 83.7
Older siblings present (≥1) 1419 / 2,810 50.5
mean / N IQR
Maternal age (yrs) 30.7 / 2,804 5.0
Maternal body mass index (kg/m2) 22.8 / 2,626 3.7
Particulate matter (PM2.5) (ug/m
3) 16.9 / 2,806 2.0
Health outcomes at 8 yrs n / N %
Wheezing phenotype*
Never/infrequent 2,109 / 2,810 75.0
Transient early 470 / 2,810 16.7
Intermediate onset 85/ 2,810 3.1
Persistent 99 / 2,810 3.5
Late onset 47 / 2,810 1.7
Allergic sensitization inhaled allergens† 389 / 1,434 27.1
*: Frequency (n) of each wheezing phenotype is calculated as the sum of the membership 
probability of all children for that phenotype. †: Defi ned as specifi c IgE concentration ≥ 0.7 IU/ml for 
at least one of the following inhaled allergens: house dust mite (Dermatophagoides pteronyssinus), 
cats, dogs, grass pollen (Dactylis glomerata), birch, Alternaria alternata.
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to gender, prematurity, birth weight, older siblings and allergy of the father. However, 
children in the study population had parents with a higher level of education, more 
often received breastfeeding and were less likely to have a mother who smoked during 
pregnancy, compared to the children who were excluded. The percentage of missing 
data on perinatal factors in the study population was less than 1% for all variables, 
apart from maternal BMI, which had 6.5% missings. In the multivariable analysis 13 
potentially confounding variables were included. Eighty-two children (2.4%) had a miss-
ing value for at least one of these variables.
Wheezing phenotypes
The percentages of children for each phenotype are presented in Table 4.1. Seventy-
fi ve percent of all children belonged to the group that never/infrequently wheezed. 
Of the children who wheezed, the largest group had transient early wheeze (16.7%), 
late onset wheeze being the least prevalent phenotype (1.7%). Figure 4.2 depicts the 
age-specifi c probability of wheeze for all phenotypes.
Age (years)
1 2 3 4 5 6 7 8
P
ro
ba
bi
lit
y 
of
 w
he
ez
e
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Never/Infrequent wheeze (75.0%)
Transient early wheeze (16.7%)
Intermediate onset wheeze (3.1%)
Persistent wheeze (3.5%)
Late onset wheeze (1.7%)
 
Figure 4.2. Probability of wheeze at each time point from birth to age 8 years for each wheezing 
phenotype in PIAMA (N = 2,810)
Prevalence of the phenotypes is shown next to the phenotypes in the legend. Figure from Savenije 
& Granell et al,5 with adjustments
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Association of perinatal risk factors with wheezing phenotypes
Parental risk factors
A family history of allergy was signifi cantly associated with a higher risk of transient 
early wheeze, persistent wheeze and late onset wheeze, but not intermediate onset 
wheeze (Table 4.2). A higher maternal body mass index (BMI) was signifi cantly associ-
ated with more transient and persistent wheezing.
Child characteristics
Gender, birth weight, pregnancy duration and admittance to a hospital after birth were 
associated with at least one wheezing phenotype, but caesarean section was not. 
Boys more often had transient early and persistent wheeze than girls. Children with a 
lower birth weight were more likely to develop transient early and intermediate onset 
wheeze. A short pregnancy duration and admittance to a hospital after birth were both 
associated with more transient early wheeze. 
Prenatal exposures
Smoking during pregnancy was the only prenatal exposure variable linked with a wheez-
ing phenotype. It signifi cantly increased the risk for transient early wheeze, and had a 
non-signifi cant trend for more persistent wheeze with a similar odds ratio. (Table 4.3)
Postnatal exposures
Breast feeding for at least 12 weeks signifi cantly decreased the risk of persistent 
wheeze, while older siblings and daycare attendance in the fi rst year increased the risk 
of transient early wheeze. Environmental tobacco smoke did not signifi cantly increase 
the risk of any wheezing phenotype. Air pollution as measured by PM2.5 appeared to be 
associated with phenotypes with a higher probability of wheezing, especially interme-
diate onset and persistent, but this was not signifi cant.
Multivariable analyses
In order to exclude confounding by correlated risk factors for wheezing we performed 
a multivariable analysis. All factors that remained signifi cantly associated with one 
or more wheezing phenotypes are presented in fi gure 4.3. In the adjusted analysis 
a parental history of allergy and male gender remained the strongest risk factors for 
wheezing during childhood, and were signifi cantly associated with more transient early 
and persistent wheeze. Two modifi able maternal factors were also associated with 
wheezing phenotypes. First, children from an older mother were less likely to develop 
transient early wheeze, but tended to develop more late onset wheeze. Second, a 
high maternal BMI was signifi cantly associated with more transient early wheeze and 
Daan BW 7.indd   80 28-10-10   13:05
81
PERINATAL RISK FACTORS FOR WHEEZING PHENOTYPES
C
H
A
P
T
E
R
 4
borderline signifi cantly associated with persistent wheeze. Low birth weight remained 
strongly associated only with intermediate onset wheeze, and a short pregnancy with 
more transient early wheeze. Smoking during pregnancy, older siblings and daycare 
Table 4.2. Crude associations of parental and child characteristics at birth with wheezing 
phenotypes
Never/ infrequent 
wheeze (n=2109)
Transient Early 
wheeze (n=470)
Intermediate 
Onset wheeze 
(n=85)
Persistent wheeze 
(n=99)
Late Onset 
wheeze (n=47)
Parental characteristics
Maternal allergy*
Frequency, % 24.8 29.5 32.8 40.4 45.0
OR (CI95%) 1.27 (1.02-1.59)
† 1.49 (0.93-2.36) 2.06 (1.36-3.12)† 2.49 (1.39-4.47)†
Paternal allergy*
Frequency, % 28.1 36.2 32.7 40.2 42.3
OR (CI95%) 1.46 (1.18-1.80)
† 1.25 (0.79-1.99) 1.74 (1.15-2.63)† 1.88 (1.05-3.34)†
Parental educational level (≥1 parent high level)
Frequency, % 53.5 51.2 51.1 50.3 21.8
OR (CI95%) 0.91 (0.74-1.11) 0.91 (0.59-1.40) 0.87 (0.58-1.31) 0.76 (0.42-1.35)
Age mother‡
Average 30.7 30.4 30.3 30.7 31.1
OR (CI95%) 0.90 (0.79-1.03) 0.83 (0.62-1.11) 1.00 (0.76-1.30) 1.14 (0.78-1.68)
Body Mass Index mother (kg/m2) ‡§
Average 22.7 23.1 23.0 23.4 23.0
OR (CI95%) 1.16 (1.03-1.30)
† 1.10 (0.86-1.42) 1.26 (1.01-1.57)† 1.10 (0.79-1.53)
Child characteristics
Gender (male)
Frequency, % 50.7 57.8 57.1 66.7 51.7
OR (CI95%) 1.41 (1.15-1.73)
† 1.37 (0.89-2.12) 2.06 (1.34-3.16)† 1.10 (0.62-1.96)
Birth weight (per kg)
Average 3.55 3.48 3.42 3.55 3.48
OR (CI95%) 0.75 (0.63-0.91)
† 0.63 (0.43-0.93)† 0.91 (0.62-1.33) 0.77 (0.45-1.33)
Pregnancy duration (per week)
Average 40.0 39.6 39.8 39.7 39.8
OR (CI95%) 0.87 (0.82-0.92)
† 0.97 (0.85-1.11) 0.91 (0.81-1.02) 0.96 (0.80-1.15)
Caesarian section
Frequency, % 8.6 8.1 8.9 8.6 9.3
OR (CI95%) 0.92 (0.64-1.33) 1.03 (0.48-2.20) 0.96 (0.47-1.99) 1.08 (0.39-3.00)
Admitted to hospital after birth
Frequency, % 11.2 15.4 13.0 12.6 13.4
OR (CI95%) 1.41 (1.06-1.70)
† 1.16 (0.61-2.22) 1.09 (0.59-2.02) 1.22 (0.51-2.90)
Never/ infrequent wheeze is reference category, all analyses were weighted for the probability 
that a child belongs to a certain phenotype (individual posterior membership probabilities). All odds 
ratios adjusted for gender, not for other possible confounders. OR (CI95%); Odds ratio with 95% 
confi dence interval. *: Defi ned positive if any of the following items were reported: asthma, hay 
fever, house dust allergy, house dust mite allergy, or pet allergy. †: Associations with a signifi cance 
level of p < 0.05. ‡: Odds ratio expressed per inter quartile range increase. §: Based on reported 
maternal weight and height before pregnancy.
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attendance remained signifi cantly associated with a higher risk of transient early 
wheeze. Breastfeeding for at least 12 weeks was the only signifi cant protective factor 
for persistent wheeze. 
Effect modifi cation was tested for gender as well as maternal allergy on all perinatal 
factors listed in Table 4.2 and 4.3, but no signifi cant interaction was found for any of 
these factors.
Table 4.3. Crude associations of perinatal exposures with wheezing phenotypes
Never/ 
infrequent 
wheeze (n=2109)
Transient Early 
wheeze (n=470)
Intermediate 
Onset wheeze 
(n=85)
Persistent 
wheeze (n=99)
Late Onset 
wheeze (n=47)
Prenatal exposures
Smoking mother during pregnancy*
Frequency, % 13.9 19.5 18.1 19.1 13.7
OR (CI95%) 1.51 (1.16-1.96)
† 1.37 (0.78-2.42) 1.48 (0.88-2.48) 0.99 (0.42-2.30)
Antibiotics by mother during pregnancy*
Frequency, % 8.8 9.7 7.0 10.7 6.7
OR (CI95%) 1.12 (0.80-1.58) 0.79 (0.34-1.84) 1.26 (0.65-2.43) 0.75 (0.23-2.37)
Meconium in amniotic fl uid
Frequency, % 19.7 17.4 17.8 20.5 21.9
OR (CI95%) 0.86 (0.65-1.15) 0.88 (0.47-1.66) 1.07 (0.61-1.85) 1.14 (0.52-2.50)
Early postnatal exposures
Breastfeeding at least 3 months
Frequency, % 48.8 43.6 43.3 36.3 43.3
OR (CI95%) 0.82 (0.67-1.01) 0.81 (0.52-1.25) 0.61 (0.40-0.93)
† 0.80 (0.45-1.44)
Older siblings present (≥1)
Frequency, % 49.3 56.2 45.5 55.7 45.2
OR (CI95%) 1.31 (1.07-1.60)
† 0.85 (0.55-1.32) 1.28 (0.85-1.92) 0.85 (0.47-1.52)
Daycare attendance in fi rst year
Frequency, % 24.3 31.5 20.5 19.2 18.3
OR (CI95%) 1.42 (1.14-1.77)
† 0.80 (0.47-1.37) 0.73 (0.44-1.22) 0.70 (0.33-1.47)
Environmental tobacco smoke exposure‡
Frequency,% 24.5 26.4 27.2 29.4 20.7
OR (CI95%) 1.11 (0.88-1.39) 1.15 (0.70-1.87) 1.29 (0.83-2.01) 0.80 (0.39-1.64)
Pets at 3 months
Frequency, % 50.0 48.4 50.6 56.2 39.2
OR (CI95%) 0.94 (0.77-1.15) 1.02 (0.66-1.58) 1.28 (0.85-1.92) 0.65 (0.36-1.17)
Particulate matter (PM2.5) at birth address (ug/m
3)§
Average 16.8 17.0 17.1 17.1 17.0
OR (CI95%) 1.15 (0.97-1.35) 1.26 (0.88-1.80) 1.28 (0.92-1.79) 1.17 (0.73-1.88)
Never/ infrequent wheeze is reference category, all analyses were weighted for the probability 
that a child belongs to a certain phenotype (individual posterior membership probabilities). All 
odds ratios adjusted for gender, not for other possible confounders. OR (CI95%); Odds ratio with 
95% confi dence interval. *: Based on parental reports during second trimester of pregnancy. †: 
Associations with a signifi cance level of p < 0.05. ‡: In the child’s house; more than 1 cigarette per 
week. §: Odds ratio expressed per inter quartile range increase in PM2.5 concentration.
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 Odds ratio 'Late onset wheeze'
0.3 0.5 0.7 1.0 1.5 2.0 3.0 5.0
(d) Late onset wheeze
increased riskdecreased risk
Odds ratio 'Persistent wheeze'
0.3 0.5 0.7 1.0 1.5 2.0 3.0 5.0
Daycare 1st yr
Older sibling present
Breastfeeding > 3 mo
Smoking in pregnancy
Pregnancy duration (wks)
Birth weight (kgs)
Gender (male)
BMI mother (kg/m2)†‡
Age mother (yrs)†
Allergy father*
Allergy mother*
(c) Persistent wheeze
increased riskdecreased risk
Odds ratio 'Intermediate onset wheeze'
0.3 0.5 0.7 1.0 1.5 2.0 3.0 5.0
increased riskdecreased risk
(b) Intermediate onset wheeze
Odds ratio 'Transient early wheeze'
0.3 0.5 0.7 1.0 1.5 2.0 3.0 5.0
Daycare 1st yr
Older sibling present
Breastfeeding > 3 mo
Smoking in pregnancy
Pregnancy duration (wks)
Birth weight (kgs)
Gender (male)
BMI mother (kg/m2)†‡
Age mother (yrs)†
Allergy father*
Allergy mother*
(a) Transient early wheeze
increased riskdecreased risk
Figure 4.3. Odds ratios of perinatal risk factors after multivariable adjustment
Never/ infrequent wheeze is reference category, all analyses were weighted for the probability 
that a child belongs to a certain phenotype (individual posterior membership probabilities). Total N 
= 2,728. *: Defi ned positive if any of the following items were reported: asthma, hay fever, house 
dust allergy, house dust mite allergy, or pet allergy. †: Odds ratios given per interquartile range 
increase. ‡: Body Mass Index. 
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DISCUSSION
Wheezing phenotypes were differentially and sometimes uniquely associated with 
perinatal risk factors. Compared to children with never/infrequent wheeze, interme-
diate onset wheeze occurred signifi cantly more often in children with a lower birth 
weight and persistent wheeze in children who were not breastfed for at least 12 weeks. 
Transient early wheeze was associated with a wider range of modifi able pre- and post-
natal risk factors, namely maternal age, maternal BMI, pregnancy duration, smoking 
during pregnancy, and daycare attendance in the fi rst year. These fi ndings support the 
hypothesis that different longitudinal wheezing patterns may have different underlying 
pathophysiologies. Furthermore these risk factors are modifi able and may therefore be 
important targets for future prevention programs.
Risk factors for transient early wheeze
The phenotype transient early wheeze was associated with several perinatal factors, 
including a family history of allergy, in line with two previous studies on wheezing 
phenotypes.11,12 A possible explanation for the association between parental asthma 
and transient wheeze in their offspring, could be that these transient wheezers are at 
increased risk of developing asthma symptoms again at adult age. A long term follow-
up of transient early wheezers confi rmed this hypothesis, and suggested it may be 
explained by tracking of a lower lung function into adulthood.13,14
Multiple modifi able factors were associated with transient wheezing, among which 
low maternal age and high maternal BMI. Both factors are strongly correlated with 
socioeconomic status, which may explain part of the association. However, the fact that 
the relations were signifi cant after adjustment for a wide range of possible potential 
confounders, indicates that a more direct effect may be present as well. A recent study 
reported maternal obesity as an independent risk factor for wheezing in early childhood: 
the authors acknowledged the possibility of residual confounding, but hypothesized 
that in utero exposure to systemic infl ammation in obesity may infl uence the develop-
ing immune system of the child.15 Another explanation for the association could be that 
maternal obesity is linked to obesity in their offspring, which may be an independent 
risk factor for the wheezing symptoms.16 Previous studies consistently linked low 
maternal age with an increased risk of wheezing in childhood, speculating this could be 
explained by both social and biological factors.17,18
Daycare attendance and the presence of older siblings were both associated with 
transient early wheeze, probably because they increase the risk of respiratory infec-
tions.19,20 Daycare attendance is a modifi able factor and given its strong association with 
transient early wheeze it is a possible candidate for prevention strategies. Importantly, 
daycare attendance seems to cause a shift in the burden of wheezing illness to an 
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earlier age. The signifi cant increase in transient early wheezing is accompanied by a 
non-signifi cant trend for less late onset wheeze.11,12 Unfortunately, this does not neces-
sarily imply that daycare causes a long-lasting preventive effect on wheezing, as we 
have previously shown using the PIAMA data.19 
Smoking during pregnancy has been consistently reported as a prenatal risk factor 
for childhood wheezing.21 Most studies found a positive association with transient 
early and/or persistent wheeze.12,22-24 Our results are consistent with this in part, and 
show that in utero smoke exposure was most strongly associated with transient early 
wheeze. An association with persistent wheeze was not demonstrated in our data. 
Previous animal studies have demonstrated that tobacco smoke can have a direct nega-
tive infl uence on lung growth and maturation.25 Apart from this direct effect, prenatal 
smoking may indirectly cause morbidity mediated by a lower birth weight. We here 
reported the independent effect of smoking, adjusted for birth weight. Avoidance of 
prenatal smoking may be a promising preventive interventions as it could lead to a 
reduction in the prevalence of transient early wheeze and at the same time reduce the 
prevalence of low birth weight, which appears to be associated with intermediate onset 
wheeze.
Risk factors for intermediate onset wheeze
A lower birth weight was the only signifi cant risk factors for intermediate onset wheeze. 
Birth weight cannot be directly infl uenced, but several modifi able factors have been re-
ported to infl uence birth weight, most notably smoking during pregnancy.26 We cannot 
easily compare our fi ndings with other studies, because the outcome of intermediate 
onset wheeze was not used previously. Confl icting results on the effect of birth weight 
on wheezing and asthma in previous studies may well have been caused by differences 
in outcome defi nitions, particularly the age of outcome assessment.27-29 Intermediate 
onset wheeze was fi rst described in the ALSPAC study and an independent analysis 
of the PIAMA data revealed a group of children with a similar pattern of wheeze.4,5 
The clear differences between risk factors for intermediate onset and other wheezing 
phenotypes may imply a different underlying pathophysiology. Possibly children with a 
lower birth weight are prone to wheezing due to disturbed airway growth and, hence, 
smaller airways. The fact that the prevalence of wheezing decreases in this group 
after the age of 5 years fi ts well with this hypothesis, because children may become 
less susceptible for wheezing illnesses when their airways increase in size.3 Why this 
specifi c phenotype becomes manifest after a symptom-free interval of several years 
remains to be elucidated.
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Risk factors for persistent wheeze
For persistent wheeze the most striking risk factor was parental allergy, in line with previous 
literature.3,11,12,22,23 Another fi nding consistent with previous literature is that in the studied 
age range boys were twice more likely to have persistent wheeze than girls.3,11,23 Contro-
versy exists about the effects of breastfeeding.30,31 We found that breastfeeding for at least 
3 months signifi cantly reduced the risk of persistent wheezing for at least 8 years, with an 
odds ratio of 0.6 (p = 0.03). Odds ratios for other wheezing phenotypes were non-signif-
icant, but all showed a trend towards protection. This implies that breastfeeding reduces 
the overall prevalence of wheezing, rather than causing a shift in age of onset. Therefore 
breastfeeding remains an important target in the prevention of asthma symptoms in the 
fi rst 8 years of life. Previous studies suggested that there is interaction between breast-
feeding, maternal allergy, and the risk of asthma. We did not fi nd evidence for this, in line 
with a previous paper on breastfeeding and childhood asthma using PIAMA data.30 Multiple 
pathways could explain the lower risk of wheezing in breastfed children. Breast milk may 
infl uence the infant’s immune system directly by immunomodulatory factors, or indirectly 
by affecting the infant’s mucosal maturation and thereby the intestinal microfl ora.32,33 
Risk factors for late onset wheeze
In the multivariate analyses maternal allergy was the only signifi cant risk factors for late 
onset wheeze, paternal allergy was borderline signifi cant. No modifi able risk factors for 
late onset wheeze were detected. This stresses the importance of genetic constitu-
tion in the development of late onset wheeze, but also suggests a lack of perinatal 
targets for the prevention of it. However, it should be noted that the small sample size 
may have reduced the power to detect any signifi cant differences. To estimate long-
term benefi ts of any preventive strategies, follow-up is needed to know which of the 
wheezing phenotypes is most strongly related with asthma symptoms in adolescence 
and/or adulthood. Late-onset wheezers are often considered as true asthmatics,34 but 
follow-up of the Tucson cohort has shown that persistent wheezers may actually be 
more likely to become asthmatic adults than those with late onset wheeze.14
The possible impact of an intervention on a risk factor depends not only on its odds 
ratio, but also on the prevalence of a risk factor in the population. The attributable fraction 
(AF) takes this into account, and is given in the online supplement. (Table E4.1) The AF of 
a risk factor is ‘the proportion of children with a specifi c wheezing phenotype that could 
be prevented by eliminating the risk factor from the population’, but it is likely an overes-
timation of the actual effect of an intervention on this risk factor. Therefore interventions 
on the risk factors for transient early wheeze given in Table E4.1 will have only a limited 
impact, with <10% reduction in transient early wheeze. Breastfeeding had the highest 
AF of all modifi able risk factors (25.6%), suggesting that it may indeed be the single 
most important target for interventions to reduce the prevalence of persistent wheeze.
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Strengths of the current study are the large sample size with high follow-up rate, and 
the longitudinal design. Regular follow-up with annual questionnaires that start before 
birth, eliminated the risk of recall bias. Such bias may have affected the results of the 
few previous studies investigating risk factors for wheezing phenotypes.12,22,24,31 We 
used an unbiased and data driven approach to prospectively identify several distinct 
wheezing phenotypes within our cohort. The use of annual recordings of wheeze al-
lowed us to detect new wheezing phenotypes, in a period that wheezing prevalence 
changes rapidly. Correct classifi cation of wheezing phenotypes remains crucial to 
understand the complex associations with a wide range of perinatal risk factors.
Some considerations should be made when interpreting our results. We found differen-
tial associations with the wheezing phenotypes, suggesting different pathophysiologies. 
Causality however cannot be proven using observational data. We adjusted our results 
for many possible confounders, but we cannot exclude that some unknown or residual 
confounding infl uenced the results. Furthermore, despite the large size of the PIAMA 
birth cohort, relatively few children were classifi ed as late onset wheezers, with limited 
power to detect signifi cant associations with perinatal risk factors. To a lesser extent this 
may have also affected the results for intermediate onset and persistent wheeze. 
We found different patterns of risk factors for the wheezing phenotypes, and this could 
imply that these phenotypes are indeed different disease entities, with different patho-
physiologies. This should be taken into account in the search for prevention strategies. 
Our data show that most modifi able risk factors may have an infl uence on transient early 
wheeze. Prevention of transient early wheeze will have the biggest impact on symptoms 
in the fi rst years of life. It is the most prevalent wheezing phenotype and there is evidence 
that these children are at increased risk for adult asthma as well.14 Prenatal smoking is 
a promising target for prevention, as it was associated with transient early wheeze and 
simultaneously causes a lower birth weight, which may lead to more intermediate onset 
wheeze. The promotion of breastfeeding for at least 3 months could have a large impact 
on persistent wheeze, which has a high risk of chronic asthma lasting into adulthood.14
In conclusion, we found that the association of perinatal factors with wheezing pheno-
types was not the same for different phenotypes. This suggests that the underlying patho-
physiology of these wheezing phenotypes may be different. We identifi ed modifi able risk 
factors that may be important targets for prevention of specifi c wheezing phenotypes.
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Supplement data Chapter 4
METHODS
Recruitment of participants
All children participated in the Prevention and Incidence of Asthma and Mite Allergy 
(PIAMA) birth cohort study. This multicentre study was conducted in 3 different regions 
of The Netherlands: north (Groningen and surroundings), central (Bilthoven, Wageningen 
and surroundings) and southwest (Rotterdam and surroundings). Recruitment took place 
between March 1996 and May 1997 by means of a validated screening questionnaire,E1 
distributed by midwifes to 10,232 pregnant woman visiting one of 52 prenatal clinics. 
According to the results of this screening the women were divided in an allergic and 
a non-allergic group. Women with any of the following self-reported symptoms were 
defi ned as allergic: asthma, hay fever, house dust allergy, house dust mite allergy or pet 
allergy. Children of allergic women were defi ned as ‘high-risk’. Based on the screening 
7,862 women (2,779 allergic and 5,083 non-allergic) were invited to participate in the 
study, approximately 50% (n = 4,146) agreed and gave informed consent (1,327 allergic 
and 2,819 non-allergic). The PIAMA cohort includes an intervention part, studying the 
effect of impermeable mattress covers, and a natural history part. (See Figure E2.1, 
data supplement chapter 2) In the present study we considered children from both the 
intervention and the natural history part. As previously published, the intervention had 
no effect on the incidence of allergy or respiratory symptoms, including the symptom 
of wheezing.E2 After birth, the study population consisted of 3,963 children. Eligible for 
the present study were children with complete data on wheezing at every age from 1-8 
years (n = 2,810). In these children 5 wheezing phenotypes were previously indentifi ed 
using Longitudinal Latent Class Analysis.E3
Perinatal factors
In total 19 possible perinatal risk factors were investigated. The following parental char-
acteristics were included: maternal allergy, paternal allergy, parental educational level, 
maternal age, and maternal body mass index (BMI). Parents were considered ‘allergic’ 
if they reported any of the following items: asthma, hay fever, house dust allergy, house 
dust mite allergy, pet allergy. Information on education of both parents was combined in 
one dichotomous variable (low vs. high), and considered ‘high’ if at least one of the par-
ents completed a bachelor or masters study. Maternal BMI was calculated on the basis 
of maternal height and weight before pregnancy, and was reported by the mother in the 
questionnaire send when the child was 1 year old. The odds ratios of both maternal age 
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and BMI were calculated per interquartile range increase. The child characteristics that 
were investigated were: gender, birth weight, pregnancy duration, caesarean section, 
and whether a child was admitted to a hospital directly after birth. The odds ratios for 
gender were calculated with girls as the reference group. Estimates for birth weight 
were calculated per kilogram increase, and estimates for pregnancy duration per week 
increase. Three prenatal exposures were investigated: prenatal smoking, prenatal use of 
antibiotics (both assessed during the second trimester of the pregnancy), and exposure 
to meconium in the amniotic fl uid which was asked when the child was three months 
old. The investigated postnatal exposures included breastfeeding, the presence of older 
siblings, daycare attendance in fi rst year, environmental tobacco smoke exposure, the 
presence of pets in the household, and exposure to particulate matter (PM2.5) at the 
child’s birth address. Breastfeeding (BF) was assessed as the total number of weeks 
that breastfeeding was given. In a previous PIAMA publication this variable was divided 
in three categories (no BF, 0-16 wks BF, more than 16 wks BF), but due to the small 
sample size in some wheezing phenotypes it was dichotomized in this paper: no breast-
feeding or less than 12 weeks vs. at least 12 weeks.E4 Daycare was defi ned as at least 
4 hours per week in a professional daycare institution, where children were exposed to 
other children under the age of 12 years. The average group size in professional daycare 
centers in the Netherlands is 10 children. Environmental tobacco smoke was assessed 
when the child was three months old, and defi ned as exposure to tobacco smoke at 
least once a week in the living room of the child’s house.
Statistical analysis
All analyses were carried out using SAS 9.1 (SAS Institute, Inc., Cary, NC). As outcome 
in this study we used wheezing phenotypes, that were previously derived in the PIAMA 
study using longitudinal latent class analysis (LLCA). This statistical approach attempts 
to identify groups of children within the population (latent classes) that have a similar 
pattern of wheeze over time. This is done by selecting subgroups within which the 
occurrence of wheeze at a certain time point, is statistically independent of the oc-
currence of wheeze at another point in time. Rather than appointing every individual 
child to a single latent class (i.e. phenotype), the model calculates for every child the 
probability of belonging to each of the identifi ed latent classes. This probability is called 
the ‘individual posterior membership probability’. Since 5 latent classes (wheezing 
phenotypes) were identifi ed in the PIAMA study, 5 posterior membership probabilities 
were calculated for every child. The association between phenotype of wheeze and 
all perinatal factors was investigated using a weighted multinomial logistic regression 
model (SAS PROC CATMOD). These multinomial models were weighted for the indi-
vidual posterior membership probabilities, in order to minimize the risk of bias due to 
phenotype misclassifi cation.
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Attributable Fraction
The aim of our study was to fi nd possible interventions to prevent wheezing illnesses 
in childhood. In order to assess the maximal possible effect of a prevention program 
on any modifi able risk factor, it is important to consider the strength of the association 
with the outcome, but also the prevalence of the risk factor in the population. Both 
aspects are taken into account in the attributable fraction (AF). The AF indicates the 
excess number of children with a wheezing phenotype associated with a specifi c risk 
factor, and is expressed as a proportion of the total number of children with the wheez-
ing phenotype. We calculated the AF for all modifi able factors that were signifi cantly 
associated with a wheezing phenotype in the multivariate analysis. The AF of a risk 
factor was estimated by calculating the expected number of cases using the regres-
sion coeffi cients of the multivariable model, after elimination of that (dichotomous) risk 
factor from the population.E5 The AF of continuous variables was estimated by changing 
the population distribution to a degree that would be clinically plausible. Therefore the 
following changes were modeled in the continuous variables: 1) maternal age was in-
creased with 5 yrs, but only in mothers < 30 yrs of age; 2) maternal BMI was decreased 
to a maximum of 25 kg/m2 for all mothers; 3) pregnancy duration was increased to a 
minimum of 39 wks for all children; and 4) birth weight was increased with 200 grams 
in all children.
RESULTS
Attributable Fraction
The results for the attributable fraction of all risk factors that were signifi cant in the 
multivariable analysis are given in Table E4.1. Transient early wheeze had the most 
signifi cant risk factors after multivariable adjustment. Parental allergy and gender were 
signifi cant risk factors, but as these factors are not modifi able, these are no targets 
for interventions. The presence of older siblings had the highest AF, but also this factor 
would in practice not be usable for an intervention. The AF of the other signifi cant risk 
factors for transient early wheeze was small (≤10%). The AF could be interpreted as 
‘the proportion of children with a specifi c wheezing phenotype that could be prevented 
by completely eliminating the risk factor from the population’. However, there are two 
important assumptions in this interpretation. First, the association of the risk factor 
with the wheezing phenotype is assumed to be completely causal. Causality cannot be 
proven using observational data. Results were adjusted for known confounders, but it 
cannot be excluded that some unknown or residual confounding infl uenced our results. 
Secondly, it is unlikely that an intervention in the general population could achieve a 
complete elimination of any of the investigated risk factors. Therefore the AF is an 
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overestimation of the actual effects of a prevention program on public health. Taking 
these considerations into account, the proportion of wheezing that may be avoided by 
interventions on perinatal risk factors is probably limited. 
The only signifi cant risk factor for intermediate onset wheeze was birth weight. The 
most important modifi able factor that can infl uence birth weight is smoking during 
pregnancy. In our data smoking during pregnancy led on average to a 200 gram reduc-
tion in birth weight, which is why we calculated the AF by modeling a 200 gram increase 
in birth weight. The AF of 12.3% is considerable, but should be interpreted with caution, 
as it may be very diffi cult to actually infl uence birth weight on a population level.
Parental allergy and male gender were associated with persistent wheeze, but are not 
modifi able. Breastfeeding was the only modifi able signifi cant risk factor for persistent 
wheeze. It had the highest AF (23.8%) of all modifi able factors, which can be explained 
by the strong odds ratio, in combination with the high proportion of mothers that did 
not give breastfeeding for at least three months (over 50%). Therefore breastfeeding 
remains an important target in the prevention of asthma symptoms in the fi rst 8 years 
of life.
The outcome of late onset wheeze was signifi cantly associated only with maternal 
allergy. As this is not a modifi able factor, we could not estimate the possible impact of 
any intervention to reduce late onset wheeze.
Table E4.1. Attributable fraction of risk factors after multivariable adjustment*
Risk factor
Transient Early 
wheeze (n=455)
Intermediate Onset 
wheeze (n=83)
Persistent 
wheeze (n=98)
Late Onset 
wheeze (n=45)
Maternal allergy† 5.9 % - 20.2 % 28.0%
Paternal allergy† 9.5 % - 16.0 % -
Age mother‡ 9.6 % - - -
Maternal BMI (kg/m2)‡§ 2.2 % - - -
Gender (male) 13.1 % - 33.0 % -
Birth weight (per kg) - 12.3% - -
Pregnancy duration (per wk) 3.8 % - - -
Smoking mother pregnancy 5.8 % - - -
No breastfeeding for ≥3 mths - - 25.6 % -
Older sibling present (≥1) 19.5 % - - -
Daycare in fi rst year 10.8 % - - -
Total N = 2,728. Never/ infrequent wheeze (n = 2,047) is reference category. Frequencies (n) of 
wheezing phenotypes calculated as the sum of the individual posterior membership probability 
of all children for that phenotype, all analyses weighted for individual posterior membership 
probability. *Analyses adjusted for: gender, parental allergy, pre- and postnatal smoke exposure, 
breastfeeding, daycare, pregnancy duration, older siblings, birth weight, maternal age, study 
region, parental level of education. †: ‘Allergy’ defi ned positive if any of the following items were 
reported: asthma, hay fever, house dust allergy, house dust mite allergy, or pet allergy. ‡: Odds 
ratios given per interquartile range increase. §: BMI is Body Mass Index.
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ABSTRACT
Rationale
Fractional exhaled Nitric Oxide (FeNO) is a biomarker of eosinophilic airway infl am-
mation. Using longitudinal latent class analysis, 5 wheezing phenotypes have been 
identifi ed, characterized by different age of onset and prognosis. We hypothesize that 
these different wheezing phenotypes have distinct patterns of airway infl ammation. 
Objectives
To assess FeNO at 4 and 8 years in children with different phenotypes of wheeze and 
atopy. 
Methods
Children participated in the PIAMA study, a prospective birth cohort in The Netherlands. 
Respiratory health was assessed yearly by questionnaires until the age of 8 years, 
these data were used to identify 5 wheezing phenotypes. Associations between FeNO 
measured at 4 and 8 years and wheezing phenotypes were investigated using weighted 
linear regression. 
Results
Complete data on wheezing phenotypes and FeNO at 4 years was available in 462 
children. Compared to the phenotype of never wheeze, FeNO at 4 years was higher 
only in intermediate onset wheeze. Data on wheezing phenotype and FeNO at 8 years 
was available for 803 children. Compared to never wheeze, FeNO at 8 years was sig-
nifi cantly higher in persistent, intermediate onset, and late onset wheeze. Stratifi ed 
analyses showed that the increase in FeNO in persistent, intermediate and late onset 
wheeze was only present in children with allergic sensitization at 8 years. 
Conclusion
FeNO measured at 8 years was associated with specifi c wheezing phenotypes, but 
only among atopic children. We speculate that the role of eosinophilic infl ammation in 
the pathophysiology of wheezing phenotypes differs between atopic and non-atopic 
children.
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INTRODUCTION
The fraction of nitric oxide in exhaled air (FeNO) is a non-invasive biomarker of eo-
sinophilic airway infl ammation with excellent reproducibility.1-5 Recent studies have 
shown that FeNO is a useful test both in large population-based studies, as in clinical 
asthma management.6,7 Elevated FeNO was found in children and adults with asthma 
and atopy, 4,6,8,9 overlapping with the distribution in normals.10,11 We previously reported 
FeNO in 4-year-old children from the Prevention and Incidence of Asthma and Mite 
Allergy (PIAMA) cohort, and found no association with classic wheezing phenotypes 
as described by Martinez in preschool children.11,12 However, FeNO may be infl uenced 
by atopy, which can develop later in life.4,13-16 The PIAMA birth cohort study provided 
the opportunity to study FeNO in relation to phenotypes of wheeze in a large group of 
children recruited from the general population. One of the special features of PIAMA 
is the yearly respiratory health assessment, which can be used to defi ne temporal 
phenotypes of wheeze. Recently, temporal phenotypes of wheeze were identifi ed by 
longitudinal latent class analysis (LLCA) in the ALSPAC study, and these phenotypes 
were differently associated with atopy and lung function.17 This analysis was repeated 
in the PIAMA study with comparable results.18 FeNO has not been studied in relation 
to phenotypes identifi ed using this novel approach. We hypothesized that the different 
wheezing phenotypes are characterized by differences in eosinophilic infl ammation, 
which would be refl ected by differences in FeNO measured at the age of 4 and 8 years. 
Because atopy is a determinant of FeNO, we stratifi ed our analysis for atopy.4 
MATERIALS AND METHODS
Study design
The Prevention and Incidence of Asthma and Mite Allergy study is a prospective birth 
cohort study in The Netherlands. Recruitment took place in 1996-1997 through prenatal 
clinics; 7,862 pregnant women were invited to participate, 4,146 (53%) agreed and 
gave informed consent. Children were labeled as high-risk (n = 1,327) and low-risk (n 
= 2,819), based on the atopic status of the mother.19 Respiratory health and asthma 
symptoms of the children were assessed yearly by questionnaires, partly based on 
the ISAAC core questionnaires, along with data on demographics and a wide range 
of asthma risk factors.20 All high-risk children and a subgroup of low-risk children were 
invited for FeNO measurement at the age of 4 years (n = 1,808) and 8 years (n = 1,554). 
A detailed description of the PIAMA study design was previously published.11,21 The 
study protocol was approved by the medical ethics committees of the participating 
medical centers.
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Study population
At the age of 4 years all high-risk (n = 1,173) and a random sample of low-risk children 
(n = 635) were invited for a medical examination, including offl ine FeNO measurement. 
Of those 1,808 children 1,269 attended the examination, and an exhaled air sample 
was obtained in 939 children. Off-line FeNO measurements of suffi cient quality were 
obtained in 595 children (63%) at age 4.11 At 8 years also all high-risk children still in 
follow-up (n = 988) and a similar, random sample of low-risk children (n = 566) were 
invited for a hospital-based medical examination including online FeNO measurement. 
Of these 1,554 children 1129 (73%) gave informed consent and attended the examina-
tion. In 39 children a FeNO measurement could not be performed due to device failure. 
Of the remaining 1,090 children at least 1 successful FeNO measurement was obtained 
in 976 children (90%), all of whom were included in our analyses. The remaining 114 
children were unable to exhale at a constant fl ow during FeNO measurement. Finally, 
wheezing phenotypes were defi ned only if children had complete data on wheezing 
for every year. A detailed fl owchart of the study population with complete data on 
wheezing phenotype and FeNO at 4 years (n = 462) and 8 years (n = 803) is presented 
in Figure 5.1.
Measurements
FeNO in 4-year-old children was measured offl ine by the balloon method,22 according 
to European Respiratory Society (ERS) / American Thoracic Society (ATS) guidelines.2,11 
FeNO in 8-year-old children was measured online using the NIOX chemiluminescence 
analyzer (Aerocrine AB, Solna, Sweden) according to ERS and ATS guidelines.1 We pre-
viously found good agreement between these on- and offl ine FeNO measurements.23 
At 8 years blood was drawn to assess sensitization to airborne allergens, defi ned as 
specifi c IgE of ≥ 0.70 IU/mL for at least one of the following allergens: house dust mite 
(Dermatophagoides pteronyssinus), cats, dogs, grass pollen (Dactylis glomerata), birch, 
Alternaria alternata.
Phenotypes of wheeze
Longitudinal latent class analysis was used by Savenije et al to defi ne wheezing 
phenotypes in PIAMA in early childhood, as originally published by Henderson et al.17 
Five wheezing phenotypes were identifi ed in the fi rst 8 years of life: never/infrequent 
wheeze (75%), transient early wheeze (17%), intermediate onset wheeze (3.1%), per-
sistent wheeze (3.5%) and late onset wheeze (1.7%). These phenotypes were compa-
rable with those identifi ed in the ALSPAC cohort.18 The fi ve phenotypes are graphically 
depicted in Figure 4.2, chapter 4.
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Statistical analysis
All analyses were carried out in SAS 9.1 (SAS Institute, Inc., Cary, NC). The associa-
tions between FeNO at 4 and 8 years and phenotypes of wheeze were investigated 
with weighted linear regression models (SAS PROC GENMOD). FeNO data were log-
 Screenings questionnaire in pregnant women (n=10,232)  
  
 Invited pregnant women (n=7,862)  
  
 Agreed with informed consent (n=4,146*)  
  
 Children in study after birth (n=3,963)  
 n=3,963  
 
È FeNO at 4 years n=3,963 È FeNO at 8 years n=3,963 
   
Invited for FeNO at 4 years 
(n=1,808) 
 Invited for FeNO at 8 years (n=1,554) 
   
 No consent (n=539) 
 
   
No consent 
(n=425) 
 
 
  
    
Informed consent measurement 
(n=1,269) 
 Informed consent measurement (n=1,129) 
   
 
No attempt 
(n=330) 
NO analyser not 
available 
 
   
No attempt 
(n=39) 
device failure NO 
analyzer 
 
 
  
    
FeNO measurement attempted 
(n=939) 
 FeNO measurement attempted (n=1,090) 
  
 
   
 
 
  
Not successful 
(n=344) due to 
fear, reluctance, 
inability, technical 
problems 
Not successful 
(n=114) due to 
inability to breath 
at constant flow   
   
FeNO measurement successful 
(n=595; success rate 63%)  
FeNO measurement successful 
(n=976; success rate 90%) 
  
 
  
  
 
  
Data on wheezing 
phenotype not 
complete (n=133) 
 
Data on wheezing 
phenotype not 
complete (n=173)   
    
Complete data on FeNO at 4 
years and wheezing phenotypes 
(n=462) 
 
Complete data on FeNO at 8 
years and wheezing phenotypes 
(n=803) 
Included in analysis at 4 years 
(n=462)  
Included in analysis at 8 years 
(n=803) 
 
Figure 5.1. Flow chart of study population at 4 and 8 years
Flow chart of the number of children participating in the study. *: These 4146 consisted of 1327 
atopic (32%) and 2819 non-atopic mothers (68%), which is a good refl ection of the general Dutch 
population.
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transformed, to achieve a normal distribution for linear regression analyses and 
back-transformations were used to calculate geometric mean FeNO for the latent 
phenotypes of wheeze. Due to the stratifi ed study design, all analyses were performed 
for the total study population as well as for the high-risk and low-risk children separately. 
The analyses were also stratifi ed for allergic sensitization at 8 years, because specifi c 
IgE is an important determinant of FeNO.4 Individual membership probabilities (each 
child gets a probability to belong to each phenotype) derived from LLCA were used as 
weight factors in the linear regression models to minimize the risk of misclassifi cation 
of the wheezing phenotypes. Gender, recent symptoms of cold, steroid use, study 
region, education of the mother and exposure to environmental tobacco smoke were 
considered as potential confounders. Confounders were included in the models based 
on their association with wheezing phenotypes, or if they changed the effect estimate 
by more than 10%. 
RESULTS
General characteristics of the study population
Baseline characteristics at 4 and 8 years are given in Table 5.1. Due to the study design, 
this population was overrepresented with high-risk children compared to the total 
PIAMA population. Compared to those invited for medical examination at 8 years (n = 
1,554), children with complete data at 8 years had a higher level of maternal education 
and lower prevalence of prenatal smoking. However, differences were small, and with 
respect to other general characteristics the groups were similar. (Table 5.1) Finally, 
among children with complete data, the proportion of never/infrequent wheeze and late 
onset wheeze was somewhat lower than in the total population with complete data. 
Associations of FeNO values at 4 years and phenotypes of wheeze
Phenotypes of wheeze were derived from yearly respiratory health assessments from 
birth up to 8 years. Geometric mean FeNO in never/infrequent wheeze was lower than 
in the remaining 4 phenotypes, but with considerable overlap. (Table 5.2) The adjusted 
geometric mean FeNO value (95% confi dence interval [CI95%]) was highest in intermedi-
ate onset wheeze 12.1 (CI95%: 9.8-15.0) ppb
 compared to never/infrequent wheeze 8.8 
(CI95%: 8.3-9.4) pbb (p < 0.001). The predictive value of FeNO at age 4 for wheezing 
phenotypes was limited, as a result of the large overlap of FeNO between groups.
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Associations of FeNO values at 8 years among different phenotypes of 
wheeze
Also at 8, there was considerable overlap in FeNO between all phenotypes. FeNO was 
highest when wheeze started later in life and persisted longer. The adjusted geometric 
mean FeNO in transient early wheeze and never/infrequent wheeze was similar (9.0 vs. 
9.6 ppb, NS). Compared to never/infrequent wheeze (9.6 (CI95%: 8.9-10.3) ppb), FeNO 
was signifi cantly higher in intermediate onset wheeze: 17.4 (CI95%: 14.0-21.6) ppb (p 
Table 5.1. General characteristics of study population
Invited for exam at 8 
yrs (n=1,554)
Complete data at 4 
yrs (n=462)
Complete data at 8 
yrs (n=803)
Gender (% females) 49 49 51
Study region
West 31 49 31
Middle 37 37 41
North 32 15 28
Maternal education level
Low 22 19 19
Middle 42 42 41
High 36 39 40
Caesarean section 9 9 10
Atopic* mother 64 63 64
Atopic* father 32 32 32
Exposure to pets in 1st yr 48 45 46
Older siblings (% present) 48 49 47
Daycare attendance in 1st yr 24 27 26
Smoking during pregnancy 16 13 14
Exposure to environmental tobacco smoke† 16 15 15
Inhaled steroid use† 9 7 8
Doctors’ diagnosis asthma† 12 12 11
Phenotypes of wheeze‡
Never/infrequent wheeze 72.5 70.0 71.0
Early wheeze 17.1 20.3 18.3
Intermediate onset wheeze 3.4 3.9 3.8
Persistent wheeze 4.4 4.2 4.9
Late onset wheeze 2.5 1.5 2.0
Specifi c IgE inhalant allergen
Positive for at least 1 of the 6 tested allergens§ 30 29 28
*: Defi ned as a positive report of hayfever, allergy and/or asthma. †: Reported at the age of 8 years. 
‡: Defi ned using longitudinal latent class analysis as previously described,18 known in 1,165/1,554 
children invited at 8 years. §: The following 6 inhalant allergens were tested for: house dust mite 
(Dermatophagoides pteronyssinus), cats, dogs, grass pollen (Dactylis glomerata), birch, Alternaria 
alternata.
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< 0.001), persistent wheeze: 12.5 (CI95%: 10.2-15.2) ppb (p < 0.001) and late onset 
wheeze: 20.7 (CI95%: 15.8-27.1) ppb (p < 0.001). The crude and adjusted geometric 
mean FeNO for each wheezing phenotype is given in Table 5.2 and the distributions 
are shown in Figure 5.2. None of the potential confounders changed the association 
between FeNO and phenotypes of wheeze to a meaningful degree. Steroids were 
Table 5.2. Crude and adjusted geometric mean FeNO per phenotype of wheeze at 4 and 8 years
FeNO at 4 years (n=462) FeNO at 8 years (n=803)
Phenotype of wheeze n* Crude Adjusted (CI95%)
† n* Crude Adjusted (CI95%)
†
Never/infrequent 324 9.0 (8.7; 9.3) 8.8 (8.3; 9.4) 570 10.2 (9.8; 10.5) 9.6 (8.9; 10.3)
Early 94 9.6 (8.6; 10.7) 9.2 (8.0; 10.6) 147 9.5 (8.5; 10.5) 9.0 (7.8; 10.4)
Intermediate onset 18 12.3 (10.2; 14.9)‡ 12.1 (9.8; 15.0)‡ 31 19.2 (16.0; 22.9)‡ 17.4 (14.0; 21.6)‡
Persistent 20 10.1 (8.4; 12.1) 9.4 (7.7; 11.6) 40 13.2 (11.2; 15.6)‡ 12.5 (10.2; 15.2)‡
Late onset 7 10.0 (7.6; 13.3) 9.3 (6.9; 12.6) 16 22.7 (17.9; 28.7)‡ 20.7 (15.8; 27.1)‡
Analyses were weighted for the probability that a child belongs to a certain phenotype (individual 
posterior membership probabilities). *: Frequency (n) of each wheezing phenotype is calculated as 
the sum of the membership probability of all children for that phenotype. †: Geometric mean FeNO 
value (95% confi dence interval) in ppb per phenotype of wheeze, adjusted for gender, recent 
symptoms of cold, study region, education of the mother and exposure to environmental tobacco 
smoke. ‡: p < 0.05 for difference in comparison with never/infrequent wheeze. 
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Figure 5.2. Box plots of FeNO at 8 years per phenotype of wheeze
Horizontal lines indicate the geometric mean FeNO. Upper/lower limits of the box, outer lines, 
and dots represent the 25th/75th, the 10th/90th, and the 5th/95th percentiles, respectively. Data 
are weighted for the probability that a child belongs to a certain phenotype (individual posterior 
membership probabilities).
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mainly used in intermediate-, late onset- and persistent wheeze, and this might lead 
to underestimation of the differences between these phenotypes and the reference 
group. We think that this is not the case because exclusion of children using steroids at 
8 years led to similar results. In order to investigate whether the association between 
FeNO and the wheezing phenotypes may be caused solely by the association between 
FeNO and wheeze at the age that FeNO was measured, we performed a sensitivity 
analyses adjusting for current wheeze at the age of 8 years. This adjustment did not 
alter the associations between
FeNO and phenotypes of wheeze
FeNO values and phenotypes of wheeze in atopic and non-atopic children We performed 
stratifi ed analyses based on atopy of the mother. The associations between FeNO and 
phenotypes were similar. However, we found signifi cant interaction with allergic sensi-
tization of the children themselves at the age of 8 years. Among children with elevated 
specifi c IgE, FeNO at 8 years was low in never/infrequent wheeze and transient early 
wheeze, and signifi cantly elevated in the remaining persistent phenotypes. In children 
without elevated specifi c IgE for inhalant allergens, FeNO at 8 years was not associ-
ated with phenotypes of wheeze. Because the numbers of children with low specifi c 
IgE were small for all wheezing phenotypes except never/infrequent, phenotypes with 
persistent symptoms (intermediate onset wheeze (n = 6), persistent wheeze (n = 16) 
and late onset wheeze (n = 4)) were combined for this analysis. Table 5.3 shows that, 
among atopic children, this combined phenotype had a signifi cantly higher FeNO (21.8 
(CI95%: 16.4-29.1) ppb) than never/infrequent wheeze (12.9 (CI95%: 11.1-14.9) ppb, p < 
0.001), while no such association was present in non-atopic children. This interaction 
is illustrated in Figure 5.3. The differences in FeNO between atopics and non-atopics 
Table 5.3. Adjusted geometric mean FeNO at 8 years per phenotype of wheeze stratifi ed for atopy
Atopy - (n=474) Atopy + (n=188)
Phenotype of wheeze n* Adjusted (CI95%)
† n* Adjusted (CI95%)
†
Never/infrequent 359 8.1 (7.5; 8.7) 107 12.9 (11.1; 14.9)
Early 90 7.5 (6.5; 8.8) 34 11.0 (8.1; 14.9)
Combined persistent phenotypes‡ 26 7.7 (6.3; 9.5) 47 21.8 (16.4; 29.1)§
Atopy of the child defi ned as specifi c IgE of ≥ 0.70 IU/ml for at least one inhalant allergen at 
the age of 8 years. Analyses were weighted for the probability that a child belongs to a certain 
phenotype (individual posterior membership probabilities). *: Frequency (n) of each wheezing 
phenotype is calculated as the sum of the membership probability of all children for that 
phenotype. †: Geometric mean FeNO value (95% confi dence interval) (ppb) per phenotype of 
wheeze stratifi ed for atopy at 8 years, adjusted for gender, recent symptoms of cold, study region, 
education of the mother, and exposure to environmental tobacco smoke. ‡: Three phenotypes with 
persistent symptoms (intermediate onset wheeze, persistent wheeze and late onset wheeze) 
were combined in this analysis. §: p < 0.05 for difference in comparison with never/infrequent 
wheeze.
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were greatest for never/infrequent wheeze (p < 0.001) and the combined phenotype (p 
< 0.001), but also signifi cant for transient early wheeze (p < 0.001). (Figure 5.3) 
DISCUSSION
We examined FeNO at 4 and 8 years in relation to phenotypes of wheeze and atopy. We 
found that FeNO at 4 years was higher only in intermediate onset wheeze compared to 
never wheeze. The association between phenotypes of wheeze and FeNO measured at 
8 years was much stronger. FeNO at 8 years was signifi cantly higher in persistent phe-
notypes of wheeze, including intermediate onset, persistent and late onset wheeze, 
only among children with allergic sensitization at 8 years.
FeNO and wheezing phenotypes
Previous studies have reported increased FeNO in asthmatic children,8,24-27 while others 
did not confi rm this.28-30 A possible explanation for these discrepancies is that ‘asthma’ 
comprises several phenotypes that may or may not share the same infl ammatory 
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Figure 5.3. Box plots of FeNO at 8 years per phenotype of wheeze, stratifi ed for atopy of the child 
defi ned as a specifi c IgE of ≥ 0.70 IU/ml for at least one of the tested inhalant allergens at the age 
of 8 years. Horizontal lines indicate the geometric mean FeNO. Upper/lower limits of the box, outer 
lines, and dots represent the 25th/75th, the 10th/90th, and the 5th/95th percentiles, respectively. 
Data are weighted for the probability that a child belongs to a certain phenotype (individual 
posterior membership probabilities). Only signifi cant (p < 0.05) differences are depicted. *: Three 
phenotypes with persistent symptoms (‘intermediate onset wheeze’, ‘persistent wheeze’ and ‘late 
onset wheeze’) were combined in this analysis.
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mechanisms.12,17,31,32 Lumping all these phenotypes together as a single disease entity 
might hamper our efforts to understand the etiology and pathophysiology of specifi c 
phenotypes.32,33 That there are such differences has been suggested in studies that 
assessed airway infl ammation using either broncho-alveolar lavage (BAL)34,35 or FeNO.36 
Only few studies investigated the association between FeNO and wheezing pheno-
types in early childhood. Moeller et al defi ned phenotypes of wheeze on the basis 
of a clinical symptom score and found higher FeNO levels in preschool children with 
persistent wheeze.37 This is in line with our present fi ndings. Brussee et al found in the 
PIAMA study only a weak association of FeNO at 4 years with phenotypes of wheeze 
up to that age, with slightly higher FeNO levels in children who wheezed at the age of 4 
years, compared to those who never wheezed.11 In the present study there was only a 
weak association between phenotype and FeNO at 4 years. This could be explained by 
an increase in eosinophilic airway infl ammation with age,38 becoming detectable only 
after the age of 4 years. Alternatively, differences in the methods of FeNO measure-
ment at 4 and 8 years might be involved, but we earlier found that these on- and offl ine 
methods give similar results,39 so this seems unlikely. At 8 years, eosinophilic airway 
infl ammation was present only in the phenotypes with persistent symptoms. Elevated 
FeNO levels were especially pronounced in the phenotypes with onset of wheezing 
after the age of 2 years. 
FeNO and atopy
We found a strong association between atopy and FeNO. This is a consistent fi nding in 
earlier studies. 8,25,28,29 Some authors suggested that the association between asthma 
and FeNO may be entirely explained by atopy, suggesting that measuring FeNO is of 
limited use in order to assess whether a child has asthma.40 The present study showed 
that the presence of atopy modifi ed the association between wheezing phenotypes 
and FeNO, and this is in line with previous studies.9,28,41,42 FeNO is a biomarker of atopy 
and the ’allergic’ asthma phenotype rather than of any type of asthma. This may partly 
explain why FeNO-guided asthma treatment has proven to be of limited success in 
studies that did not take atopic status into account.9 In the present study FeNO levels 
differed substantially between the wheezing phenotypes in atopic children at 8 years, 
which suggests that FeNO can be helpful to differentiate between wheezing phenotypes 
in atopic children. Furthermore it shows that all wheezing phenotypes occur in atopic 
and non-atopic children, but that the pathophysiology of wheeze in these two groups 
is probably different, with a predominance of eosinophilic infl ammation selectively in 
atopic children with persistent phenotypes of wheeze. Other mechanisms may play a 
role in the pathophysiology of transient or persistent wheeze in non-atopic children. 
These include smaller airway caliber and/or neutrophilic airway infl ammation.34,35
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Strengths and limitations
A strong point of our study is that we assessed wheezing prospectively, without the 
possibility of recall bias, and that the wheezing phenotypes were discovered without 
pre-specifi ed constraints in two large birth cohorts, using longitudinal latent class analy-
sis.17,18,43 Well-standardized FeNO measurements,44 objective assessment of atopy at 8 
years, and the large size of the PIAMA cohort with good follow-up allowed us to detect 
signifi cant differences in FeNO in less common phenotypes, even after stratifi cation 
for atopy. 
A point of consideration in the interpretation of the data is that some children were 
using inhaled steroids while FeNO was measured, which potentially decreased FeNO.4 
However, any such effect seems limited because a sensitivity analysis after exclusion 
of steroid users did not change the results. In addition, one should take into account 
the possibility that the reported association between FeNO and phenotypes of wheeze 
solely depends on the relation between FeNO and current wheeze at the age of 8 
years. This seems unlikely, because adjustment for current wheeze at 8 years did not 
alter any of the associations between FeNO and phenotypes of wheeze. Furthermore, 
the small sample size of FeNO measurements at the age of 4 years should be noted, 
especially in the late onset wheeze phenotype. In the stratifi ed analyses of FeNO at 
8 years we presented the 3 phenotypes with persistent symptoms as a combined 
phenotype, due to the low sample size of non-atopic wheezers. Importantly, results 
remained similar both in size and signifi cance when these phenotypes were analyzed 
separately. Because FeNO was measured at 4 and 8 years, we cannot exclude that 
FeNO might have been increased in transient early wheeze before the age of 2, at the 
time when wheeze was still present.41,45
Implications
FeNO measured at 8 years differed between specifi c wheezing phenotypes in the fi rst 
8 years of life, but only among atopic children. Our fi ndings at 8 years may help to 
understand the pathophysiology of different wheezing phenotypes in early childhood. 
CONCLUSION
FeNO measured at 8 years differed between wheezing phenotypes, only in atopic 
children. Hence, we speculate that the pathophysiology of wheezing phenotypes dif-
fers between atopic and non-atopic children, with eosinophilic airway infl ammation in 
atopic, but not in non-atopic children with persistent wheeze. Whether or not eosino-
philic infl ammation is indeed causally involved in the pathogenesis of wheeze remains 
to be shown.
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ABSTRACT
Objective
Under- and overtreatment of asthma may be a serious problem especially in young 
children, but the evidence is scarce and no longitudinal data are available. Our aim was 
to longitudinally investigate whether inhaled medication use in young children was in 
agreement with asthma symptoms.
Methods
Data were used from the ‘Prevention and Incidence of Asthma and Mite Allergy’ birth 
cohort, consisting of 3,963 children born in the Netherlands. Between age 2 and 8 years 
children were followed-up using annual postal questionnaires. Age-specifi c prevalences 
of asthma symptoms were assessed and compared with reported use of inhaled bron-
chodilators and/or corticosteroids.
Results
The proportion of current wheeze decreased with age. About a third of ‘current wheezers’ 
did not use any inhaled medication during the years in which symptoms were reported. 
At 8 years 30% of children with reported ‘severe current asthma symptoms’ were not 
using inhaled corticosteroids. On the other hand, up to 50% of children with inhaled 
corticosteroids for at least 2 years did not report any wheezing during those 2 years.
Conclusions
The proportion of symptomatic children without appropriate treatment was substantial 
throughout childhood, even when parents reported prolonged or severe symptoms. 
Treatment of asymptomatic children with inhaled corticosteroids increased with age 
and accounted for up to a third of all inhaled steroid use at 8 years. These fi ndings 
suggest that under- and overtreatment of asthma in children was common.
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INTRODUCTION
Asthma symptoms are highly prevalent in children but an asthma diagnosis is diffi cult at 
young age when symptoms are nonspecifi c. Nonetheless it is important that asthmatic 
children are adequately treated with bronchodilators (BD) and inhaled corticosteroids 
(ICS) or leukotriene receptor antagonists, as these reduce symptoms and improve 
quality of life.1-3 On the other hand, the majority of symptomatic preschool children will 
outgrow their symptoms during childhood.4 Long-term prescription of ICS in children, 
without regular evaluation, may lead to overtreatment. 
Indeed some previous studies have shown evidence that considerable undertreat-
ment as well as overtreatment of asthma exists in children.5-9 Only few studies have 
addressed under- and overtreatment in preschool children, in whom it is particularly 
diffi cult to make an accurate asthma diagnosis.7-9 Importantly, previous studies were 
all cross-sectional in design and could not follow symptoms and medication use over 
multiple years.5-13
Using the longitudinal data from the ‘Prevention and Incidence of Asthma and Mite 
Allergy’ (PIAMA) birth cohort we investigated whether medication use corresponded 
with parental report of asthma symptoms in children aged 2 to 8 years. By inspect-
ing medication use among children with asthma symptoms of different severity, type 
and duration we estimated the rate of undertreatment. Reports of asthma symptoms 
among long-term ICS users were assessed to evaluate possible overtreatment.
PATIENTS AND METHODS
Study population
Recruitment of the PIAMA cohort took place in 1996-1997 by means of a screening 
questionnaire distributed to 10,232 pregnant women visiting one of 52 prenatal clinics 
in The Netherlands.14 Based on this screening 7,862 women were invited and 4,146 
(53%) agreed and gave informed consent. Their children were followed-up annually for 
8 years, using postal questionnaires for parental completion, based on the International 
Study of Asthma and Allergies in Childhood (ISAAC) core questionnaires.15 A detailed 
description of the study has been published elsewhere.16
Defi nitions
Parents were asked about their child’s airway symptoms every year. Data on shortness 
of breath and prescription of specifi c types of inhaled medication was collected only 
after the age of 2 years. Several symptom outcomes were defi ned at the ages of 3-8 
years, each pertaining to the past 12 months. ‘Current wheeze’ was assessed with 
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the question: “Has your child had wheezing or whistling in the chest in the last 12 
months?”, and ‘Current shortness of breath’ with: “Has your child had tightness of the 
chest or shortness of breath in the last 12 months?” These symptoms were considered 
‘frequent’ if parents reported 4 or more episodes in the past year. A range of asthma 
symptoms was inspected in relation to medication use. A child was considered to have 
‘Severe current asthma symptoms’ when the parents reported wheezing in the past 
year AND an episode of wheeze or shortness of breath severe enough to limit speech 
to 2 words at the time and/or 4 or more episodes of wheeze/shortness of breath severe 
enough to keep the child awake at night. All national and international guidelines used 
during the study period advise maintenance therapy with ICS in children with severe 
asthma symptoms.1,17 ‘Doctors diagnosed current asthma’ was assessed using the 
question: “Did a doctor ever diagnose asthma in your child AND has your child had 
asthma in the last 12 months?”. 
Information on asthma medication was collected by the question: “Has your child had 
medication for lung problems prescribed by a doctor in the last 12 months?” Parents 
were asked to specify the medication from a list that included generic and brand names 
of all medication registered for asthma treatment in the Netherlands. Inhaled asthma 
medication use was categorized annually in 4 groups: 1) no inhaled medication; 2) only 
BD; 3) only ICS; 4) BD and ICS. Cromones were not advised by national asthma guide-
lines and rarely prescribed during the study (<0.2%). Leukotriene receptor antagonists 
were introduced in Dutch guidelines in 2003 and only 7 children used montelukast at 8 
years.17 Therefore, only BD and ICS were considered in our analyses.
Statistical analyses
Proportions of children with inhaled medication and different types of asthma symptoms 
were compared at every year of age using SAS software version 9.1 (SAS Institute, 
Inc., Cary, NC). Longitudinal data allowed us to differentiate children with incidental 
wheezing, from those with wheezing in 2 consecutive years. Inhaled medication in 
asymptomatic children may imply either overtreatment, or a good treatment response. 
During the study period, guidelines recommended to reduce and eventually withdraw 
ICS in children who have become completely free of wheeze using 3-monthly inter-
vals.18,19 Therefore we considered ICS use in at least 2 consecutive years without a 
single reported episode of symptoms as suggestive for overtreatment. We performed 
complete case analyses for every time point, excluding children with missing data at a 
certain age from the analysis only at that specifi c age.
Daan BW 7.indd   118 28-10-10   13:06
119
ASTHMA SYMPTOMS AND MEDICATION IN CHILDHOOD
C
H
A
P
T
E
R
 6
RESULTS
Study population
From the 4,146 included mothers, 183 (4.5%) dropped out before returning any postna-
tal questionnaires due to various reasons (e.g. stillbirth, language barrier, not interested, 
moved). General characteristics of the study population at baseline (n = 3,963) are given 
in Table 6.1. Of the baseline population 199 children (5.0%) were lost to follow-up before 
the age of 3 years. The remaining 3,764 returned at least 1 questionnaire between 
the age of 3-8 years and were included in the analyses. The age-specifi c response 
rates are given in Table 6.1: 3,033 children (77% of baseline) completed a questionnaire 
every single year from age 3-8. Children who were lost to follow-up before age 3 (n = 
199) or missed at least 1 questionnaire thereafter (n = 731) were similar to children 
with complete data (n = 3,033) with respect to gender, pregnancy duration, delivery by 
caesarean section, proportion with older siblings, and allergy of the father. However, 
children with complete data had a higher level of parental education, were more likely 
to be ever breastfed, and less likely to be exposed to cigarette smoke during pregnancy 
(data not shown). The average response rate between 3-8 years was 88% from baseline 
and at 8 years 3,314 children (84%) returned a completed questionnaire.
Table 6.1. Population characteristics at baseline and annual response rate
Characteristic n (%)
Baseline population 3,963 (100)
Gender (boy) 2,056 (52)
Preterm birth 190 (5)
Caesarean section 332 (9)
Older siblings (present) 1,994 (51)
Allergic mother 1,237 (31)
Allergic father 1,217 (31)
Breastfeeding ever given 3,200 (82)
Education mother (low) 894 (23)
Smoking in pregnancy 556 (14)
Questionnaire returned at age:
(% from baseline)
3 yrs 3,693 (92)
4 yrs 3,561 (90)
5 yrs 3,518 (89)
6 yrs 3,472 (88)
7 yrs 3,373 (85)
8 yrs 3,314 (84)
every age (3-8 yrs) 3,033 (77)
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Prevalence of asthma symptoms and inhaled medication
Current wheezing at least once was reported by 15.8% at 3 years and showed a 
gradual decline to 5.9% at age 7. (Table 6.2) The prevalence of shortness of breath and 
markers for symptom severity such as speech limiting, nightly or frequent symptoms 
all decreased with age. The prevalence of ‘doctors diagnosed current asthma’ did not 
decrease and had the highest prevalence at 8 years. BD use decreased with age and 
ICS use varied between 7-8% between ages 2 and 8 years. When ICS were prescribed 
after the age of 2, they were often continued for multiple years. Figure 6.1 shows that 
at the age of 5, only 20% of children using ICS started ICS in that year. At 8 years over 
70% of ICS users had been using ICS for at least 3 years. 
Undertreatment
Which proportion of symptomatic children indeed received asthma medication? Figure 
6.2 depicts the age-specifi c proportions of inhaled medication among children with dif-
ferent defi nitions of asthma symptoms. Among current wheezers at 3 years 29% used 
both ICS and BD, and 43% did not use any inhaled medication that year. (Figure 6.2a) 
Medication use increased until 5 years. At 7 and 8 years over 30% of current wheezers 
did not use inhaled medication. Medication use among children who reported current 
Table 6.2. Age-specifi c prevalence of symptoms and medication use
Asthma symptoms (%)
age
2-3 yrs
age
3-4 yrs
age
4-5 yrs
age
5-6 yrs
age
6-7 yrs
age
7-8 yrs
Wheezing
Current wheezing 15.8 11.9 9.6 7.8 5.9 6.7
Frequency
1-3 times per year 12.0 8.7 6.6 5.6 4.5 5.3
≥4 times per year 3.8 3.2 3.0 2.2 1.4 1.4
Shortness of breath
Current shortness of breath 15.0 12.9 12.1 10.4 7.5 8.9
Frequency
1-3 times per year 11.2 9.1 8.1 7.5 5.5 6.6
≥4 times per year 3.8 3.8 4.0 2.9 2.0 2.3
Speech limiting symptoms 3.3 2.5 1.9 1.5 1.1 0.9
Awake at night due to symptoms 13.0 11.4 10.1 7.6 5.5 5.1
Doctors diagnosed current asthma 4.2 4.2 4.0 3.9 2.8 4.6
Inhaled medication (%)
age
2-3 yrs
age
3-4 yrs
age
4-5 yrs
age
5-6 yrs
age
6-7 yrs
age
7-8 yrs
Bronchodilators 12.9 10.5 10.7 9.3 7.8 7.5
Inhaled corticosteroids 8.0 7.8 8.1 7.7 6.8 6.5
Bronchodilators and inhaled 
corticosteroids
6.3 6.3 6.7 6.1 5.4 4.7
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Figure 6.1. Number of years that inhaled 
corticosteroids were used after the age 
of 2 years
ICS: Inhaled corticosteroids. Numbers 
above bars represent the absolute 
number of children who used inhaled 
corticosteroids that year. Example: At age 
3-4 yrs n=273 children were using ICS; 
60% of those children were using ICS for 
the 2nd year in a row, 40% started using 
ICS at age 3-4 yrs for the 1st time. Note: 
only inhaled corticosteroid use after the 
age of 2 yrs was taken into account.
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Figure 6.2. Proportion of inhaled medication among children with symptoms of different duration 
and severity
(a) Current wheezing; (b) Current wheezing and wheezing in previous year; (c) Severe current 
asthma symptoms; (d) Current wheezing and doctors’ diagnosed current asthma. Numbers above 
bars represent the absolute number of children who reported symptoms that year.
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wheezing in 2 consecutive years is given in Figure 6.2b. The proportion receiving medi-
cation was only slightly higher in this subgroup and at 8 years 30% was still not using 
any inhaled medication. The number of children with severe current asthma symptoms 
was smaller, n = 53 at 8 years. The proportion that used ICS in this group increased 
with age, but at 8 years 30% did not use ICS. (Figure 6.2c) Our data further indicate 
that over 90% of the untreated children with severe asthma symptoms consulted a 
medical doctor in the year of symptoms. Consequently, it is likely that parents indeed 
took their symptomatic child to the doctor, and that the majority of the undertreatment 
might have occurred because doctors did not adequately recognize or treat asthma 
symptoms. In children with a current doctors’ diagnosis of asthma there appeared to 
be less undertreatment. Among children with doctors’ diagnosed current asthma, more 
than 90% of the current wheezers was using inhaled medication, and 70-80% used 
ICS, irrespective of age (Figure 6.2d).
Overtreatment
Of all children who received ICS at the age of 3 years 67% reported current wheezing, 
the majority less than 4 episodes per year. (Figure 6.3a) Among ICS users the propor-
tion of children who did not wheeze increased over time to well over 50% at age 7 and 
8 years. Less than half of children with current ICS use reported ‘doctors diagnosed 
current asthma’. This was still the case at 8 years, at which point the majority of ICS 
users had been using ICS for several years. (Figure 6.3b) Considering that ICS may 
not have been used for the entire year, e.g. as part of a medication trial to confi rm an 
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Figure 6.3. Proportion of asthma symptoms among children currently using inhaled corticosteroids
(a) Current wheezing, with frequency; (b) Doctors’ diagnosed asthma with symptoms. ICS: 
Inhaled corticosteroids. Numbers above bars represent the absolute number of children who 
reported current inhaled corticosteroid use that year.
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asthma diagnosis,18,19 we inspected symptoms in children with ICS over multiple years. 
Figure 6.4a depicts wheezing symptoms in the past 2 years among children who were 
using ICS in 2 consecutive years. At the age of 3-4 years, 22% of these children did 
not report a single episode of wheezing for the entire 2 year period. At the age of 8 
years this percentage had increased to 50% (n = 72). This group represented 36% of 
all children using ICS and 2.3% of the entire study population at 8 years. Wheezing is 
not the only symptom for which ICS are prescribed, and therefore we also considered 
‘current shortness of breath’. Among children who reported ICS use at the age of 7 and 
8, 26% did not report a single episode of wheezing or shortness of breath during that 
2 year period. (Figure 6.4b) At least 80% of children with ICS but no symptoms had 
reported wheezing prior to ICS initiation (data not shown).
DISCUSSION
Our data on 6 years longitudinal follow-up showed a substantial proportion of asthma 
undertreatment, even in children with prolonged or severe symptoms, which decreased 
only little with age. At the same time a considerable proportion of all children with 
long-term ICS use had not reported any asthma symptoms for the past 2 years, which 
is suggestive for overtreatment. This possible overtreatment increased with age and 
accounted for one third of all prescriptions at the age of 8 years.
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Figure 6.4. Reported symptoms among children using inhaled corticosteroids for at least 2 
consecutive years
(a) Wheezing symptoms; (b) Asthma symptoms (wheezing and/or shortness of breath). ICS: 
Inhaled corticosteroids. Numbers above bars represent the absolute number of children who were 
using inhaled corticosteroids for at least 2 consecutive years.
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Undertreatment
Evidence that inadequate treatment of asthma symptoms may be a serious problem 
has been shown in population surveys in Europe as well as the United States.7,8 Most 
previous studies on the adequacy of asthma treatment in children included school chil-
dren of 8 years and older.5,6,10-13 Given the occurrence of different wheezing phenotypes 
at preschool age, fi ndings from those studies cannot be generalized to younger chil-
dren. In preschoolers, undertreatment may be more common than in older children.7,9 
A limitation in all previous studies was the cross-sectional design. Our longitudinal data 
allowed us to investigate the course of symptoms and medication use over multiple 
years. Considering that an asthma diagnosis becomes more reliable in older children, 
we expected that the rate of undertreatment would decrease with age. Indeed the pro-
portion of current wheezers without any medication decreased slightly until the age of 
5, but remained stable thereafter around 35%. We found that the dissociation between 
symptoms and treatment was not limited to short time periods. Among children who 
wheezed in 2 consecutive years, a third did not use any inhaled medication. In children 
with severe asthma symptoms the use of ICS has been strongly recommended by na-
tional and international asthma guidelines throughout the study period.1,18-20 We found 
that ICS use increased gradually with age in children with severe symptoms, but that 
still more than one third of children with severe asthma symptoms did not use ICS at 
8 yrs.
Undertreatment may be due to problems in diagnosing asthma in children, and this is 
supported by our fi nding that 40% of all current wheezers did not use any inhaled medi-
cation, compared to only less than 10% in those with a doctor’s diagnosis of asthma. 
Therefore it seems important that guidelines not only focus on medical treatment, but 
also on the ability of doctors to recognize and correctly diagnose asthma in children. 
Overtreatment
Little is known about the rates of overtreatment, as most surveys included only pa-
tients with documented asthma.5,8,10,12,13 Treatment without apparent indication was 
documented in up to 23% of preschool children.6,9 We found rates increasing to 50% at 
8 years. Evidently, the absence of symptoms may be a desired effect of the medication 
indicating good treatment rather than overtreatment, and this can only be assessed us-
ing longitudinal data. According to guidelines at the time of the study period treatment 
with ICS should be evaluated with 3-month intervals, and stepped down and eventually 
stopped in asymptomatic patients, especially young children.18,19 Hence, we reasoned 
that children with ICS during 2 consecutive years without a single episode of wheeze 
were probably overtreated. The proportion of children with ICS but no wheezing in 
the past 2 years gradually increased, and most of these children had reported asthma 
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symptoms prior to ICS initiation. This suggests that overtreatment resulted from failure 
to withdraw ICS while symptoms disappear. 
A novel fi nding was the high proportion of children using ICS without ‘doctors 
diagnosed current asthma’, often for 2 years or more. Recent guidelines indeed pro-
mote ICS before an asthma diagnosis is made, but only as a short trial to support 
the diagnosis.20,21 The prolonged mismatch between diagnosis and treatment confi rms 
that doctors regularly prescribe ICS without the parents being aware of an asthma 
diagnosis.22 This is unfortunate, as good asthma education improves management of 
childhood asthma,23 and effective communication about the diagnosis and treatment 
helps to prevent both under- and overtreatment.
Strengths and limitations
This is the fi rst longitudinal study to report on possible under- or overtreatment of 
asthma in children. Previous cross-sectional studies may have classifi ed any mismatch 
between symptoms and medication use as incorrect treatment. Our longitudinal data 
allowed us to quantify the extent of avoidable under- or overtreatment during multiple 
years, taking into account reported symptoms and medication use in previous years. 
Secondly, considering the large sample size, high follow-up and annual response rates, 
our results may be extrapolated to the general Dutch population and, perhaps, other 
Western European countries.8 If any bias resulted from the relatively few missing ques-
tionnaires, it most likely led to an underestimation of the mismatch between symptoms 
and treatment. Missing data occurred more frequently in children whose mother had a 
low level of education, which is a risk factor for incorrect treatment.24
An important limitation of our study is that symptoms were based on parental report. 
This limitation is shared with all previous surveys, and resembles clinical practice, 
where asthma management in children is also based on parental report. Likewise, 
medication use was recorded using parental report. To estimate the reliability of these 
data, we compared our fi ndings with those in a subgroup of 777 children, for whom 
medication data were retrieved directly from the child’s pharmacy. This comparison 
showed very high agreement (> 97%) between parental reported medication use and 
pharmacy prescription data, suggesting that parental self-report of medication use is an 
appropriate source of data to asses ICS use in children.25 Finally, we are not informed 
about medication dosage and frequency. Therefore we cannot exclude that some symp-
tomatic children received insuffi cient ICS doses.6,8 
Implications
To avoid undertreatment, it may be worthwhile to actively screen children for asthma 
symptoms in primary and secondary care. Easy-to-use clinical scores to predict the 
likelihood of persistent asthma symptoms in preschool children may be helpful for this 
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purpose.26,27 An improvement in symptoms could be caused by a treatment effect, but 
also by the natural course of asthma, especially if the improvement is prolonged.28 If 
symptoms disappear completely, ICS should be gradually withdrawn in order to avoid 
overtreatment.19 More recent guidelines emphasized the importance of this advice 
for preschool children.29 The high percentage of ICS users without symptoms during 
multiple years implies that a critical reappraisal of the continuation of ICS may be 
worthwhile, especially in school aged children.
CONCLUSION
We found evidence for under- and overtreatment in children with asthma. Undertreat-
ment decreased with age, and at 8 years one third of children with asthma symptoms 
did not receive appropriate medication, even if symptoms were prolonged or severe. At 
the same time up to one third of children chronically using ICS did not report any asthma 
symptoms for the past 2 years. These fi ndings suggest that over- and undertreatment 
of asthma in children is common.
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ABSTRACT
Rationale
Clinicians have diffi culty in diagnosing asthma in preschool children with suggestive 
symptoms.
Objective
We sought to develop a clinical asthma prediction score for preschool children who 
have asthma-like symptoms for the fi rst time.
Methods
The Prevention and Incidence of Asthma and Mite Allergy birth cohort followed 3,963 
children for 8 years. Between 0 to 4 years, 2,171 children (55%) reported ‘wheezing’ 
and/or ‘coughing at night without a cold’. In these children possible predictor variables 
for asthma were assessed at the age respiratory symptoms were fi rst reported. 
Asthma was defi ned as wheezing, inhaled steroid prescription, or a doctor’s diagnosis 
of asthma at both age 7 and 8 years of age.
Results
Eleven percent of children with symptoms at 0 to 4 years had asthma at 7 to 8 years. 
Eight clinical parameters independently predicted asthma at 7 to 8 years of age: male 
gender, postterm delivery, parental education and inhaled medication, wheezing fre-
quency, wheeze/dyspnea apart from colds, respiratory infections, and eczema. In 72% 
of the cases, the model accurately discriminated between asthmatic and nonasthmatic 
children. A clinical risk score was developed (range, 0-55 points). Symptomatic children 
with a score of less than 10 points had a 3% risk, whereas children with a score of 30 
points or greater had a 42% risk of asthma.
Conclusion
A risk score based on 8 readily available clinical parameters at the time preschool chil-
dren fi rst reported asthma-like symptoms predicted the risk of asthma at 7 to 8 years 
of age.
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INTRODUCTION
Most preschool children with symptoms suggestive of asthma do not have asthma 
and are unlikely to respond to asthma treatment.1,2 If simple clinical parameters could 
identify children with early symptoms who have a high risk of asthma, this would allow 
for better targeting of secondary prevention measures and treatment for those children 
who are most likely to benefi t. Also, doctors could be more restrictive when prescribing 
treatment to those who probably have transient conditions other than asthma. 
A number of factors that may help to identify early-onset asthma have been reported, 
including a family history of atopy, eczema, and wheezing or wheezing frequency.3-8 
Only few studies predicted asthma in children at the age when symptoms occurred.4,5 
Recently, Frank et al followed 201 wheezing children and reported ‘wheeze after exer-
cise’ and ‘family history of atopy’ as the only signifi cant predictors of later wheeze.5 
However, since these data were not prospectively collected from birth, these authors 
were unable to exclusively select children with a fi rst episode of symptoms. This would 
be important because prediction of asthma becomes clinically relevant as soon as sug-
gestive symptoms fi rst appear. 
The aim of the present study was to develop a prediction rule for the development 
of asthma in children who have their fi rst symptoms between the ages of 0 and 4 
years, that could be useful in primary care settings, and that is based on data collected 
prospectively over a long period of time. For this purpose, we used data from the 
Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort, in which 
3,963 children were followed from birth up to the age of 8 years and in which adherence 
was very good. In children who had reported symptoms suggestive of asthma between 
the ages of 0 and 4 years, the combination of factors that best predicted asthma at 
the age of 7 to 8 years was assessed by using variables that can be easily obtained 
in practice. The resulting model was translated into a simple score that is feasible in a 
primary or secondary care setting to quantify the likelihood of development of asthma.
METHODS
Study population
Recruitment took place in 1996-1997. A screening questionnaire was distributed to 
10,232 pregnant women who attended one of 52 prenatal clinics in the Netherlands. 
Based on this screening, 7,862 women (2,779 allergic and 5,083 nonallergic) were invited 
to participate in the study; 4,146 agreed and gave written informed consent. Question-
naires for parental completion, partly based on the International Study of Asthma and 
Allergies in Childhood core questionnaires,9 were sent to the parents during pregnancy, 
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when the children were aged 3 and 12 months, and yearly thereafter up to the age of 8 
years. The eligibility criterion for the present study was at least one positive response 
to the following questions in the annual questionnaires at age 1 to 4 years: “Has your 
child had wheezing or whistling in the chest in the last 12 months?”, “Has your child 
had cough during the night, when he/she did not have a cold or a chest infection, in 
the last 12 months?”, or both. Children who did not have these early symptoms were 
not eligible and were excluded from our analyses. Details of the study design have 
been published previously.10 The PIAMA birth cohort study included an intervention part 
investigating the effect of mite-impermeable mattress covers. Of the population eligible 
for the current study, 242 (11%) children had used these covers. Because this had no 
effect on any of the investigated associations, these children were included in the fi nal 
analyses. A screening questionnaire was used to select only atopic mothers for the 
intervention part. Importantly, the fi nal study population (including the intervention and 
the natural history part) was not enriched for atopic mothers. See the Methods section 
and Figure E7.1 in the data supplement for further details on study design. The study 
protocol was approved by the medical ethics committees of the participating university 
hospitals.
Predictor variables
Based on previous literature and availability within our dataset we, selected 26 candidate 
predictor variables. All variables had to be easy to assess in general practice and not 
involve invasive tests or time-consuming measurements. Parental questionnaire data 
were used to asses all variables at the age of fi rst report of symptoms. To mimic clinical 
practice, when composing the predictor variables, we only used information gathered 
up to the year of fi rst presentation. Candidate predictor variables were family history of 
atopic diseases (6 variables tested), perinatal factors (8 variables tested), environmental 
factors (4 variables tested), and the child’s pattern of symptoms (8 variables tested). 
(Table 7.1) Age at fi rst symptoms was defi ned as a categorical variable. Parental report 
of number of serious infections per year was recorded in 3 classes (0, 1-2, and ≥3) 
and included in the model as a linear variable, with the assumption that the effect 
of frequent infections was 1.5 times as strong as the effect of infrequent infections. 
All remaining predictors were included as dichotomous variables. For both categorical 
variables “wheezing” and “pregnancy duration” 2 dichotomous dummy variables were 
included in the model. The symptom “dyspnea” was not asked for at 1 or 2 years 
because it was considered unreliable at this age. Therefore the variables “wheezing 
and/or dyspnea apart from colds” and “exercise-induced wheezing and/or dyspnea” 
were scored negative by default in children aged 1 or 2 years. 
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Outcome measures
The following 3 items of the questionnaires were used for the case defi nition of asthma: 
1) at least one episode of wheezing; 2) inhaled steroids prescribed by a medical doctor; 
3) doctor’s diagnosis of asthma (a parental report of a doctor’s diagnosis of asthma at 
any time and a parental report of asthma during the past 12 months). In the analyses 
children were only considered positive for asthma if they had one or more positive 
items at age 7 and one or more positive items at age 8 years. Thereby we aimed to 
select only children with clinically relevant chronic asthma symptoms.
Data analyses
Univariate associations between candidate predictor variables and the outcome of 
asthma were investigated using SAS software version 9.1 (SAS Institute Inc., Cary, 
NC). In the eligible study population the overall proportion of missing data on candidate 
predictor variables was very low (<1%) and follow-up to the age of 8 years was 95%. In 
a standard complete case analysis, subjects with one or more missing values (on any 
variable) are excluded from analysis. Missing data were imputed using the Multivariate 
Imputation by Chained Equations package in the statistical program R (version 2.5.1) 
to avoid any bias that may result from such a complete case analysis.11,12 Multivariable 
analysis was performed by backward stepwise logistic regression, to select combina-
tions of predictor variables. Likelihood ratio statistics were used as a criterion for selec-
tion. Candidate predictors were removed from the model if the corresponding p-value 
was greater than .01. Interaction terms between different candidate predictors were 
tested if effect modifi cation was considered likely based on previous literature. Interac-
tion with age and “atopic mother” was tested for all predictor variables. Calibration of 
the model was assessed both graphically and with the Hosmer-Lemeshow Chi-Square 
statistic. The fi nal model’s ability to discriminate between asthmatic and nonasthmatic 
children was assessed by using the C-index (equivalent of area under the curve in 
receiver operator characteristic curve). We considered a C-index of greater than 0.7 
to be acceptable for a prognostic model.13 Internal validation of the fi nal model was 
performed by using the bootstrap resampling technique.14,15 For 200 bootstrap samples, 
a new model was selected according to the above procedure and tested on the original 
sample. This enabled us to estimate the bias (i.e., optimism) caused by overfi tting. 
Regression coeffi cients and the C-statistic of the fi nal model were corrected for the 
calculated optimism. These regression coeffi cients were multiplied by a factor of 10 to 
create a simple risk score for use in clinical practice. Multivariate regression analyses 
and model validation were performed using R version 2.5.1 (Free Software Foundation, 
Inc., Boston, Mass).16
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Table 7.1. General characteristics of study population of children who reported symptoms between 
age 0 to 4 years and univariate relationship with asthma at 7 to 8 yrs
All children* 
(n=2,171)
n (%)
Asthma 
at 7-8 yrs
(n=240)
n (%)
OR (CI95%)
for asthma
p-value†
Age at onset of symptoms‡
0-1 year 1,157 (53) 143 (60) 1.7 (1.0-2.9) 0.042
1-2 years 423 (19) 47 (20) 1.5 (0.9-2.7) ns
2-3 years 366 (17) 33 (14) 1.2 (0.7-2.2) ns
3-4 years (=reference) 225 (10) 17 (7) ref. -
Reported symptom(s)
Cough at night§ 1,314 (62) 137 (57) 0.8 (0.6-1.1) ns
Wheezing
No wheezing (=reference) 941 (43) 62 (26) ref. -
1-3 times/year 860 (40) 98 (41) 1.8 (1.3-2.5) <0.001
>3 times/year 370 (17) 80 (33) 3.9 (2.7-5.6) <0.001
Family history
Parental asthma 389 (18) 67 (28) 1.9 (1.4-2.6) <0.001
Parental inhaled medication 372 (17) 77 (32) 2.6 (1.9-3.5) <0.001
Parental hay fever 885 (41) 129 (54) 1.8 (1.4-2.4) <0.001
Sibling asthma 129 (6) 22 (9) 1.7 (1.1-2.8) 0.025
Sibling hay fever 57 (3) 10 (4) 1.7 (0.9-3.5) ns
Sibling eczema 402 (19) 51 (21) 1.2 (0.9-1.7) ns
Perinatal factors
Male gender 1,196 (55) 162 (68) 1.8 (1.4-2.4) <0.001
Caesarean section 191 (9) 31 (13) 1.6 (1.1-2.5) 0.018
Low birth weight (<2500 g) 94 (4) 15 (6) 1.6 (0.9-2.8) ns
Breastfeeding ever 1,793 (83) 190 (79) 0.8 (0.6-1.1) ns
Older sibling(s) 1,109 (51) 134 (56) 1.2 (0.9-1.6) ns
Medium/low education parent(s)¶ 1,659 (76) 199 (83) 1.6 (1.1-2.2) 0.013
Smoking during pregnancy|| 325 (15) 41 (17) 0.8 (0.6-1.2) ns
Delivery
Term (=reference) 1,948 (90) 204 (85) ref. -
Preterm (<37 wks) 118 (5) 15 (6) 1.2 (0.7-2.2) ns
Post-term (>42 wks) 105 (5) 21 (9) 2.1 (1.3-3.5) 0.003
Environmental factors at age of report of symptoms
Daycare 819 (38) 71 (30) 0.7 (0.5-0.9) 0.006
Smoking in parental house** 632 (29) 67 (28) 0.9 (0.7-1.3) ns
Pet ownership 1,221 (56) 128 (53) 0.9 (0.7-1.1) ns
Avoidance pets (due to allergy) 606 (28) 98 (41) 1.9 (1.5-2.5) <0.001
Child’s other symptoms at age of report of symptoms
Wheezing/dyspnea apart from colds§†† 79 (4) 20 (8) 2.9 (1.7-4.9) <0.001
Wheezing/dyspnea exercise induced†† 68 (3) 14 (6) 2.2 (1.2-3.9) 0.013
Nose symptoms§ 908 (42) 126 (53) 1.6 (1.2-2.1) <0.001
Resp. tract infections‡‡
No infections (=reference) 655 (30) 43 (18) ref. -
1-2 times/year 993 (46) 111 (46) 1.8 (1.2-2.6) <0.001
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RESULTS
Study population
Of the 4,146 included mothers, 183 (4.5%) dropped out before returning the fi rst post-
natal questionnaire for various reasons (e.g., stillbirth, language barrier, not interested, 
moved). Of the 3,963 remaining children, 2,171 (55%) reported an episode of wheez-
ing, coughing at night, or both between the ages of 0 to 4 years. Because only those 
children with early symptoms were eligible, the population for the present analysis 
consisted of 2,171 children. In more than half of the children, fi rst symptoms were 
reported before the age of 1 year. (Table 7.1) The symptom of coughing at night (62%) 
was slightly more prevalent than wheezing (57%). At the age of 8 years, complete data 
on the outcome measure was available from 1,921 children (88% of the eligible study 
population). Complete data on all predictor variables was available from 1,854 (85%) 
children. The percentage of missing data per individual predictor variable did not exceed 
2%. Children with at least 1 missing value on predictor variables, outcome variables, 
or both (n = 486) were less likely than children with complete data (n = 1,685) to have 
parents who both had a high level of education (19 vs. 25%), to have been breastfed 
(79 vs. 84%) and to attend daycare (33 vs. 40%), and more likely to have been exposed 
to cigarette smoke during pregnancy (19 vs. 13%) and have had a low birth weight (8 
vs. 4%). This shows that complete case analyses would refer to a study population 
that is not representative of the original study population. To match the distribution 
All children* 
(n=2,171)
n (%)
Asthma 
at 7-8 yrs
(n=240)
n (%)
OR (CI95%)
for asthma
p-value†
≥3 times/year 523 (24) 86 (36) 2.8 (1.9-4.1) <0.001
Eczema
Doctor’s diagnosis ever 809 (37) 127 (53) 2.1 (1.6-2.7) <0.001
Eczematous rash present§§ 465 (21) 89 (37) 2.4 (1.8-3.2) <0.001
Ever admitted for respiratory problem 65 (3) 17 (7) 3.0 (1.7-5.3) <0.001
All numbers and odds ratios refer to imputed dataset (n = 2,171). *: All children in eligible study 
population reported wheezing and/or coughing at night at least once between the age of 0 and 4 
years. †: Signifi cance calculated using Wald Chi-square test. ‡: p for trend (Cochran-Armitage test) = 
0.012. §: In period without a cold, fl u or chest infection. ¶: Defi ned as an education below the level 
bachelor/masters (HBO/University in Dutch system) for at least one of the parents. ||: Defi ned as 
any smoking, at last 4 weeks after estimated date of conception. **: Defi ned as smoking in the 
child’s house more than once a week. ††: Data only available for children aged 3 or 4 years at fi rst 
report of symptoms; at age 1 and 2 considered negative by default. ‡‡: Parental report of number of 
serious respiratory, throat, nose, and/or ear infections such as fl u, infection of the throat, infection 
of the middle ear, sinusitis, bronchitis or pneumonia in the last 12 months. §§: Defi ned as parental 
report of itchy rash on at least one of following locations: folds of elbows, behind knees, around 
ears or eyes, in front of ankles.
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of characteristics of the original dataset, these variables were taken into account in 
constructing the imputed dataset. Thus our results pertain to the imputed dataset, 
including all 2,171 children.
Outcome asthma
Two hundred and forty (11%) children had symptoms, medication, or both at the ages 
of both 7 and 8 years and were thus defi ned as cases. (Table 7.2) The prevalence of 
asthma symptoms and medication use at the age of 7 years was similar to the preva-
lence at the age of 8 years. Only 10% of the children with asthma (n = 25) exclusively 
reported wheezing; the majority (90%) also used medication, had a doctors’ diagnosis 
of asthma, or both. Asthma prevalence in the imputed dataset was 1.5% higher than 
in the complete dataset. Considering all children initially included in the birth cohort (n 
= 3,963), 85% of the children with asthma at 7 to 8 years reported cough, wheeze, or 
both at some point in the fi rst 4 years of life. Apparently, children without these early 
symptoms accounted for only 15% of asthma diagnoses at 7 to 8 years of age.
Univariate analysis
The risk of asthma decreased with increasing age of report of fi rst symptoms. A family 
history of asthma, hay fever, or both was clearly associated with an increased risk of 
asthma, especially parental use of inhaled medication. Male gender, caesarean section, 
low level of parental education, relatively long pregnancy duration, and avoidance of 
pets because of allergies in the family were all signifi cantly associated with a higher 
prevalence of asthma in this population of children with early symptoms. Children at-
tending daycare at the age that symptoms were fi rst reported had a lower prevalence of 
asthma at 7 to 8 years of age. Apart from the symptom “cough at night” (which was an 
inclusion criterion) all symptoms investigated were signifi cantly positively associated 
with asthma. Results of all univariate analyses are given in Table 7.1.
Table 7.2. Prevalence of features of asthma at age 7 and 8 years
Age
Wheezing at 
least once
Inhaled steroid 
prescriptions
Doctor’s diagnosis of 
asthma*
Asthma† 
(positive on ≥ 1 item)
% (n) % (n) % (n) % (n)
7 yrs 10.0 (216) 11.9 (259) 5.0 (108) 16.7 (362)
8 yrs 11.0 (239) 11.0 (238) 6.0 (130) 17.0 (370)
Both at 7 and 8 yrs 4.8 (105) 7.9 (172) 3.4 (73) 11.1 (240)
All numbers refer to imputed dataset (n = 2,171). *: Defi ned as a parental report of a doctor’s 
diagnosis of asthma ever, in combination with parental report of asthma in the past 12 months. 
†: Only children with ≥ 1 item positive at age 7 and 8 years were considered to have asthma in 
subsequent analyses.
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Multivariate analysis
In the multivariate analysis male gender, postterm delivery, parental education, parental 
inhaled medication, wheezing frequency, wheezing/dyspnea apart from colds, respira-
tory tract infections, and eczema remained as independent predictors of asthma. (Table 
7.3) Age did not signifi cantly contribute nor did interaction terms of predictors with age. 
Odds ratios for individual predictors are reported before and after internal validation. The 
discriminative power of the model, represented by the C-index, was 0.72 after validation. 
A clinical prediction score was developed by assigning points for each predictor vari-
able based on its regression coeffi cient. (Table 7.3) A score for each individual child was 
calculated using the equation shown in the legend of Table 7.3. The score ranged from 
0 to 55, with a median of 15.5. Figure 7.1 depicts the predicted risk of asthma at 7 to 8 
years for every prediction score value. The risk of asthma increases with an increasing 
prediction score. In Figure 7.2 the predicted risk is compared with the observed risk in 
our population per score category with 5-point intervals. Because only a minority (2%) 
Table 7.3. Multivariate prediction model for asthma
Predictor variable
Before validation*
OR (95% CI)
After validation*
OR (95% CI)
Points in 
prediction 
score¶
1 Male gender 1.7 (1.3-2.3) 1.6 (1.2-2.1) 4.6
2 Post-term delivery 2.3 (1.3-4.0) 2.1 (1.2-3.6) 7.3
3 Medium/low education parent(s) 1.6 (1.1-2.3) 1.5 (1.1-2.2) 4.2
4 Inhalation medication parent(s) 2.4 (1.8-3.3) 2.2 (1.6-3.0) 7.7
5 Wheezing frequency†
1-3 times/yr 1.6 (1.1-2.3) 1.5 (1.1-2.1) 4.2
≥ 4 times/yr 2.8 (1.9-4.2) 2.5 (1.7-3.6) 9.1
6 Wheezing/dyspnea apart from colds‡ 2.3 (1.3-4.1) 2.0 (1.1-3.7) 7.1
7 Serious infections†
1-2 times/yr 1.7 (1.3-2.2) 1.6 (1.2-2.1) 4.6
≥ 3 times/yr 2.2 (1.4-3.3) 2.0 (1.3-3.0) 6.9
8
Doctor’s diagnosis of eczema and eczematous rash 
present
2.6 (1.9-3.5) 2.3 (1.7-3.1) 8.2 +
C-index§ 0.743 0.717
55.1
Hosmer-Lemeshow (p-value) 0.822 0.538
*: Internal validation performed using bootstrapping method. †: ‘None’ is reference category: 0 
points. ‡: Only available for children aged 3 or 4 years, in younger children negative by default. 
§: Equivalent of ‘Area Under Curve’ in ‘Receiver Operator Characteristic’ (ROC) curve. ¶: Points 
calculated based on regression coeffi cients after validation (log(OR) multiplied by a factor 10). 
Individual risk score can be calculated using following equation: Individual score = 4.6 x Gender 
(boy=1, girl=0) + 7.3 x Postterm delivery (yes=1, no=0) + 4.2 x Medium/low education at least 
1 parent (yes=1, no=0) + 7.7 x Inhalation medication by at least 1 parent (yes=1, no=0) + 4.2 x 
Infrequent wheezing (yes=1, no=0) + 9.1 x Frequent wheezing (yes=1, no=0) + 7.1 x Wheezing/
dyspnea apart from colds (yes=1, no=0) + 4.6 x Infrequent serious infections (yes=1, no=0) + 6.9 
x Frequent serious infections (yes=1, no=0) + 8.2 x Diagnosis eczema and rash present (yes=1, 
no=0)
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of children had a score of greater than 35 points, they were combined into a single 
category. Figure 7.2 shows that the model is well calibrated, which is confi rmed by the 
Hosmer-Lemeshow test. (Table 7.3) Of the 561 children with a predictor score of less 
than 10, only 18 (3%) had asthma at the age of 7 to 8 years. In contrast, 50% (17/34) of 
the children with a score of at least 35 at fi rst presentation of symptoms had developed 
asthma by the age of 7 to 8 years. Dichotomizing the prediction score at a certain cutoff 
Asthma prediction score
0 5 10 15 20 25 30 35 40 45 50 55
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20%
40%
60%
80%
100%
Predicted risk asthma
 
Figure 7.1. Predicted risk of asthma development at 7 to 8 years by prediction score
5-point categories* of asthma prediction score
0-5 5-10 10-15 15-20 20-25 25-30 30-35 >35
0%
20%
40%
60%
80%
100%
Predicted risk asthma per category
Observed risk asthma per category
(n=209)
(n=473) (n=158)
(n=349)
(n=521)
(n=352)
(n=75)
(n=34)
Figure 7.2. Predicted and observed risk of asthma development at 7 to 8 years per prediction score 
category
Number of children observed per category given between brackets. Expected risk estimated 
using the average score per 5 point category. *: Estimate for the merged category (≥35 points) is 
weighed by the number of children actually observed at each 5 point subcategory between 35-55.
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value leads to a test with a dichotomous (positive/negative) result, which could be used 
to assist in clinical decisions in general practice. Sensitivity and specifi city corresponding 
to ascending cutoff values are graphically displayed in a receiver operator characteristic 
curve. (Figure 7.3) Table 7.4 further reports the predictive values and percentages of 
children with positive scores at the different cutoff values. For comparison with cur-
rent practice, the predictive value of a doctor’s diagnosis of asthma in the year when 
symptoms were fi rst reported is given in Figure 7.3 and Table 7.4. Thereby it should be 
noted that for a “doctor’s diagnosis of asthma”, all information that is available in clinical 
practice can be considered (e.g., allergy tests, lung function tests, medication trial, refer-
ral to secondary/tertiary medical centers). Our prediction rule merely uses simple items 
from the medical history and, with an appropriate cutoff, performs better. The proportion 
of children with asthma at 7 to 8 years of age accounted for by children at highest risk 
according to the prediction rule is plotted in Figure 7.4. It can be seen from this fi gure that 
half of the population with the highest prediction score account for 80% of all asthma 
cases at 7 to 8 years of age. By selecting a cutoff of 20 points, 28% of the population will 
have a positive score (high risk) and this group accounted for 60% of all asthma cases. 
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Figure 7.3. ROC-curve of categorised prediction score on outcome asthma at 7 to 8 years
Cutoff values of prediction scores are reported in curve (dots). Area under the ROC-curve (C-index) 
for the categorised score is 0.736 (before validation). Also sensitivity and specifi city for doctor’s 
diagnosis of asthma at the age when symptoms were fi rst reported (between 0 to 4 yrs) are 
displayed (square).
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Figure 7.4. Proportion of children with asthma at 7 to 8 years explained by the proportion of 
children at highest risk, according to the prediction score
Cutoff values of prediction scores are reported in the curve (dots). Also data for doctor’s diagnosis 
of asthma at the age when symptoms were fi rst reported (between 0 to 4 yrs) are displayed 
(square).
Table 7.4. Test characteristics at various cutoff points of prediction score for asthma at 7 to 8 yrs
Cutoff value
N positive 
test (%)*
Sensitivity Specifi city
Positive predictive 
value
Negative predictive 
value
≥ 10 1,610 (74) 93 28 14 97
≥ 15 1,137 (52) 82 51 17 96
≥ 20 616 (28) 60 76 23 94
≥ 25 268 (12) 36 91 32 92
≥ 30 109 (5) 19 97 42 91
≥ 35 34 (2) 7 99 50 90
Doctors’ diagnosis 
asthma†
310 (14) 29 88 23 91
*: Number (%) of children within our dataset with a positive test result at different cutoff values. A 
‘positive test’ is defi ned as an individual score equal to or above the chosen cutoff value. †: Defi ned 
as a parental report of a doctor’s diagnosis of asthma at the age symptoms were fi rst reported 
(between 0 to 4 yrs).
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DISCUSSION
In this study we developed a prediction rule for the risk of asthma at 8 years of age, to 
be used when preschool children present with symptoms suggestive of asthma for the 
fi rst time. From a large prospective database, we identifi ed 8 easily obtainable clinical 
parameters that best characterized the risk of asthma at 7 to 8 years of age.
Algorithms to predict development of asthma in children have been reported 
previously. However, differences in design and analysis should be considered when 
comparing the results. Although some authors developed a model for use in the 
general population,3,17 others restricted their analysis to a selection of children with 
early symptom, such as wheeze or cough.4-7 We restricted our analysis to children who 
reported “wheezing”, “coughing at night without a cold or chest infection”, or both. We 
based our selection on these symptoms because they are prevalent in young children 
and suggestive of childhood asthma.18,19 Another important consideration is that most 
studies developed a prediction rule using all available information at a fi xed age.3,6,7,17 
Consequently, these prediction rules are valid only for this fi xed age rather than at the 
age of symptom onset. In a recent study by Frank et al, the investigators followed 
children of different ages with a parental report of wheeze.5 In 201 children aged 0 to 
4 years, they found only “wheeze after exercise” and “history of eczema or hayfever” 
to be predictive for wheezing after at least 6 years of follow-up. Interestingly, wheezing 
frequency or severity was not associated with symptom persistence. In their study 
data were not collected longitudinally from birth. Therefore the analysis could not be 
focused on the age of fi rst symptoms, when prediction of asthma becomes relevant. 
Also, the fact that 51% of their original population was lost to follow-up might have 
been a source of bias.5
How do our fi ndings compare with those from previous studies? A risk index de-
veloped in the Tucson Children’s Respiratory Study also included wheezing frequency, 
eczema, and parental asthma as major criteria.3 This study reported wheezing apart 
from colds as a minor risk factor. The German Multicentre Allergy Study birth cohort 
reported male gender and parental atopy as independent predictors for symptom 
persistence in children with wheeze before the age of 3 years,7 and an algorithm to 
predict asthma from the Isle of Wight birth cohort included parental history of asthma 
and frequency of respiratory infections.6 All these earlier studies also included invasive 
allergy tests in their algorithm. This was also done in a Dutch case-control study by 
Eysink et al.4 For reasons of practical applicability, we included only clinical information 
that is easily obtainable in a primary care setting. In contrast to earlier studies, we found 
postterm delivery as a predictor of asthma development. The fact that we found this 
association does not necessarily imply a causal relationship. It may well be explained 
by correlated risk factors, such as meconium aspiration, caesarean section, birth order 
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and/or high birth weight.20-23 High socioeconomic status was consistently linked with 
a lower prevalence of childhood asthma,24,25 but this is the fi rst study to report it as an 
independent predictor in a prognostic model.
The predictive power of our rule is not easily comparable to other studies because of 
differences in study design and objective. The test characteristics of the stringent risk 
index by Castro-Rodriguez et al to predict asthma at 8 years are similar to our prediction 
rule at a cutoff of 30 points.3 (Table E7.1 data supplement) Considering that our rule 
predicted asthma in children at a much younger age (mean, 1.8 vs. 3 yrs), did not require 
any laboratory tests, and was corrected for over-optimism by bootstrapping, we propose 
that our prediction rule can have an added value over the currently available risk scores. 
Second, we compared the index by Castro-Rodriguez et al with our prediction score by 
applying both algorithms to our own dataset using only variables from clinical history 
(eosinophils not included) at the age symptoms were fi rst reported. (Data supplement 
and Table E7.2 for further details.) We found that our prediction rule had better predictive 
power in symptomatic preschool children at the age of fi rst symptoms. 
A strong point of our study is its size. The PIAMA birth cohort is the largest birth 
cohort used to predict asthma in children. Further strengths are good adherence and 
little missing data. In combination with the multivariate imputation, this limits the risk 
of selection bias.12,26,27 Unlike most previous studies, we performed internal validation 
by bootstrapping, which leads to more realistic estimates of regression coeffi cients and 
discriminative power of the model.15 By closely following clinical practice in the selec-
tion of our eligible population and predictor variables, we have developed a clinical tool 
that can be used at the moment it is of most clinical relevance. Finally, since the original 
study population of the PIAMA birth cohort is a refl ection of the general population, our 
results may be valid for the Netherlands and, perhaps, other Western countries.
There are some limitations that should be considered when interpreting our results. 
First, information on dyspnea in children younger than 3 years is lacking in our database 
and diffi cult to retrieve reliably from parental reports. We cannot exclude that such 
information would contribute to the prediction. Consequently, we may have underesti-
mated the predictive value of this variable. Second, in the absence of a universal gold 
standard, the defi nition for asthma remains arbitrary. We decided to consider asthma 
as reported asthma symptoms, medication, or both at both ages 7 and 8 years because 
we aimed to predict chronic disease with clinical relevance. In a sensitivity analysis in 
which asthma was defi ned as doctor’s diagnosis plus symptoms at 7 to 8 years of age, 
our prediction rule did not lose any of its predictive power (C-index 0.752). 
We developed our prediction rule in a population selected on the basis of symptoms 
reported by questionnaire. Will these children indeed see a general practitioner? We 
propose that most parents will visit a general practitioner when their children have 
wheezing, nightly cough, or both, especially when their children are young (1-2 years of 
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age). This is supported by our data: 1,577 (73%) children received a doctor’s diagnosis 
of a respiratory illness in the year of fi rst symptoms. Clearly, these children consulted 
a medical doctor with respiratory symptoms, and the prediction rule could have been 
used. A validation of our prediction rule in this subgroup showed that it had a similar 
predictive value (C-index 0.726) and that all included questions remained signifi cant 
predictors of later asthma at 7 to 8 years (p = 0.05, see data supplement and Table 
E7.3 for details). This strongly supports that our prediction rule is relevant and valid for 
children presenting in general practice. Before our prediction rule can be implemented, 
an external validation on a separate dataset should be performed.
Wheezing and coughing are very common in children.19 More than half of the chil-
dren in this birth cohort reported one of these symptoms before the age of 5 year, 
the majority already in the fi rst year of life. Treatment with inhaled medication could 
be effective for some but is costly and can be troublesome to administer to young 
children, and there is little evidence base for the use of inhaled corticosteroids in viral 
induced intermittent wheeze.2 It remains a challenge for the clinician in general practice 
to differentiate children with transient symptoms from children who will have chronic 
asthma, especially if only a few risk factors are present. This is illustrated by the fact 
that in our birth cohort only 10% of children who received asthma medication in the fi rst 
year of life were still using this medication 3 years later.28 A trial with asthma medication 
could be helpful to confi rm the diagnosis,29 but spontaneous improvement while taking 
steroids can easily be misinterpreted as a favourable treatment effect. Despite these 
diffi culties, clinicians will need to make treatment decisions. Our prediction score may 
help to improve the accuracy of the prognosis and reduce undertreatment or overtreat-
ment in individual children, simply by combining readily available clinical information. 
The positive predictive value of our prediction score was twice as high as that of 
reported doctor’s diagnoses at the same age, with similar negative predictive values. 
Apparently, the combination of 8 simple clinical questions had a better predictive value 
than the complete workup that is current practice for preschool children. We therefore 
propose that our prediction score could serve as a practical and useful tool for clinicians 
who deal with preschool children presenting with symptoms suggestive of asthma, es-
pecially in a primary care setting. At a cutoff of 15 points, half of the children will have a 
negative test result. Because 96% of these children will not develop asthma, this might 
well justify a conservative approach with reassurance of the parents. Increasing cutoff 
points could be used to imply different clinical actions, such as a specifi c IgE test, start 
of a trial with inhaled medication, or even referral to secondary care. Optimal cutoff 
points may vary between different settings, and an extensive analysis falls outside the 
scope of this article. Nonetheless, a reliable risk assessment in individual children is an 
essential step towards individualized asthma therapy. 
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In conclusion, we have developed an asthma prediction score that uses 8 easily obtain-
able clinical parameters and can be used in preschool children who present with asthma 
symptoms to predict asthma at the age of 7 to 8 years. Children with a low score (<10) 
at onset of symptoms had a risk of only a few per cent of having asthma at 8 years, 
whereas children scoring 30 or higher had a risk of greater than 40%. The score could 
potentially be helpful for prognosis and treatment decisions in these young children.
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METHODS
All children participated in the Prevention and Incidence of Asthma and Mite Allergy 
(PIAMA) birth cohort study. This multicentre study was conducted in 3 different regions 
of The Netherlands: north (Groningen and surroundings), central (Bilthoven, Wagenin-
gen and surroundings) and southwest (Rotterdam and surroundings). Recruitment 
took place between March 1996 and May 1997 by means of a validated screening 
questionnaire,E1 distributed by midwifes to 10,232 pregnant woman visiting one of 52 
prenatal clinics. According to the results of this screening the women were divided 
in an allergic and a non-allergic group. Women with any of the following self-reported 
symptoms were defi ned as allergic: asthma, hay fever, house dust allergy, house dust 
mite allergy or pet allergy. Children of allergic women were defi ned as ‘high-risk’. Based 
on the screening 7,862 women (2,779 allergic and 5,083 non-allergic) were invited to 
participate in the study, approximately 50% (n = 4,146) agreed and gave informed 
consent (1,327 allergic and 2,819 non-allergic). The PIAMA cohort includes an interven-
tion part, studying the effect of impermeable mattress covers, and a natural history 
part. Only high-risk children could participate in the intervention study. As previously 
published, the intervention had no effect on the incidence of allergy or respiratory 
symptoms.E2 Furthermore the intervention was no signifi cant predictor of asthma in our 
study, and had no signifi cant interaction with any of the candidate predictor variables 
tested. Therefore, we considered the complete PIAMA study population (both the 
intervention and the natural history part) in the present study. After birth, this study 
population consisted of 3963 children. Importantly, the proportion of children with an 
allergic mother (31%) in the PIAMA is very similar to the proportion in the general 
Dutch population. For the current study only children with a positive response to the 
questions in the annual questionnaires at age 1-4 years “Has your child had wheezing 
or whistling in the chest in the last 12 months” and/or “Has your child had cough during 
the night, when he/she did not have a cold or a chest infection, in the last 12 months” 
were eligible. Figure E7.1 presents how the fi nal study population was arrived at in the 
form of a fl owchart.
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 Screenings questionnaire in pregnant women (n=10,232)  
    
 Invited pregnant women (n=7,862*)  
    
 Agreed with informed consent (n=4,146)  
    
 Children in study after birth (n=3,963)  
  
Lost to follow-up at 1 
n=54 
 Symptoms† in 1st yr? 
 Yes 
(n=1,157) 
 
n=1,157 
 
  
    
  
No 
(n=2,752)   
   
Lost to follow-up at 2 
n=21 
 Symptoms in 2nd yr?  Yes 
(n=423) 
 
n=1,580  
 
  
  
No 
(n=2,308)   
   
Lost to follow-up at 3 
n=24 
 Symptoms in 3rd yr? 
 
Yes 
(n=366) 
 
n=1,946  
  
 
  
No 
(n=1,918)   
Lost to follow-up at 4 
n=11 
 Symptoms in 4th yr? 
 
Yes 
(n=225) 
 
n=2,171  
   
  
No 
(n=1,682)    
 
Not eligible for study 
(n=1,682)    
 
Eligible study population 
n=2,171 
 
 
 
No (n=109); 
Lost to follow-up after 
reported symptoms 
 Follow-up until age 7-8 yrs? 
 
 
Yes: 2,062  
(95% of eligible 
study population) 
 
 
No (n=141); 
Questionnaire not 
returned at 8 yrs 
 Complete data on outcome 
at 7-8 yrs? 
 
 
Yes: n=1,921 
(88% of eligible 
study population)  
 
Figure E7.1. Flowchart of study population
*: 2,779 allergic and 5,083 non-allergic mothers were invited, as determined before initiation of 
the study based on a power calculation. Of the 4,146 women that were included in the study, the 
proportion of allergic women (31%) was very similar to that in the general Dutch population. †: 
Symptoms were defi ned as a positive response to the questions “Has your child had wheezing or 
whistling in the chest in the last 12 months” and/or “Has your child had cough during the night, 
when he/she did not have a cold or a chest infection, in the last 12 months”. Reasons for loss 
to follow-up included: not motivated, illness of child, repeated non-response, moved, personal 
reasons.
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RESULTS
Comparison with previous literature
Due to differences in study design and objective the predictive power of our rule is not 
easily comparable to other studies. Castro et al developed a risk index for the prediction 
of asthma in preschool children.E3 An important difference between their study and 
ours is that they predicted asthma in children at the age of three years, regardless of 
the age of onset of symptoms. Secondly, their algorithm included blood eosinophils. 
We choose not to include any invasive and/or time consuming tests because our aim 
was to develop a prediction rule with which a doctor can instantly calculate the risk of 
later asthma. Despite these differences it is worthwhile to compare the yield of their 
algorithm with our risk score. Table E7.1 gives the test characteristics of the loose and 
stringent risk index as reported by Castro et al to predict asthma at 8 years.E3 The same 
information is given for our prediction rule at a cut-off of 21 and 30 points (which leads 
to comparable groups of children with a positive test). It can be seen that sensitivity and 
specifi city as well as predictive values are similar at both cut-off values. In summary 
we found similar test characteristics of the two algorithms despite the following differ-
ences: (1) the majority of children in our study was 1 year old at the time of prediction 
(compared to 3 years in paper by Castro et al); (2) our prediction rule did not include any 
invasive tests (such as blood eosinophils); (3) unlike the study by Castro et al, our study 
adjusted for over-optimism by using an internal bootstrap validation; (4) our study used 
a more strict defi nition of asthma. Therefore we propose that our prediction rule can 
have an added value over this currently available risk score.
Secondly we aimed to assess whether the new clinical predictor variables that were 
found are of added value over those previously reported. We did this by comparing the 
variables included in the paper by Castro et al with those in our prediction rule, using 
our own dataset. Apart from eosinophil counts we annually collected all the information 
Table E7.1. Comparison of predictive yield of PIAMA risk with predictive yield as reported by Castro 
et al.
Risk score
N positive 
test (%)
Sensitivity Specifi city
Positive 
predictive value
Negative 
predictive value
PIAMA score at cut-off ≥ 21 506 (23) 54 80 25 93
Loose index Castro et al.* 180 (23) 51 82 29 91
PIAMA score at cut-off ≥ 30 109 (5) 19 97 42 91
Stringent index Castro et al.* 39 (5) 16 97 44 88
*: Taken from table 2, 5 and 6 of paper by Castro et al.E3 Note that prediction was performed at the 
fi xed age of 3 years, that a lab test (eosinophilia) was included, and that sensitivity, specifi city and 
negative predictive values were calculated using the complete study population (including children 
who never wheezed).
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included in the risk index by Castro: infrequent wheezing, frequent wheezing, doc-
tors’ diagnosis of parental asthma, doctors’ diagnosis of eczema, allergic rhinitis, and 
wheezing in absence of a respiratory infection. Using information up to the year of fi rst 
symptoms and following their algorithm (without considering the factor eosinophilia) we 
calculated the risk of later asthma for every child within our own dataset. This resulted 
in three categories: (1) low risk of asthma: ‘negative loose index’; (2) intermediate risk 
of asthma: ‘positive loose index but negative strict index’; and (3) high risk of asthma: 
‘positive strict index’. We then compared the risk score according to Castro with our 
own internally validated PIAMA risk score. For this purpose, we also categorized our 
continuous PIAMA risk score in three identical categories (at similar cut-off points as 
the Castro risk score). The C-index of the Castro risk score was 0.628 vs. the PIAMA 
risk score 0.696. This implies that while using easily obtained variables from clinical his-
tory, the PIAMA score could better discriminate between asthmatic and non-asthmatic 
children. Importantly, by restricting the PIAMA score to only 3 categories predictive 
information was lost. In clinical practice a continuous score could provide a more 
accurate individual risk assessment. Indeed, with the PIAMA score as a continuous 
variable the C-index rises to 0.740. Detailed results of this analysis including sensitivity, 
specifi city and predictive values of the two risk scores are given in Table E7.2. This table 
illustrates that all indices are higher in our prediction score than in the risk index by 
Castro et al. Apparently the use of the additional variables (gender, pregnancy duration, 
infection frequency, parental education, and parental inhaled medication rather than 
parental asthma) is of added value in the prediction of later asthma.
External validity of prediction rule
We developed our prediction rule in a population selected on the basis of symptoms 
reported by questionnaire. Will these children indeed see a general practitioner? We 
Table E7.2. Comparison of risk index by Castro et al with the PIAMA risk score categorised to three 
equal categories within the PIAMA dataset (using only variables from clinical history)
Castro risk score* PIAMA risk score
n (%) Sens Spec PPV NPV n (%) Sens Spec PPV NPV
Low risk† 1,573 (72) 1,555 (72)
Intermediate risk‡ 402 (19) 49 75 20 92 416 (19) 60 76 23 94
High risk§ 196 (9) 20 92 25 90 196 (9) 31 93 37 92
C-index¶ 0.628 0.696
Hosmer-Lemeshow 0.190 0.856
*The algorithm as described by Castro et al. E3 was followed, without considering the variable of 
eosinophilia. Only information up to the age of fi rst presentation was used. †: Low risk of asthma: 
‘negative loose index’. ‡: Intermediate risk of asthma: ‘positive loose index but negative strict 
index’. §: High risk of asthma: ‘positive strict index’. ¶: Equivalent of ‘Area Under Curve’ in ‘Receiver 
Operator Characteristic’ (ROC) curve.
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assume that most parent will present at a general practitioner when their child has 
respiratory symptoms such as wheezing or coughing at night without a cold, especially 
if the child is very young. (The majority of children were under the age of 1 year when 
they had fi rst symptoms.) This is an important assumption, because a general practitio-
ner will only be able to use a prediction rule if children seek medical attention. To check 
the assumption and thereby the external validity of our results we performed a valida-
tion of our prediction rule in a subgroup of children who reported a doctors’ diagnosis of 
a respiratory illness in the same year as they had symptoms. Of these children we can 
be certain that they presented at a medical doctor, with respiratory symptoms. The fol-
lowing doctors’ diagnosed respiratory illnesses were included: bronchitis, pneumonia, 
pertussis, fl u, throat infection, croup, pseudo-croup, otitis media and asthma. Of the 
2,171 children 1,577 (73%) reported at least one of these diagnoses in the year of 
fi rst symptoms. The percentage of children with asthma at 7-8 years in this subgroup 
(11.7%) did not differ signifi cantly from the percentage in the total population (11.0%).
Table E7.3 gives the results of the developed model in the total population and in the 
subgroup with a doctors’ diagnosis of a respiratory illness. It can be seen from the table 
that the regression coeffi cients of all variables remained more or less stable. The level 
of signifi cance of some factors decreased. This can be partly explained by the weaker 
associations with asthma at 7-8, but also partly by the decrease in sample size (n = 
Table E7.3. Validation of multivariate model in subgroup of children with a doctors’ diagnosis of 
respiratory illness in the year of fi rst symptoms (n = 1,577)
Predictor variable
Total population
(n=2,171)
OR (95% CI)
p - value
Validation in 
subgroup
(n=1,577)
OR (95% CI)
p - value
1 Male gender 1.7 (1.3-2.3) <0.001 1.9 (1.3-2.6) <0.001
2 Post-term delivery 2.3 (1.3-4.0) 0.003 2.0 (1.1-3.7) 0.039
3 Medium/low education parent(s) 1.6 (1.1-2.3) 0.010 1.5 (1.0-2.2) 0.057
4 Inhalation medication parent(s) 2.4 (1.8-3.3) <0.001 2.3 (1.6-3.2) <0.001
5 Wheezing frequency*
1-3 times/yr 1.6 (1.1-2.3) 0.007 1.4 (1.0-2.1) 0.078
≥ 4 times/yr 2.8 (1.9-4.2) <0.001 2.7 (1.8-4.1) <0.001
6 Wheezing/dyspnoea apart from colds† 2.3 (1.3-4.1) 0.007 2.7 (1.4-5.0) 0.002
7 Serious infections*
1-2 times/yr 1.7 (1.3-2.2) <0.001 1.5 (1.1-2.0) 0.028
≥ 3 times/yr 2.2 (1.4-3.3) <0.001 1.8 (1.2-2.7) 0.028
8
Doctor’s diagnosis of eczema and 
eczematous rash present
2.6 (1.9-3.5) <0.001 2.2 (1.6-3.2) <0.001
C-index‡ 0.743 - 0.726 -
Hosmer-Lemeshow (p-value) 0.822 - 0.805 -
*: ‘None’ is reference category: 0 points. †: Only available for children aged 3 or 4 years, in 
younger children negative by default. ‡: Equivalent of ‘Area Under Curve’ in ‘Receiver Operator 
Characteristic’ (ROC) curve.
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1,577 vs. n = 2,171). Most factors remained strong and very signifi cant independent 
predictors of asthma at 7-8. The overall predictive power of the model decreases slightly 
from 0.743 to 0.726. 
In conclusion, we fi nd that all variables in our original prediction rule were also 
signifi cant predictors in this subpopulation of children with a doctors diagnosis of a 
respiratory illness. This strongly supports our assumption that the prediction rule that 
was developed in this study has good validity in children who present at a medical 
doctor in the year of fi rst symptoms. 
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ABSTRACT
Rationale
For clinicians it remains very diffi cult to predict whether preschool children with symp-
toms suggestive of asthma will develop asthma in later childhood.
Objective
To investigate whether measurement of fraction of exhaled nitric oxide (FeNO), inter-
rupter resistance (Rint), or specifi c immunoglobulin E (IgE) in 4-year-old children with 
suggestive symptoms can predict asthma symptoms up to age 8 years.
Methods
Children were recruited from the PIAMA birth cohort. All children with symptoms sug-
gestive of asthma at age 3 or 4 years, who were invited for medical examination at age 
4 (n = 848) were eligible. Associations of FeNO (n = 308), Rint (n = 482) and specifi c IgE 
(n = 380) at 4 years with wheezing and asthma at the ages of 5-8 years were assessed 
using repeated measurement analyses. The added predictive value of these objective 
tests was then investigated by including parameters for clinical history in the model.
Results
FeNO and specifi c IgE measured at 4 years were associated with wheezing and asthma 
at 8 years. Both tests remained signifi cant predictors also after mutual adjustment and 
adjustment for clinical history: odds ratio on wheezing at 8 years for FeNO (10log-scale, 
per interquartile range) 1.6 (CI95%:1.1-2.2) and for specifi c IgE 2.8 (CI95%: 1.9-4.1). Rint 
was signifi cantly associated with wheezing at age 6, but not at 7 and 8 years.
Conclusions
In preschool children with symptoms suggestive of asthma, both FeNO and specifi c IgE 
measured at age 4, but not Rint, improved the prediction of asthma symptoms until the 
age of 8 years, independent of clinical history.
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INTRODUCTION
In preschool children, asthma-like symptoms such as wheezing and coughing are highly 
prevalent.1 Unfortunately, children with transient symptoms are not easily distinguished 
from those with persistent asthma on the basis of reported symptoms. Objective tests 
to support an asthma diagnosis include spirometry, to assess airway obstruction and 
reversibility; bronchoprovocation, to assess airway responsiveness; and sputum induc-
tion to measure airway infl ammation, a hallmark of asthma.2 These tests are diffi cult 
to perform in children under the age of 6 years since active cooperation is necessary.3 
Non-invasive measurement of the fraction of exhaled nitric oxide (FeNO) has received 
much interest due to its ability to refl ect eosinophilic airway infl ammation.4,5 Several 
studies have shown elevated FeNO values in children with asthma or atopy.6-12 Moeller 
et al showed that FeNO could distinguish between the different phenotypes of pre-
school wheezers.13 However, prospective data on the prognostic value of FeNO in 
preschool children on later symptoms are scarce. In clinical practice, measurement of 
FeNO would only be worthwhile if it offers an added predictive value over information 
that is already available, such as a standard clinical history. This has not been inves-
tigated so far. Interrupter resistance (Rint) measurement can be easily performed in 
young children and correlates with asthma symptoms.14-16 Specifi c immunoglobulin E 
(IgE) to inhalant allergens in young children is associated with the risk of persistence of 
asthma symptoms.17-20 
The aim of our study was to prospectively investigate whether FeNO, Rint and/or 
specifi c IgE at the age of 4 years in children with respiratory symptoms could be used 
to predict asthma symptoms up to the age of 8 years. We used data from the ‘Preven-
tion and Incidence of Asthma and Mite Allergy’ (PIAMA) birth cohort.21 Children were 
eligible if they reported ‘wheeze’, ‘shortness of breath’ or ‘nightly cough without a cold’ 
at the age of 3 or 4 years. FeNO, Rint and specifi c IgE were measured at the age of 4 
years and children were followed until the age of 8 years. The added value of the tests 
to predict asthma symptoms until the age of 8 was calculated.
METHODS
Study population
Recruitment of the PIAMA cohort took place in 1996-1997; 7,862 pregnant women were 
invited to participate; 4146 women (53%) agreed (1,327 allergic and 2,819 non-allergic, 
based on a validated screening questionnaire).22 Their children were followed up for 8 
years, using questionnaires for parental completion, partly based on the International 
Study of Asthma and Allergies in Childhood (ISAAC) core questionnaires.23 At 4 years, 
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all children with an allergic mother and a random sample of children with a non-allergic 
mother were invited for a medical examination, including measurement of FeNO, Rint 
and specifi c IgE levels (n = 1,808). A detailed description of the study design has been 
published previously.21 The study protocol was approved by the medical ethics com-
mittees of the participating university hospitals. For the current study, we selected all 
children who were invited for the medical examination at 4 years and who reported at 
least one respiratory symptom suggestive of asthma (wheeze, shortness of breath, or 
cough at night without a cold) in the questionnaire at age 3 or 4 years (n = 848) (Figure 
8.1).
FeNO, Rint and specifi c IgE measurement
FeNO at age 4 was measured offl ine according to European Respiratory Society (ERS)/
American Thoracic Society (ATS) guidelines.24 For every child, duplicate exhaled air 
samples and an ambient air sample were collected in Mylar balloons, and analyzed us-
ing a chemiluminescence analyzer (Sievers NOA 280B, Boulder, Colorado, USA). FeNO 
was expressed in parts per billion (ppb). Rint was measured in kPa/l with MicroRint 
(MicroMedical, Rochester, Kent, UK) during expiration, with occlusion of the airway at 
peak expiratory fl ow. Median values for at least fi ve acceptable measurements were 
calculated. Detailed descriptions of both measurement techniques were previously 
published.8,16,25 Sensitization was defi ned as specifi c IgE of ≥ 0.70 IU/ml for at least 
one of 6 tested airborne allergens. To assess the added predictive value of these mea-
surements over reported clinical history, three variables previously shown to have the 
highest predictive value on later symptoms were selected:26 1) Allergic mother (yes/no); 
2) Doctors diagnosis of eczema ever until age 4 (yes/no); 3) Wheezing frequency during 
4th year of life (no/ 1-3 times per year/ ≥ 4 times per year). Mothers were considered 
‘allergic’ if they reported any of the following items: asthma, hay fever, house dust 
allergy, house dust mite allergy, pet allergy. 
Outcomes
Based on data from the annual questionnaires at age 5 to 8 years the following dichoto-
mous outcomes were defi ned, each pertaining to the past 12 months:
  · Wheezing: at least one episode
  · Inhaled steroid prescription by a medical doctor
  · Doctors diagnosis of asthma: a parental report of a doctors’ diagnosis of asthma at 
any time AND a parental report of asthma symptoms during the past 12 months
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Statistical analysis
Univariate associations between FeNO, Rint and specifi c IgE measurements and 
respiratory outcomes were investigated with logistic regression. FeNO values had a 
right-skewed distribution; a normal distribution was achieved after 10log-transformation. 
 
Invited for medical exam at age 4 yrs (n=1,808) 
 
allergic mother n=1,173 non-allergic mother n=635 
 
Respiratory symptoms* at age 3 or 4 yrs (n=848) 
(eligible study population)  
 
ÈFeNO n=848 ÈRint n=848  Èspecific IgE n=848 
  
 
No consent FENO 
(n=180) 
 
  
 
No consent Rint 
(n=180) 
 
  
 
No consent 
specific IgE 
(n=308) 
 
 
   
Informed consent FeNO (n=668)  Informed consent Rint (n=668)
 
 
Informed consent specific IgE 
(n=540) 
  
 
   
 
 
   
  
No attempt 
(n=179) 
NO analyzer not 
available 
No attempt (n=14) 
MicroRint not 
available 
  
   
FeNO measurement attempted 
(n=489)  
Rint measurement attempted 
(n=654)  
Blood collection for specific 
IgE attempted (n=540) 
  
 
  
  
 
  
  
 
 
 
Not successful 
(n=140) due to 
fear, reluctance, 
inability 
 
Not successful 
(n=133) due to 
fear, reluctance, 
inability 
 
No blood 
collected (n=131) 
fear or technical 
problems    
FeNO measurement successful 
(n=349; success rate 71%)  
Rint measurement successful 
(n=521; success rate 80%)  
Blood collection successful 
(n=409; success rate 76%) 
 
 
  
 
 
  
 
 
 
 
Exclusions (n=43) 
due to technical 
problems (n=33), 
bad measurement 
quality (n=10) 
 
Exclusions (n=39) 
due to use 
bronchodilator <24 
hours before 
measurement 
 
Lab analyses 
unsuccessful for 
at least 1 
allergen (n=29)    
FeNO measurement available 
(n=306)†  
Rint measurement available 
(n=482)  
Specific IgE for 6 airborne 
allergens‡ available (n=380) 
 
Figure 8.1. Flow chart of study population
All 848 eligible children enter each of the 3 arms of the fl owchart. *: Respiratory symptoms were 
defi ned as a positive response to at least one of the following 3 questions: “Has your child had 
wheezing or whistling in the chest in the last 12 months?” and/or “Has your child had tightness of 
the chest or shortness of breath in the last 12 months?” and/or “Has your child had cough during 
the night, when he/she did not have a cold or a chest infection, in the last 12 months?” †: Out of 
306 children with available FeNO 51 used steroids at the age of 4 years; these children were not 
excluded from analysis. ‡: The following 6 airborne allergens were tested for: House dust mite 
(Dermatophagoides pteronyssinus), cat, dog, grass pollen (Dactylis glomerata), birch, and Alternaria 
alternata.
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Generalized estimating equations (GEE) were used to take into account the correlation 
between repeatedly measured outcomes in the same individual. Variables for clinical 
history were included in the model to examine additional predictive value the tests 
over clinical history. The study design was stratifi ed for allergy of the mother and any 
interaction with this variable was investigated. After a complete case analysis, missing 
data were multiple times imputed to check for any bias that could result from complete 
case analysis.27,28 The ‘Multivariate Imputation by Chained Equations’ (MICE) procedure 
in the statistical program R version 2.6.2 was used to create 10 imputed datasets (n = 
848).29,30 Results were combined using PROC MIANALYZE in SAS 9.1 (SAS Institute, 
Inc., Cary, NC). Finally, a model was built including clinical history, specifi c IgE and FeNO, 
which allowed us to estimate the added predictive value of FeNO over the combination 
of clinical history and specifi c IgE. The data supplement provides a detailed description 
of study design, analysis and the multiple imputation procedure (Table E8.1).
RESULTS
Study population
At the age of 4 years 1,808 children were invited for medical examination, of whom 848 
(46%) reported at least one of the following symptoms at 3 or 4 years: wheeze (n = 379), 
shortness of breath (n = 385), or nightly cough (n = 592). The eligible study population 
therefore consisted of 848 children. An acceptable FeNO measurement was obtained 
from 306, Rint from 482, and specifi c IgE from 380 children. (Figure 8.1) We compared 
children with and without available values for these measurements separately, with 
respect to baseline characteristics and symptoms at 8 years. (Table 8.1) Children with 
available FeNO values (n = 306) were similar to children without (n = 542), the only 
difference being educational level of the mother. Children with Rint values (n = 482) 
were also more likely to have a mother with higher education than children without Rint 
measured (n = 366), and had signifi cantly less symptoms at the age of 8. Children with 
IgE data were more likely to be boys, to have an allergic mother, older siblings and to 
be exposed to cigarette smoke in utero, compared with children with missing IgE data. 
With respect to symptoms at baseline and at 8 years there were no major differences. 
The distribution of clinical symptoms and objective tests that were used to predict later 
asthma symptoms is given in Table 8.2.
Predictive value of FeNO
A higher FeNO at 4 years was associated with signifi cantly more wheezing and steroid 
use between the ages of 5 and 8 years. The association remained more or less stable 
over the 4 year follow-up period, with an odds ratio per interquartile range (IQR) in-
Daan BW 7.indd   160 28-10-10   13:06
161
ASTHMA PREDICTION USING FENO, RINT, AND SPECIFIC IGE
C
H
A
P
T
E
R
 8
Table 8.1. General characteristics of eligible study population
Baseline characteristics
Eligible study 
population (N=848)
FeNO
(N=306)
Rint 
(N=482)
Specifi c IgE 
(N=380)
n/N % % % %
Gender (female) 391/848 46 47 47 41†
Allergic mother 567/848 67 66 66 72†
Allergic father 289/846 34 35 35 35
Maternal education level
Low 195/832 23 21 20 23
Middle 366/832 44 41 43 43
High 271/832 33 38* 36* 34
Caesarean section 86/834 10 10 11 7†
Pets in the house (at birth) 473/844 56 54 55 54
Older sibling present 422/846 50 49 52 59†
Smoking during pregnancy‡ 147/831 18 18 17 21*
Smoking in house (at age 4)§ 191/798 24 26 23 24
Symptoms at baseline (age 3-4)
Wheeze 379/848 45 47 45 48
Shortness of breath 385/848 45 48 46 47
Cough at night¶ 592/848 70 73 70 69
Symptoms at age 8 yrs
Wheeze 104/730 14 13 13 14
Inhaled steroid use 109/722 15 15 12† 16
Doctors’ diagnosis asthma|| 55/700 8 8 6† 9
For each variable children with and without available data were compared. Signifi cance of 
differences was tested using a Chi-square test. *:p <0.05; †:p < 0.01. ‡: Positive if mother reported 
smoking at least 4 weeks after estimated date of conception. §: Smoking in the child’s house more 
than once a week. ¶: In period without a cold, fl u or chest infection. ||: Defi ned as a parental report 
of a doctor’s diagnosis of asthma ever, in combination with parental report of symptoms in the 
past 12 months.
Table 8.2. Variables used to predict asthma symptoms
Clinical symptoms and objective tests
Clinical symptoms n/N %
Allergic mother 567/848 67
Wheezing in 4th year of life  
Infrequent (1-3 times/yr) 179/848 21
Frequent (>3 times/yr) 64/848 8
Doctors’ diagnosis eczema 388/848 46
Objective tests Median (range) IQR†
FeNO in ppb* (n=306) 9.05 2.40 - 45.9 6.30
10log-transformed FeNO 0.96 0.38 - 1.66 0.29
Rint in kPa.L-1 (n=482) 0.93 0.14 - 1.99 0.32
n/N %
Positive specifi c IgE 102/380 27
*: Particles per billion; †: Inter quartile range.
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crease in 10log(FeNO) on ‘wheezing’ at 8 years of 2.1 (95% confi dence interval [CI95%]: 
1.3-3.3). (Figure 8.2) A signifi cant association with doctors’ diagnosis of asthma was 
present only at age 7. Inclusion of three variables for clinical history in the model had 
very little effect on the odds ratios: FeNO remained signifi cantly associated with later 
symptoms, independent of clinical history. Multiple imputed data analyses produced 
similar associations. (Data supplement, Figure E8.1) Fifty-one children used steroids at 
the age of 4, which may have infl uenced FeNO measurement. In a sensitivity analysis, 
exclusion of these children from the analysis led to slightly stronger associations with 
the outcomes ‘doctors diagnosis of asthma’ and ‘steroid use’. A charcoal NO scrubber 
was used while collecting exhaled air to eliminate an infl uence of ambient NO on FeNO 
measurements, but some association between FeNO and ambient air NO remained. 
Adjustment of our models for ambient NO did not change our results.
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Figure 8.2. Predictive value of FeNO measured at 4 yrs 
on all outcomes at 5-8 yrs
Black dots are crude odds ratios for FeNO (per IQR 
increase in 10log(FeNO)). *: Open dots are adjusted for 
clinical history (allergic mother/ doctors’ diagnosis of 
eczema/ wheezing at age 4).
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Predictive value of Rint
Rint values at age 4 were associated with symptoms at age 5 and 6. The association 
decreased after the age of 6 and was no longer signifi cant at 8 years. (Figure 8.3) 
Adjustment for clinical history further decreased the association between Rint and all 
outcomes. The adjusted odds ratio per IQR increase Rint for wheezing at 8 years was 
1.1 (CI95%: 0.7-1.6). Multiple imputed analyses did not change this. (Data supplement, 
Figure E8.2)
Predictive value of specifi c IgE
A positive specifi c IgE to any airborne allergen had a strong association with later symp-
toms. (Figure 8.4) The association remained stable over the 4 year follow-up. At age 8 
the odds ratio for ‘wheezing’ was 6.6; CI95%: 3.5-12.7. When clinical history was taken 
into account the odds ratios decreased considerably, but the associations remained 
strongly signifi cant for all outcomes (OR 4.3; CI95%: 2.1-9.1 for wheezing at 8 years). 
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Figure 8.3. Predictive value of Rint measured at 4 yrs 
on all outcomes at 5-8 yrs
Black dots are crude odds ratios for Rint (per IQR 
increase). *: Open dots are adjusted for clinical 
history (allergic mother/ doctors’ diagnosis of eczema/ 
wheezing at age 4).
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Odds ratios for specifi c IgE decreased considerably on all outcomes in the multiple 
imputed analysis. (Data supplement, Figure E8.3) Since such analyses are less likely 
to be infl uenced by selection bias, these estimates are probably more reliable. In the 
imputed analyses specifi c IgE remained the strongest predictor of later symptoms, 
even when clinical history was taken into account. 
Combination of clinical history, FeNO and specifi c IgE
These results imply that both FeNO and specifi c IgE, independent of clinical history at 
4, signifi cantly improve the prediction of asthma symptoms up to the age of 8 years. 
The question remains whether FeNO still has an added value, when clinical history 
and specifi c IgE are already known. We investigated this in a combined model which 
included FeNO, specifi c IgE and clinical history. Complete data on all variables was avail-
able from 185 children; the eligible population comprised 848 children. Analyses on the 
outcome ‘wheezing’ at age 8 were performed in both populations. (Table 8.3) Estimates 
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Figure 8.4. Predictive value of specifi c IgE measured 4 
yrs on all outcomes at 5-8 yrs
Black dots are crude odds ratios for specifi c IgE. *: Open 
dots are adjusted for clinical history (allergic mother/ 
doctors’ diagnosis of eczema/ wheezing at age 4).
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for FeNO and specifi c IgE were constant in both analyses. The level of signifi cance 
increased in the multiple imputed analysis, but even in the complete case analysis 
(n = 185) FeNO remained borderline signifi cant. (Table 8.3) Importantly, we found no 
interaction between FeNO and either ‘specifi c IgE’ or ‘allergic mother’. To visualize the 
clinical implications of our fi ndings, the predicted probability of wheezing is plotted 
Table 8.3. Predictive value FeNO and specifi c IgE on ‘wheezing’ (with mutual adjustment and 
adjustment for clinical history)*
FeNO† Specifi c IgE
n = 185 
FeNO and IgE both available
1.65 (CI95%: 0.94 - 2.89)
p=0.078
2.86 (CI95%: 1.38 - 5.91)
p=0.005
n = 848
Total eligible population
1.57 (CI95%: 1.10 - 2.23)
p=0.016
2.78 (CI95%: 1.90 - 4.07)
p<0.001
Odds ratios (95% confi dence interval) of FeNO and specifi c IgE on the outcome of ‘wheezing’, 
using complete case data (n=185) and multiple imputed data (n=848). *: Odds ratios for FeNO 
and specifi c IgE were mutually adjusted for each other, and for three variables on clinical history 
(allergic mother/ doctors diagnosis of eczema/ wheezing at age 4). †: Odds ratios for FeNO are 
calculated per interquartile range increase in 10log-transformed FeNO.
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Figure 8.5. Predicted probability of ‘wheezing’ depending on FeNO at 4 yrs
Predicted probability for ‘wheezing’ at age 8 is modelled for FeNO values (unit: parts per billion) 
measured at age 4, adjusted for specifi c IgE, allergic mother, doctors’ diagnosis of eczema and 
wheezing frequency at age 4. Different lines represent children with different subsets of risk 
factors. Horizontal axis in log-scale. *: Vertical gray line represents geometrical mean FeNO in 
study population and can be used to determine the pre-test probability of wheeze at 8 for individual 
children.
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against FeNO values measured at 4 yrs. (Figure 8.5) Different lines represent children 
with different subsets of risk factors. When all risk factors are absent, FeNO appears to 
be of limited clinical value, because the post-test probability remains low even at higher 
FeNO values. However, in children with an intermediate or high pre-test probability 
of later wheezing, a FeNO-test at the age of 4 could change the post-test probability 
to a degree that would be relevant in clinical practice. For example, in children with 
an allergic mother, eczema and specifi c IgE, but with infrequent wheezing at 4 (thick 
dashed line, Figure 8.5) risk of asthma symptoms at 8 ranged from 25-70% depending 
on FeNO measured at 4 years.
DISCUSSION
We show that in preschool children with symptoms suggestive of asthma, measure-
ment of FeNO and specifi c IgE could predict later asthma symptoms, up to the age of 
8. Both tests had an added predictive value, independent of each other and of clinical 
history.
Several studies investigating the association between FeNO and airway symptoms in 
children reported a higher FeNO in wheezing and asthmatic children.6,7,9,11 Malmberg and 
colleagues even reported an 86% sensitivity and 92% specifi city of FeNO to diagnose 
asthma, clearly superior to conventional bronchoprovocation testing and spirometry.9 
Importantly, these studies selected children already known to have asthma, and healthy 
controls. Such a case-control design is likely to cause selection bias with overestimation 
of a test’s diagnostic performance.31 In unselected groups of schoolchildren much lower 
diagnostic performance of FeNO was reported.12,32 Age is important when comparing 
different studies, due to heterogeneous respiratory disorders and changing FeNO 
during childhood.33,34 In children aged 4 years higher FeNO values were measured in 
recurrent wheezers and in children with doctors’ diagnosed asthma, with considerable 
overlap.8,10 Moeller et al showed that FeNO could be used to distinguish between dif-
ferent phenotypes of preschool wheezers, based on their clinical history up to the age 
of 4. However, FeNO will only have a clinical benefi t if it offers additional information 
compared to clinical history.13 Previous studies were cross-sectional, and very little is 
known about the predictive value of FeNO on later asthma in preschool children. We 
performed a 4 year follow-up and took the child’s clinical history into account to assess 
the true additional predictive value of FeNO on later asthma. This refl ects the clini-
cal setting in which FeNO would be used. Our prospective analysis shows that FeNO 
measured at 4 years indeed improved prediction of asthma until the age of 8 years. 
Cross-sectional studies have reported higher Rint in asthmatics compared to controls, 
with considerable overlap.14,15,35 Previous analysis of our own data at age 4 showed 
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a higher Rint in persistent wheezers, compared to children who never or transiently 
wheezed.25 The only prospective study on the predictive value of Rint measurements 
was performed in a cohort of 110 children diagnosed with asthma (aged 2-5 yrs) and 
found no association between Rint and asthma medication after 3 years follow-up.36 Our 
study recruited children from a population-based cohort, based on reported respiratory 
symptoms, and results were similar: Rint at 4 did not discriminate between children 
with or without symptoms at 8 years. Although Rint was associated with symptoms up 
to 2 years after measurement, it was not useful in the long-term management of indi-
vidual children. Thirty-nine children (7%) were excluded because bronchodilators were 
used within 24 hours prior to Rint measurement. When these children were included, 
the predictive power of Rint was even smaller. Nonetheless, selective exclusion of this 
group of high risk children may have decreased the power to detect an association of 
Rint with later symptoms.
Prospective studies showed that children with positive specifi c IgE for inhalant al-
lergens were more likely to develop wheeze19 and asthma18 in childhood. Even when 
information from patient history is considered, specifi c IgE improved prediction of later 
asthma.17,20 Our results show that the predictive value of specifi c IgE measured at 4 
years remains high until the age of 8. Importantly, our data allowed us to investigate the 
independent added value of specifi c IgE and FeNO measurements at 4. Several authors 
reported raised FeNO levels in atopic rather than asthmatic children.32,37 Consequently, 
it has been proposed that any predictive value of FeNO on asthma might be explained 
by its correlation with specifi c IgE.38 Our combined analysis shows that even though 
FeNO and specifi c IgE are correlated, they both independently contributed to the pre-
diction of later asthma symptoms.
Major strengths of this study are its longitudinal design and large sample size. In the 
selection of the eligible population and the statistical analysis we aimed to mimic the 
clinical setting. This enabled us to estimate the true added value of the tests and hence 
their clinical relevance.
Selection bias could have resulted from incomplete data. However, we found that 
children with complete data did not differ from those with incomplete data. Further-
more, a multiple imputed analysis including all eligible children led to similar results and 
did not change any of our conclusions (data supplement). Secondly, the PIAMA study 
is an unselected birth cohort, but due to overrepresentation of children with an allergic 
mother in the medical examination at 4, our eligible population included more children 
with an allergic mother. If the predictive value of FeNO, Rint or specifi c IgE differs 
between children with and without an allergic mother, this would limit generalizability 
of our fi ndings. We consider this unlikely since there was no interaction between any 
of the tests and the variable ‘allergic mother’. Hence, our fi ndings may be generalizable 
to all children in the general population with asthma symptoms at 3-4 years. Although 
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steroid use is well known to decrease FeNO, we decided to include 51 (17%) children 
who used inhaled corticosteroids at 4. This may have led to some underestimation of 
the predictive power of FeNO, but we preferred this over selective exclusion of 51 high 
risk children. Finally, in order not to overestimate the added prognostic value of FeNO, 
Rint and specifi c IgE over a clinical history we tested which variables for clinical history 
were the best prognostic indicators for later symptoms, and added the 3 variables 
with the strongest association in our multivariable analysis.39 Including a variable for 
wheezing phenotype (multi-trigger wheeze/ viral induced wheeze/ no wheeze) in our 
models did not decrease the predictive ability of any of the three investigated tests.
Do our fi ndings have clinical relevance? In the management of wheezing preschool 
children a fi rst step will always be to take a full medical history. Secondly, a specifi c IgE 
test has the highest predictive value for symptom persistence. FeNO measurement as 
a next step can signifi cantly improve prediction of later asthma symptoms, especially in 
children with an intermediate pre-test risk. 
In conclusion, we demonstrated that in preschool children with symptoms sugges-
tive of asthma, both FeNO and specifi c IgE at age 4 predicted asthma symptoms until 
the age of 8 years independently, and independent of clinical history. Specifi c IgE had 
the highest predictive value, the added value of FeNO was limited. Nevertheless, in 
children with an intermediate or high risk, FeNO substantially changed the risk of later 
wheezing and asthma to a degree that may be relevant in clinical practice.
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Supplement data Chapter 8
METHODS
Recruitment of participants
All children participated in the Prevention and Incidence of Asthma and Mite Allergy 
(PIAMA) birth cohort study. This multicentre study was conducted in 3 different regions 
of The Netherlands: north (Groningen and surroundings), central (Bilthoven, Wagenin-
gen and surroundings) and southwest (Rotterdam and surroundings). Recruitment 
took place between March 1996 and May 1997 by means of a validated screening 
questionnaire,E1 distributed by midwifes to 10,232 pregnant woman visiting one of 52 
prenatal clinics. According to the results of this screening the women were divided 
in an allergic and a non-allergic group. Women with any of the following self-reported 
symptoms were defi ned as allergic: asthma, hay fever, house dust allergy, house dust 
mite allergy or pet allergy. Children of allergic women were defi ned as ‘high-risk’. Based 
on the screening 7,862 women (2,779 allergic and 5,083 non-allergic) were invited to 
participate in the study, approximately 50% (n = 4,146) agreed and gave informed con-
sent (1,327 allergic and 2,819 non-allergic). The PIAMA cohort includes an intervention 
part, studying the effect of impermeable mattress covers, and a natural history part. In 
the present study we considered children from both the intervention and the natural 
history part. As previously published, the intervention had no effect on the incidence 
of allergy or respiratory symptoms.E2 Furthermore there was no association between 
the intervention and the measurements of FeNO, Rint or specifi c IgE. At 3 months and 
4 years all high-risk children (n = 1,327) and a subsample of the low-risk children (n = 
625) would be invited for a medical examination. (See Figure E2.1, data supplement 
chapter 2, for fl ow chart) Eligible for the present study were only children who were 
invited for the medical examination at 4 years (n = 1,808) and who, in addition, had a 
positive response to at least one of the following 3 questions in the questionnaire at 
age 3 or 4 years:
  · Has your child had wheezing or whistling in the chest in the last 12 months?
  · Has your child had tightness of the chest or shortness of breath in the last 12 
months?
  · Has your child had cough during the night, when he/she did not have a cold or a 
chest infection, in the last 12 months?
In total n = 848 children fulfi lled these criteria and were included in the study population. 
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Table E8.1. Associations between predictor variables, outcomes, and covariates in children with 
missing and children with available data
Predictor variables
Variables used in imputation
FeNO at 4 Rint at 4 Specifi c IgE at 4
Nmissing
= 542
Navailable
= 308
Nmissing
= 366
Navailable
= 482
Nmissing
= 447
Navailable
= 380
% usable 
cases
r(FeNO)
% usable 
cases
r(Rint)
% usable 
cases
r(Specifi c IgE)
Predictor variables
FeNO at age 4 - n.a. 16 0.12 39 0.22
Rint at age 4 44 0.12 - n.a. 40 0.05
Specifi c IgE at age 4 26 0.22 27 0.05 - n.a.
Model covariates (clinical history)
Wheezing frequency at age 4 91 0.05 89 0.21 91 0.21
Atopy of mother 100 0.03 100 0.05 100 0.03
Eczema at age 4 95 0.08 94 0.02 95 0.16
Outcome variables
(wheezing/ steroid use/ shortness of breath/ asthma diagnosis)
At age 5 90 0.15 89 0.16 89 0.21
At age 6 88 0.14 86 0.21 86 0.22
At age 7 85 0.13 80 0.18 82 0.30
At age 8 84 0.20 81 0.11 82 0.25
Variables related to missingness of predictor variables*
Maternal age 100 0.08 100 0.02 100 0.06
Maternal education 98 0.05 98 0.02 98 0.05
Paternal education 95 0.07 95 0.04 95 0.07
Degree of urbanization 100 0.03 100 0.08 100 0.01
Study region 100 0.11 100 0.09 100 0.01
Presence older siblings 100 0.01 100 0.02 100 0.17
Caesarian section 99 0.05 99 0.09 99 <0.01
Pregnancy duration 99 0.13 100 0.06 99 0.05
Eczema siblings 99 <0.01 99 0.04 99 0.10
Variables related to value of predictor variables*
Avoidance of allergens indoors 99 0.02 99 0.03 99 0.15
Wheezing age 1 94 0.02 95 0.13 94 <0.01
Wheezing age 2 97 0.02 96 0.12 96 0.08
Wheezing age 3 97 0.02 96 0.13 98 0.08
Shortness of breath age 4 92 0.10 90 0.10 91 0.13
Steroid use age 4 89 0.08 87 0.14 88 0.09
Asthma diagnosis age 4 81 0.04 79 0.06 78 0.10
Blood eosinophils at age 4 37 0.23 25 0.09 0 n.a.
FeNO measured at age 8 45 0.16 39 0.01 42 0.28
Rint measured at age 8 57 <0.01 49 0.44 52 0.10
Specifi c IgE measured at age 8 56 0.12 47 0.08 46 0.39
*: Predictor variables are FeNO, Rint and Specifi c IgE measured at age 4.
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Data collection
Questionnaires were sent to participating parents for self-completion at the 3rd 
trimester of pregnancy, 3 months after birth, at the age of 1 and yearly thereafter. 
The fi nal questionnaire was sent at the age of 8. Information was collected on birth 
and socioeconomic characteristics; indoor environmental, lifestyle, and demographic 
factors; and on the child’s health in at every age (e.g. allergies, eczema, respiratory 
symptoms, doctors’ diagnoses and medication use).
FeNO Measurement at age 4
Exhaled FeNO was measured offl ine by the balloon method, according to European 
Respiratory Society/American Thoracic Society guidelines.E3 Children were asked to 
take a deep breath through a charcoal NO-scrubber, and to exhale immediately into a 
collection device employing dynamic fl ow restriction, using a two-way valve. Exhalation 
fl ow was kept constant at 50 mL·s–1 over a pressure range of 5–20 cm H2O. Mouth 
pressure was monitored during the measurement using a manometer. After discarding 
dead space air for 3–4 s, exhaled air was collected in a NO impermeable 150 ml Mylar 
balloon (Jurjen de Vries BV, Leeuwarden, the Netherlands).E4 For every child, duplicate 
exhaled air samples and a sample of ambient air were collected. Balloons were sealed, 
stored and analysed within 8 h with a chemiluminescence analyser. Exhaled FeNO is 
expressed in particles nitric oxide per billion (ppb). In the western and middle areas of 
the Netherlands, a Sievers NOA 280 analyser (Boulder, CO, USA; sensitivity 0.5 ppb, de-
tection range 0.5–500,000 ppb, sample fl ow 200 ml·min–1, sampling rate 4·s–1 (middle), 
20·s–1 (western)), was used. In the northern area, an Ecophysics CLD 700 AL analyser 
(Ecophysics, Basel, Switzerland; sensitivity 1 ppb, detection range 0–50,000 ppb, sam-
ple fl ow rate 700 ml·min–1, data sampling rate 0.5·s–1) was used. A check for systematic 
differences between the different NO analysers was performed by measuring balloons 
fi lled with calibration gas on all analysers on the same day. This analysis revealed a good 
agreement, with no signifi cant systematic differences between the analysers.E5
Rint measurement at age 4
Measurements were carried out using the MicroRint (Micro Medical Ltd, Rochester, UK), 
a portable device including a shutter and pneumotachograph, connected to a palmtop 
computer with an online display showing mouth pressure, time of shutter closure, Rint 
values, and the median value of all Rint data recorded during one session. Its software 
calculates Rint (expressed in kPa.L-1) using the back extrapolation technique to t = 15 ms 
after shutter closure during 100 ms. A maximum of 10 tracings can be gathered for each 
measurement. Daily calibrations of pressure and fl ow (volume) were carried out using a 
manometer and a 2-L precision pump. All measurements were carried out with a fi lter 
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(Micro Medical Ltd) in place for reasons of hygiene, and to prevent dysfunction of the 
pneumotachograph due to any saliva.E6
Specifi c IgE measurement at age 4
Specifi c immunoglobulin E (IgE) to inhalant allergens (house dust mite (Dermatopha-
goides pteronyssinus), cat, dog, grass (Dactylis glomerata), birch (Betula verrucosa) and 
mould (Alternaria alternata)) were determined by a Radio Allergo Sorbent Test. Atopy was 
defi ned as specifi c IgE concentration >0.70 IU·mL–1 for at least one inhalant allergen. 
Statistical Analysis
Logistic regression was used to investigate the relationship between the three mea-
surements (FeNO, Rint and specifi c IgE) and respiratory outcomes assessed at the 
ages of 5, 6, 7 and 8 years. A longitudinal analyses was then performed, combining 
information on the outcomes at every age in one model. In this analysis we have to take 
into account that the repeated measurements in the same individual are correlated, 
in order to calculate correct standard errors and p-values of our estimates. A General-
ized Estimation Equations (GEE) model was used. As correlations between repeated 
measurements can be expected to depend on the time lag between 2 measurements, 
a 3-dependent correlation matrix was modelled. Interaction of the measurements with 
age (as a categorical variable) was included in the GEE model, in order to allow the 
associations to vary with age.
Besides a complete case analysis, a multiple imputed analysis was performed to 
investigate and correct for any bias that may result from complete case analysis.E7 The 
imputed datasets were created following the guidelines as described by van Buuren 
et al.E8 Apart from all variables in the fi nal models, the following variables (due to their 
strong association with the missing data) were used in the imputation matrix: region, 
urbanisation, parental education, age mother, pregnancy duration, mode of delivery, 
number of siblings, pet avoidance due to allergy, symptoms of wheeze/dyspnea/
eczema, eosinophilic count at age 4, Rint measurements at age 8, total and specifi c 
IgE measured at age 8, FeNO measured at age 8. The benefi t of an imputed analysis 
depends on two factors: 1) the strength of the association between the imputed vari-
able and variables used for the imputation; and 2) the availability of complete data 
on these variables used for imputation. In Table E8.1 these data are summarized in 
two columns for each predictor variable (FeNO/ Rint/ Specifi c IgE). The fi rst column 
represents the % of usable cases, which is the proportion of children with missing data 
on the predictor variable that have data available on the variable used for imputation.E8 
The second column represents the correlation (Spearman’ s coeffi cient) between the 
predictor variable and the variable used for imputation, among the children with avail-
able data. Using the ‘Multivariate Imputation by Chained Equations’ (MICE) procedure 
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in the statistical program R version 2.6.2, ten imputed datasets with each n = 848 
subjects were created.E9,10 All 10 datasets were analysed using above specifi ed GEE 
models and results were then combined using PROC MIANALYZE in SAS 9.1 (SAS 
Institute, Inc., Cary, NC).
RESULTS
Results from the multiple imputation analyses are reported here. Figure E8.1 displays 
the odds ratios of 10log-transformed FeNO (per IQR increase) on all outcomes. Odds 
ratios at different ages were calculated by including an interaction term with age (as a 
categorical variable) in the model. Compared with complete case analysis none of the 
associations changed direction, but most associations decreased slightly in strength. 
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Figure E8.1. Predictive value of FeNO measured at 4 
yrs on all outcomes at 5-8 yrs, using multiple imputation 
analysis
Black dots are crude odds ratios for FeNO (per IQR 
increase in 10log(FeNO)). *: Open dots are adjusted for 
clinical history (allergic mother/ doctors’ diagnosis of 
eczema/ wheezing at age 4).
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Confi dence intervals narrowed, which can be explained by the fact that multiple imputa-
tion makes it possible to use all available data. All odds ratios that were signifi cant in the 
complete case analysis remained signifi cant in multiple imputed analysis. 
Figure E8.2 gives the odds ratio of Rint (per IQR increase) on all outcomes. There 
were very little differences between results from complete case and multiple imputa-
tion analysis.
Figure E8.3 and gives the odds ratios of a positive specifi c IgE on all outcomes. 
Compared with complete case analysis all odds ratios of IgE decrease in strength in 
the multiple imputed analyses, especially for the outcomes ‘steroid use’ and ‘doctors 
diagnosis of asthma. This decrease is much more pronounced than for the other 2 
tests: FeNO and Rint. Again we see that confi dence intervals are decreased in the 
multiple imputed analysis. None of the associations change direction and all odds ratios 
remain strongly signifi cant.
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Figure E8.2. Predictive value of Rint measured at 4 yrs 
on all outcomes at 5-8 yrs, using multiple imputation 
analysis
Black dots are crude odds ratios for Rint (per IQR 
increase). *: Open dots are adjusted for clinical history 
(allergic mother/ doctors’ diagnosis of eczema/ wheezing 
at age 4).
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Figure E8.3. Predictive value of specifi c IgE measured 
4 yrs on all outcomes at 5-8 yrs, using multiple 
imputation analysis
Black dots are crude odds ratios for specifi c IgE. *: 
Open dots are adjusted for clinical history (allergic 
mother/ doctors’ diagnosis of eczema/ wheezing at 
age 4).
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Chronic, recurrent respiratory symptoms constitute one of the most common problems 
presented to general practitioners and pediatricians.1 Symptoms such as wheezing and 
coughing are extremely common in young children, and the prevalence only increased 
in the last decades.2 Large birth cohort studies in different parts of the world have 
aimed to gain understanding of the causes and the natural history of asthma symp-
toms, particularly wheeze, in children.3-5 The PIAMA study is one of these, and previous 
analyses of this cohort have led to signifi cant advances in our knowledge on different 
aspects of childhood asthma.6 Two major themes with respect to wheezing in preschool 
children remain largely unresolved, and we aimed to address both these themes in 
this thesis. First, there is still no conclusive evidence on which environmental factors 
may have contributed to the recent rise in the prevalence of asthma and allergies. This 
knowledge is essential in the search for new ways to prevent asthma development in 
the future. Second, how can infants and preschool children with transient symptoms 
be distinguished from those who will actually develop asthma. In the present chapter 
we will discuss the main fi ndings of the reported studies, in the context of current 
literature. We will emphasize the scientifi c and clinical implications of our fi ndings, and 
make suggestions on direction of future research.
STUDY DESIGN
Strengths and limitations
The PIAMA study is a prospective birth cohort study in the Netherlands. Mothers of 
the participating children were selected in the second trimester of pregnancy, and a 
wide range of data on pre- and post natal exposures was collected before the children 
experienced respiratory symptoms for the fi rst time. That is important, because it 
excludes the risk of recall bias, which could be an issue in cross-sectional or case-
control studies. The availability of data on many different perinatal factors allowed us 
to investigate these as possible risk factors for asthma, but also to include these in the 
analysis as possible confounders. This reduces the risk of confounding bias, but residual 
confounding cannot be excluded entirely, because there may have been unknown or 
incompletely assessed confounders.
The PIAMA study participants were recruited from the general Dutch population. 
Maternal allergy was used as a selection variable for allocation of participants to the 
different study arms, but the total PIAMA study population was not enriched with 
allergic mothers. It should be realized that some selection bias may have occurred 
due to selective non-response. Compared to the general Dutch population, the PIAMA 
study population contained more parents with a high education, more parents of Dutch 
ethnic origin, and fewer parents who smoked. Furthermore, information bias may have 
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occurred due to selective loss to follow-up. The attrition rate was very low and about 
90% of the children were still in follow-up at the age of 8 years. However, children who 
were lost to follow-up or had missing data in at least one questionnaire, more often had 
parents with a lower level of education. Therefore results from the PIAMA study may 
not be completely generalizable to the general population, especially with respect to 
prevalence estimates of asthma symptoms. However, many of the reported associa-
tions are probably valid, because it is not likely that all associations are substantially dif-
ferent among children form a high or low socio-economic status. Furthermore, if there 
was evidence for effect modifi cation, the analyses could be stratifi ed and corrected for 
parental education, as well as a range of correlated variables. In a study with a follow-up 
of multiple years, the risk increases that some children have missing data on at least 
one questionnaire or specifi c question. Traditionally, statistical models would remove all 
subjects with a single missing value on the analyzed variables from the analysis. This 
method of ‘complete case analysis’ can lead to considerable bias, by selection of the 
study population.7,8 The risk of bias is reduced by using statistical modules that make 
it possible to also include subjects with some missing data in the analyses, such as 
single or multiple imputations.9 These techniques were used in chapter 3, 7 and 8 of 
this thesis. 
A limitation of observational research in general, is that it is not possible to prove cau-
sality between any of the reported risk factors and the development of asthma.10 Only 
in a randomized controlled trial the risk of reverse causation and residual confounding 
can be fully eliminated. It should be noted that some factors in practice cannot be 
studied using a randomized design, for example the number of older siblings. In that 
case an observational study is the best achievable study design, and causality simply 
cannot be proven.
Longitudinal research
A prospective design with repeated measurements may be especially important in 
pediatric asthma research. Recent longitudinal studies have made clear that childhood 
asthma can be highly variable with respect to symptoms as well as time course.4,11-13 
The prevalence of wheeze decreases rapidly in the fi rst years of life, and only a minority 
of preschool children with wheeze will develop asthma lasting into adulthood.11,12 On the 
other hand, children who are free of symptoms during infancy and preschool years, may 
develop asthma after the age of 4 years.11,12 The varying course of asthma symptoms 
in early life complicates research in this fi eld in two important ways. First, it affects 
the search for early risk factors for childhood asthma. If the associations between risk 
factors and asthma symptoms change over time, then the result of a study may depend 
on the age at which the outcome ‘asthma’ is assessed. Previous studies on risk factors 
for asthma have repeatedly shown contradictory results, which may partly be explained 
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by differences in the age of outcome assessment. In chapter 2 and 3 of this thesis we 
investigated the effects of birth weight, daycare attendance, and older siblings, on the 
prevalence of asthma symptoms.14,15 Indeed, both studies confi rmed that the associa-
tions between risk factors and asthma symptoms change over time. Second, the fact 
that asthma symptoms are so nonspecifi c and variable in young children complicates 
an early asthma diagnosis.16 Both issues underline the importance of longitudinal data 
collection and analysis. Therefore, in the PIAMA study respiratory health was annually 
assessed between the age of 0-8 years, and longitudinal statistical methods were used 
to analyze the data.
ASTHMA AND WHEEZING PHENOTYPES IN CHILDHOOD
We found the associations between risk factors and asthma symptoms to change with 
age, as described in both chapter 2 and 3. This could be explained by different mecha-
nisms.14,15 First, it is possible that all wheezing disorders in childhood are in principle 
a single disease, but with a variable presentation. The age at which wheezing starts 
might be explained by the time that a child is exposed to certain risk factors, such as 
respiratory infection. For example, a child attending daycare in the fi rst year of life may 
wheeze at that age because of exposure to many respiratory pathogens. The same 
child not attending daycare may start to wheeze at 4 years, when confronted with a 
high infection load in elementary school.
A second possibility however, may be that wheezing disorders in childhood are not a 
single disease, but comprise a heterogeneous group of several discrete disease enti-
ties.17 In current literature, this is certainly the most widely accepted view on childhood 
wheezing and asthma.3,18-20 The Tucson group fi rst introduced the concept of differ-
ent wheezing phenotypes, based on the age of symptom onset.11 Their longitudinal 
classifi cation in early transient, persistent and late onset wheeze has become widely 
accepted.21-24 Indeed, if perinatal risk factors are differentially associated with differ-
ent wheezing phenotypes, this would explain their changing association with age. The 
last decade several phenotype classifi cations have been suggested, based on clinical 
symptoms (e.g. type, age, and severity of symptoms) and/or objective measures (e.g. 
bronchial hyperresponsiveness and atopy).18,19,25-27 In the PIAMA study wheezing phe-
notypes were recently defi ned using a data-driven statistical method called longitudinal 
latent class analysis (LLCA). Because there is no gold standard for the defi nition of 
wheezing phenotypes, and the underlying disease processes are insuffi ciently under-
stood, it is diffi cult to validate these phenotypes.20 An important fi nding supporting 
the validity of the phenotype classifi cation by LLCA is the fact that the wheezing phe-
Daan BW 7.indd   185 28-10-10   13:06
CHAPTER 9
186
notypes in PIAMA were similar to those previously found in the independent ALSPAC 
birth cohort.28 
Question remains however, whether the wheezing phenotypes in PIAMA represent 
disease entities with a different underlying pathophysiology. In chapter 4 we found 
differential associations of the wheezing phenotypes with perinatal risk factors. The 
newly identifi ed phenotype of intermediate onset wheeze was the only phenotype sig-
nifi cantly associated with a lower birth weight. Daycare attendance and older siblings 
only increased the risk of transient early wheeze. Breastfeeding on the other hand 
appeared to decrease the risk of wheezing throughout childhood. These differential 
associations could imply that different causal mechanisms play a role in the develop-
ment of the wheezing phenotypes, but causality cannot be proven on the basis of 
these observational data.10 Furthermore, the smaller sample size in the less frequent 
phenotypes may be responsible for some of the non-signifi cant results. Replication 
of our fi ndings in a large independent birth cohort would be worthwhile, to increase 
statistical power and reduce the risk of chance fi ndings.
Asthma is associated with various patterns of chronic airway infl ammation, and if 
differences in types of infl ammation could be demonstrated between children with 
different wheezing phenotypes, this would support the evidence that childhood asthma 
consists of several disease entities with a different pathophysiology. Indeed results from 
our study on exhaled nitric oxide (FeNO), a marker of eosinophilic airway infl ammation, 
showed different levels of FeNO among the different wheezing phenotypes (chapter 5). 
FeNO levels at 8 years were higher in the phenotypes with a high probability of wheeze 
after the age of 4 years. These fi ndings could imply that eosinophilic infl ammation is 
present only in wheezers with persistent symptoms, and that different infl ammatory 
mechanisms may be responsible for other transient phenotypes. However, we did not 
measure FeNO in the fi rst years of life and therefore we cannot exclude that FeNO may 
have been elevated also in transient wheezers at the age they had wheeze. Indeed two 
previous studies have shown elevated levels of FeNO in infants, preceding respiratory 
symptoms in the fi rst years of life.29,30 Furthermore, recent fi ndings suggest that even 
within the same children the type of airway infl ammation may change over time (A. 
Bush, London, personal communication).
Our study (chapter 5) further showed that FeNO levels differed between atopic and 
non-atopic children. FeNO was elevated in the phenotypes with a high probability of 
wheeze after the age of 4 years, but only in the subgroup of atopic children. Therefore, 
our fi ndings suggest that the pathophysiology of wheezing also differs between atopic 
and non-atopic children.27 This implies that an asthma phenotype defi nition based only 
on the time course of symptoms may not be accurate, and that a defi nition which 
includes markers for atopy may better refl ect the underlying disease entities. In this 
context it should be realized that although wheezing is considered the most important 
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clinical symptom of asthma, ‘wheezing’ and ‘asthma’ are not synonymous. Several 
other characteristics may be considered as determinants of asthma phenotypes, such 
as allergy, cough, need for medication, or symptom severity.19,26,27,31 Including these 
items may lead to the discovery of different asthma phenotypes (fewer or more), useful 
for basic researchers investigating the etiology of asthma, and perhaps eventually for 
physicians treating patients with asthma – and for the patients themselves.20
EARLY RISK FACTORS AND THE PREVENTION OF CHILDHOOD ASTHMA
The most consistent risk factor for asthma in children is a family history for atopy and/
or asthma. It has been known for a long time that genetic predisposition plays a crucial 
role in the development of asthma.32 The patterns of inheritance suggest that multiple 
genes are involved, that interact with each other and with environmental factors.33 A 
second consistent fi nding in epidemiologic data confi rmed in the PIAMA study is that 
boys more often have asthma symptoms than girls, at least before puberty.34 Although 
genetic and gender differences are two major risk factors for asthma development, 
these factors are rather stable over time and cannot be easily infl uenced. This implies 
that it is unlikely that these factors can explain the recent rise in childhood asthma, nor 
could they be used as possible targets for asthma prevention. Therefore we will not 
focus on these risk factors in this discussion.
Following the rise in asthma prevalence, research groups all around the world have 
tried to fi nd lifestyle and environmental factors that could explain the pandemic, in 
order to fi nd possible targets for asthma prevention. So far there are only few modifi -
able perinatal factors for which there is convincing evidence that they increase the risk 
of asthma. In the PIAMA study several perinatal risk factors for asthma development 
(e.g. exposure to house dust mite,35 presence of pets,36 breastfeeding,37 caesarean 
section,38 nutrition during pregnancy,39 maternal40 and childhood41 overweight) have 
been previously studied and extensively discussed. This discussion focuses on the 
perinatal factors that were investigated in this thesis, and that may have implications 
for the prevention of childhood asthma. This thesis presents detailed analyses on the 
age-specifi c associations between birth weight, exposure to tobacco smoke, daycare 
attendance and older siblings on the one hand and the development of respiratory 
infections, asthma symptoms, airway hyperresponsiveness and allergy on the other 
hand. Furthermore it present a combined analysis of these and several other perinatal 
risk factors (e.g. caesarean section, pets, breast feeding, pregnancy duration, maternal 
age and body mass index), investigating their association with longitudinally defi ned 
wheezing phenotypes. 
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Smoking
Probably the most unequivocal risk factor for asthma symptoms in childhood is paren-
tal smoking. In line with numerous previous reports,42 we found that smoking during 
pregnancy signifi cantly increased the risk of childhood wheeze, especially transient 
early wheeze (chapter 4). Furthermore, in chapter 2 we showed that in children with a 
low birth weight the effects of smoking (during pregnancy and after birth) signifi cantly 
increased the risk of respiratory symptoms in the fi rst 7 years of life.14 The adverse 
effects of smoking are evident, but it should also be noted that these effects are not 
large enough to explain the overall increase in asthma prevalence. Results from chapter 
4 suggest that cessation of smoking would lead to 5.8% reduction in transient early 
wheeze.
Breastfeeding
The evidence on the effect of breastfeeding is less clear. Although some studies have 
reported a higher prevalence of asthma in breastfed children, most studies support a 
protective effect on asthma and allergies.43,44 We found breastfeeding to be the only 
factor with a signifi cant protection of persistent wheeze, with a population attributable 
risk of about 25%. Assuming a directly causal association, this implies that if all moth-
ers would breast feed their children for at least 3 months, the prevalence of persistent 
wheeze in the general population could decrease from 3.5% to 2.6%. Based on these 
fi ndings, in combination with results from previous studies, we propose that breast-
feeding is one of the most important targets for asthma prevention. 
Birth weight
We found that a low birth weight, which is a marker of reduced intrauterine growth, 
was associated with more respiratory symptoms after the age of 2 years. Possibly 
reduced intrauterine growth is associated with a disturbed development of the immune 
system, leading to an increased risk of atopy and wheeze after the age of 2 years. On 
the other hand, children with a lower birth weight may simply have smaller airways that 
are more easily obstructed during infections, and are therefore more prone to airway 
symptoms. However, this hypothesis cannot explain why symptoms become manifest 
after a symptom-free interval of several years. Unfortunately, birth weight is not a factor 
that is easily modifi able. The most important modifi able factor that can positively infl u-
ence birth weight is smoking during pregnancy, which further supports the possible 
positive effects of smoking cessation.
Other factors
For many perinatal risk factors (e.g. early exposure to pet allergens, house dust mite, 
caesarean section, maternal age or body mass index) there is still no conclusive evi-
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dence on the association with childhood asthma and allergy. This is mainly due to the 
fact that several epidemiological studies have led to confl icting results. Partly these 
differences may be explained by the previously mentioned diffi culties in the defi nition 
of ‘childhood asthma’. Many studies have used proxy outcomes for ‘asthma’, such as 
allergy, atopy, wheeze, shortness of breath, medication use, emergency room visits, 
or a combination of several of these items. Importantly, many studies have used a 
cross-sectional design, and the age of outcome assessment varied greatly. Another 
possible explanation for the confl icting fi ndings, are the genetic differences between 
the investigated populations. In the presence of certain genes an environmental fac-
tor may increase the risk for asthma development, while in the absence of this gene 
the environmental factor could be protective. This interaction with genetics has been 
previously shown for several possible risk factors, including exposure to environmental 
tobacco smoke, air pollution and bacterial endotoxins.45,46
Hygiene hypothesis
Several hypotheses have been proposed to explain the recent rise in the prevalence of 
asthma and allergies.47 Probably the best-known explanation in both the scientifi c and 
lay community, is the concept that increased exposure to microbes in early life may 
have a preventive effect on the development of asthma and allergies.48 This association 
was fi rst reported by Strachan in 1989, who found that children with more siblings 
developed fewer allergies than children from smaller families.49 Later immunological 
research found a plausible mechanism for this association. Infections early in life may 
cause a shift in the TH1/TH2 balance, from Th2 cells (that are involved in the pathogen-
esis of allergy) towards Th1 cells.50,51 Hence, the absence of infections could lead to 
insuffi cient development of TH1 immunity. Recent immunological analyses have chal-
lenged this concept, and it is likely that other immune mechanisms are also involved.52 
Nevertheless, the combination of the epidemiological and immunological fi ndings led 
to the postulation of the hygiene hypothesis, which states that the reduced exposure 
to infectious diseases in recent times may be responsible for the rising prevalence of 
asthma and allergies.49 The hygiene hypothesis has been subject to much debate in 
scientifi c literature.52 Some epidemiological studies clearly contradict the hypothesis. 
First there are several studies that have consistently shown that infections in early life 
are associated with an increased risk of later asthma, rather than a decreased risk.53-58 
It should be noted that these results could be explained by reverse causation; children 
with a predisposition for asthma may be more susceptible to symptomatic respiratory 
infections, and this would explain their positive association.52 In chapter 3 we reported 
the associations between daycare, siblings and the development of asthma and al-
lergy.15 Both daycare and older siblings were strong risk factors for respiratory infec-
tions. Our results show that children with older siblings and early daycare experienced 
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most infections in the fi rst year of life, but had no protection against asthma or allergy 
at the age of 8 years. Because there is no association between asthmatic constitu-
tion and daycare attendance or older siblings, these results cannot be explained by 
reverse causation. On the other hand there have also been several studies that show 
a protective effect of exposure to infections. For example, children exposed to high 
levels of bacterial endotoxins have a decreased risk of allergic asthma.59-61 Furthermore, 
analysis of PIAMA data has shown that children born by caesarean section may have 
an increased risk for asthma, especially if they have allergic parents.38 This association 
may be explained by delayed colonization with microbes after caesarean section, which 
could predispose the child to later asthma and allergy development. These confl ict-
ing results do not necessarily mean that the hygiene hypothesis should be discarded. 
They do however suggest, that the reality is more complex than the original hypothesis 
suggested.49 The effect of early infections with common respiratory viruses on the 
development of asthma and allergy is not necessarily the same as the effect of expo-
sure to specifi c bacteria and their endotoxins. Future research will need to focus on 
exposure to specifi c microorganisms, rather than infections in general, in order to fi nd 
novel preventive or therapeutic strategies. For example, recent studies suggest that 
infections with human rhinovirus could be one of the most important risk factors for 
childhood wheezing and possibly the development of chronic asthma.62 Unfortunately, 
to date there are still no practical implications that can be deduced from the hygiene 
hypothesis, for the prevention of asthma and allergies.52
Practical implications
Based on literature and our own results in this thesis there is enough evidence to make 
some recommendations for current clinical practice.
− There is suffi cient evidence to strongly advise against smoking during pregnancy. 
The effects on the incidence of asthma symptoms in childhood are limited, but 
highly signifi cant. Also smoking in the presence of children should be discouraged, 
especially for children with a low birth weight, who are more vulnerable for the 
effects.
− Early daycare attendance exposes children to more infections in early life, and is not 
associated with the prevalence of asthma at 8 years. Parents of children with a high 
risk of morbidity form respiratory infections may be advised to consider individual 
child care, irrespective of the child’s risk of developing asthma later.63
− Mothers should be advised to breast feed their child. Breastfeeding for 3-4 months 
reduces the risk of asthma symptoms in the fi rst 8 years of life. The protective effect 
appears to be stable over 8 years and is present in children with and without a family 
history of allergy.
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EARLY DIAGNOSIS AND PREDICTION
The variable nature of respiratory symptoms in early childhood complicates the diag-
nosis and treatment of asthma in young children.16 Previous studies have aimed to 
predict which children are at high risk of developing asthma, primarily for prevention 
purposes.64,65 The hypothesis was that if children with asthma symptoms were treated 
aggressively with anti-infl ammatory medication at a young age, this could change the 
course of asthma development and reduce symptoms in later life. Unfortunately, three 
independent trials have conclusively shown that aggressive treatment in symptomatic 
young children reduces current symptoms, but does not lead to a reduction in symp-
toms after medication is withdrawn.66-68 Early aggressive treatment is therefore not 
effective as a secondary prevention strategy.
It remains important for clinicians to be able to diagnose asthma at an early age, 
because it allows for adequate treatment. Analysis of data from the PIAMA study 
(chapter 6) shows that a delayed diagnosis of asthma is associated with higher rates 
of undertreatment, in line with previous cross-sectional reports.69,70 Furthermore, we 
found a considerable risk of overtreatment with inhaled corticosteroids in preschool 
children. Most preschool children will only suffer from transient airway symptoms. If 
symptoms subside in children using inhaled corticosteroids, it remains unclear whether 
this resulted from a positive treatment effect, or simply from the natural course of the 
wheezing symptoms. Our fi ndings emphasize the importance of making an accurate 
risk assessment of symptom persistence in young children before inhaled steroids 
are initiated. Furthermore, it stresses the need to perform regular follow-up in young 
children who use inhaled steroids. If children remain free of symptoms, inhaled steroids 
should be decreased and eventually stopped, in order to avoid overtreatment (this 
thesis).71 Regular follow-up is actually advised by the GINA as well as national asthma 
guidelines, but apparently this advise is often not followed in clinical practice.72,73
Diagnosis of asthma using clinical symptoms
Several research groups have created algorithms from reported clinical symptoms to 
predict which symptomatic young children will develop asthma.12,64,74-79 Many differ-
ences between these studies make it diffi cult to compare the derived prediction rules. 
Study design, study population, defi nition of predictor and outcome variables, outcome 
prevalence, and prediction rule cut-off points all differ between the reported studies, 
and this may affect their results. A common fi nding of previous studies is that it remains 
diffi cult to make an accurate asthma prognosis in preschool wheezing children on the 
basis of simple clinical fi ndings. The reported positive predictive values are fairly low, 
around 35-55%.64,74,77,80
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The reported independent predictors for the development of chronic asthma vary 
between the different studies, but some predictor variables are reported in multiple 
studies. Wheezing history appears to be the most important risk indicator for symp-
toms persistence.12,64,76,77 Eczema of the child,12,64,77 a family history of atopy,12,64,76-78 
frequency of respiratory infections74,78 and wheezing in the absence of a cold64,77 were 
also previously reported signifi cant predictors. Our study (chapter 7) confi rms these 
variables as the most important predictors for persistent asthma, and presents a practi-
cal new algorithm that provides a prediction at the time of fi rst wheeze, based on 
a weighted appreciation of the most important clinical factors.80 Before this can be 
implemented in clinical practice external validation in an independent cohort should 
be performed. If externally validated, the rule may be used in primary care to make an 
individual assessment of a child’s risk of persistent asthma. Given the limited predictive 
power, a prediction rule with clinical symptoms should not be used as the only means 
to diagnose chronic asthma, but may be used to guide further clinical decisions. Several 
options are possible, such as a conservative approach with reassurance of the parents, 
further investigations, start of a trial with inhaled medication or referral to specialist 
care.
The use of FeNO in the early diagnosis of asthma
An important clinical research question was whether FeNO measurement in preschool 
children with wheeze is helpful in the diagnosis and prediction of childhood asthma. 
Previous studies on this subject led to varying conclusions. Several studies have shown 
elevated FeNO in school-age children with asthma or asthma symptoms. Sivan et al 
even reported an 80% sensitivity and 92% specifi city for an asthma diagnosis.81 In 
preschool children fewer studies were performed, but Malmberg et al also found an 
86% sensitivity and 92% specifi city to diagnose asthma in a selected population of 
asthmatics and healthy controls.82 These high predictive indices are in contrast with 
reports from two population based studies, that found much smaller differences in 
FeNO between children with and without asthma symptoms.83,84
In order to estimate the clinical benefi t of a test, some aspects in the study design 
need to be considered. First, comparison of a selected group of asthmatics with healthy 
controls poorly refl ects clinical practice, where many children present with intermedi-
ate symptoms, without a clear distinction between cases and controls.85 Second, a 
test that differentiates between asthmatics and non-asthmatics is not useful in a set-
ting where it is already known which children are asthmatic. In practice, an important 
potential of an asthma test is whether it can predict if a child will still suffer from asthma 
in the coming years. Third, FeNO will only be clinically useful if it adds new information 
to the available information, such as clinical symptoms, lung function and allergy tests.
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In chapter 8 we aimed to estimate the added predictive value of FeNO at 4 years on 
asthma symptoms until 8 years, taking into account these considerations. Although we 
found that FeNO was higher in children with persistent symptoms, the added predic-
tive value was smaller than some previous reports suggested.81,82,86 This suggests that 
in clinical practice the value of FeNO as a diagnostic test for asthma may be more 
limited than originally proposed.87 Nevertheless it is a simple, non-invasive test that 
does contain useful supplementary information. Especially in symptomatic preschool 
children with intermediate risk of persistent asthma, FeNO helps to predict the risk of 
symptom persistence (this thesis).
The use of Rint in the early diagnosis of asthma
Several studies have reported that Rint measurements are associated with asthma 
symptoms in children, and that Rint could be used to measure the effects of beta-2-
agonists.88-90 The value of Rint in the early diagnosis of asthma remains less clear. No 
studies assessed the additional value of Rint to other clinical information. One previous 
study investigated the predictive value of Rint on the need for asthma medication in 
the following three years, but this was in a selected population of ‘asthmatic’ children 
aged 2-7 years.91 The authors concluded that a high Rint measurement was not a risk 
factor for symptom persistence. In chapter 8 we found similar results in a population 
based sample of symptomatic preschool children. Rint was signifi cantly associated with 
symptoms in the 2 years following the measurement, but no longer thereafter. After 
clinical symptoms were taken into account, the additional value of a Rint measurement 
appeared to decrease even further. We therefore conclude that there is currently no 
evidence that Rint is a useful test to diagnose asthma in preschool children.
There may be several explanations for the fact that Rint does not appear to be use-
ful in the diagnosis and prognosis of wheezing preschool children. First, resistance 
of the upper airways including the oral cavity is probably not associated with asthma 
symptoms, but it can have a considerable effect on the Rint measurement, making the 
results less reliable.92 Secondly, it should also be noted that in the PIAMA study most 
children performed lung function tests during a clinically stable period. Possibly, Rint 
measured during a period with severe symptoms could have a stronger predictive value 
on later symptoms. On the other hand, it could be reasoned that the airway resistance 
as measured by Rint, is also refl ected by reported clinical symptoms. In that case Rint 
would not add any additional information over a readily available clinical history.
The use of specifi c IgE in the early diagnosis of asthma
There is little doubt that the presence of specifi c IgE is predictive for asthma, as sev-
eral longitudinal studies have confi rmed the association between atopy and asthma 
development in children.12,76,79,93 It is also clear that specifi c IgE is a useful test in the 
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diagnosis and prognosis of asthma in young children, especially IgE against inhalant 
allergens,76,79 but at a young age IgE against food allergens such as hens egg is also 
valuable.94 Results from the PIAMA study confi rmed this: the presence of specifi c IgE 
at 4 years was strongly associated with asthma symptoms until the age of 8 years, 
even after clinical history was taken into account (this thesis). Therefore specifi c IgE for 
inhalant allergens should have a place in clinical practice when preschool children are 
suspected of asthma.
CONCLUSIONS
Asthma symptoms are very common in childhood, and affect more than half of all 
preschool children in the Netherlands. We found that early daycare attendance and 
older siblings are associated with more infections and asthma symptoms in the fi rst 
years of life, but do not protect against asthma or allergy at the age of 8 years. Children 
with a lower birth weight had more respiratory symptoms between the age of 2-7 
years, especially if they were exposed to environmental tobacco smoke. The promotion 
of breastfeeding seems the most promising target for the prevention of asthma, as it 
appeared to reduce the prevalence of wheeze throughout childhood.
Even if preventive measures are successfully applied, asthma symptoms will remain 
a common problem in young children, and an early asthma diagnosis is important in 
order to start adequate treatment. The use of a simple clinical prediction rule at the 
onset of symptoms can help to assess the risk of symptoms persistence in preschool 
children. Specifi c IgE and FeNO can be assessed, as they independently improve the 
prediction of symptom persistence. Notwithstanding the positive predictive values of 
these tests, it remains diffi cult to accurately identify those children who will develop 
persistent asthma, and therefore regular follow-up is important, also to avoid under- or 
overtreatment.
DIRECTIONS FOR FUTURE RESEARCH
In the PIAMA study the association between a wide range of early risk factors and 
the development of respiratory symptoms in childhood has been investigated. Little is 
known on the early risk factors for adolescent or adult onset asthma. In order to gain 
more insight in the changes that take place during adolescence, further follow-up of the 
PIAMA cohort would be valuable. Follow-up is also needed to fi nd out what the long 
term prognosis is of the longitudinal wheezing phenotypes that were derived in from 
PIAMA study. 
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Future research should try to take into account the problems of defi ning ‘childhood 
asthma’. Previous literature and studies in this thesis have made clear that asthma 
is a highly variable syndrome that may comprise several distinct disease entities. An 
accurate defi nition of the outcome ‘asthma’ is essential in the search for etiologic risk 
factors for its development. Therefore efforts should be made to fi nd meaningful and 
universally accepted criteria for asthma phenotypes, that can be used in epidemio-
logical studies and, perhaps in clinical care. Epidemiological research in a prospective 
observational study is a powerful tool to detect risk factors for asthma symptoms, and 
to generate hypotheses on causal mechanisms. However, to understand the underlying 
pathophysiology, we need to combine this knowledge with the discoveries in the fi eld 
of basic immunology and human genetics. Better understanding of basic immunology 
can help to defi ne meaningful asthma phenotypes, and this can improve precision of 
basic and genetic research into causes and mechanisms. Any implications of such 
insights for clinical practise will need to be addressed in appropriate clinical trials.
We presented an asthma prediction rule using 8 clinical characteristics, to improve 
the early diagnosis of asthma in preschool children. Before this rule is implemented in 
primary care, the rule should be prospectively validated in an independent cohort.
We have shown that FeNO can be a used to improve the diagnosis of asthma in 
symptomatic preschool children. Future research may focus on other tests that can 
further improve the identifi cation of preschool children with a high risk of persistent 
asthma symptoms. In order to be suitable for young children, such a test should not 
require active cooperation and preferably be non-invasive. Possibly, the analysis of 
volatile substances in exhaled air, or infl ammatory mediators in exhaled breath con-
densate may reveal new biomarkers for infl ammatory airways disease, not limited to 
the eosinophilic phenotype, and this may be important for predicting the persistence of 
asthma symptoms and the effect of treatment.
Development of Genome Wide Association (GWAS) analysis has created the opportu-
nity to detect association between hundred-thousands of genes and the development 
of asthma in birth cohorts, such as PIAMA. This fi eld of genetic epidemiology aims 
to fi nd new “asthma genes”. Understanding of how these genes and their products 
interact with environmental factors, may lead to the identifi cation of causal pathways 
in the pathophysiology of asthma. This could pave the way to entirely new therapeutic 
interventions, as well as preventive strategies. Furthermore, the possibility that newly 
identifi ed genes or gene-products could be used to improve an early asthma diagnosis 
should be further explored.
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SUMMARY
SUMMARY
In this thesis we investigated which pre- and perinatal factors are associated with the 
development of childhood asthma and allergy, and which of those may be used to 
prevent asthma. Secondly, we investigated if it is possible to diagnose asthma in very 
young children, who reported symptoms for the fi rst time. Therefore we assessed the 
predictive value of information from clinical history, and of three additional tests that 
can be performed in preschool children: 1) fraction of nitric oxide in exhaled air (FeNO); 
2) interrupter resistance (Rint); and 3) specifi c immunoglobulin E (IgE).
Chapter 1 is a general introduction to the different aspects of childhood asthma that 
were investigated in this thesis. It also provides the aims of the studies that were 
performed and describes the outline of the thesis.
Chapter 2 describes a study on the association between birth weight and the devel-
opment and course of respiratory symptoms and asthma in the fi rst 7 years of life. 
Children born at term in the PIAMA birth cohort (n = 3,628) were followed for 7 years 
and respiratory health was assessed every year. We demonstrated that a lower birth 
weight was associated with more respiratory symptoms between the age of 1 to 7 
years. However, the association decreased with age and was no longer signifi cant at 
7 years. The effect of birth weight on respiratory symptoms was signifi cantly greater 
among the children who were exposed to tobacco smoke, than among those who were 
not exposed.
We concluded that a lower birth weight in children born at term is associated with a 
transiently increased risk of respiratory symptoms, and that this effect is enhanced by 
environmental tobacco smoke exposure.
Chapter 3 reports a study on the associations between daycare early in life, the pres-
ence of older siblings, and the development of asthma and allergic sensitization in the 
fi rst 8 years of life. Previous studies have shown that both daycare and older siblings 
expose young children to more infections early in life, and that this might have a preven-
tive effect on the later development of asthma and allergy. In the PIAMA birth cohort 
(n = 3,963) respiratory health was assessed yearly, and at the age of 8 years allergic 
sensitization (specifi c IgE) and airway responsiveness were measured. We found that 
children who attended daycare before the age of 2 years had more respiratory infections 
and symptoms in the fi rst years of life, and fewer infections and symptoms between 
4 and 8 years. At 8 years however, early daycare was not protective for asthma symp-
toms, allergic sensitization or airway hyper-responsiveness.
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We concluded that early daycare is associated with an increase in airway symptoms 
until the age of 4, but does not offer a lasting protection against asthma or allergy.
Chapter 4 describes the results of an analysis of the association between a wide range 
of perinatal factors and the development of different longitudinal patterns of wheez-
ing (wheezing phenotypes). Five longitudinal wheezing phenotypes were previously 
defi ned using longitudinal latent class analysis; never/infrequent wheeze (n = 2,047), 
transient early wheeze (n = 455), intermediate onset wheeze (n = 98), persistent 
wheeze (n = 83), and late onset wheeze (n = 45). We found the following independent 
perinatal risk factors for transient early wheeze: male gender, maternal and paternal 
allergy, low maternal age, high maternal body mass index, short pregnancy duration, 
smoking during pregnancy, presence of older siblings, and daycare attendance. Risk 
factors for persistent wheeze were male gender, maternal and paternal allergy, and 
breastfeeding for less than 12 weeks. Intermediate onset wheeze was only associated 
with a lower birth weight and late onset wheeze only with maternal allergy. 
Therefore we conclude that wheezing phenotypes are differentially and sometimes 
uniquely associated with perinatal risk factors, which could imply that these pheno-
types have different underlying pathophysiologies. Some of the identifi ed risk factors 
are modifi able, and may be important targets for asthma prevention.
In chapter 5 we compared FeNO, a biomarker for eosinophilic airway infl ammation, 
measured at the ages of 4 and 8 years, between the different longitudinal wheezing 
phenotypes. Compared to the phenotype of never/infrequent wheeze, FeNO at 4 years 
was signifi cantly higher only in intermediate onset wheeze, but the difference was rela-
tively small. At 8 years, FeNO was signifi cantly higher in the phenotypes of persistent, 
intermediate onset, and late onset wheeze, in comparison to never/infrequent wheeze. 
Stratifi ed analyses further showed that the increased FeNO at 8 years in persistent, 
intermediate and late onset wheeze was only present in children with allergic sensitiza-
tion. 
We concluded therefore that FeNO at 8 years is associated with specifi c wheezing 
phenotypes, but only among atopic children. We speculated that the pathophysiology 
of wheezing phenotypes may differ between atopic and non-atopic children, and that 
eosinophilic airway infl ammation may be present only in atopic children.
Chapter 6 presents a study on the agreement between prescribed asthma medication 
on the one hand, and asthma symptoms and doctors’ diagnosis of asthma on the other 
hand in children aged 2 to 8 years. We found that about a third of the children with 
current wheeze did not use any inhaled medication during a given year with symptoms. 
Even among children with severe asthma symptoms at 8 years, 30% reported that they 
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did not use inhaled corticosteroids, the fi rst choice treatment for persistent asthma. On 
the other hand, about half of the children who were using inhaled corticosteroids for at 
least 2 years did not report any wheeze during those 2 years.
We concluded that under- and overtreatment of asthma symptoms seemed common 
in children aged 2 to 8 years. The prevalence of overtreatment increased with age, 
implying that regular follow-up in children using asthma medication remains important.
Chapter 7 presents a study in which a clinical asthma prediction score was developed, 
to diagnose asthma in preschool children who have suggestive symptoms for the fi rst 
time. In the PIAMA study children who had asthma symptoms (wheeze and/or cough 
at night) for the fi rst time before the age of 5 years were selected (n = 2,171). In 
these children, possible predictor variables for asthma at 8 years were assessed at the 
age that the respiratory symptoms were fi rst reported. We found 8 clinical parameters 
that independently predicted asthma at 8 years. A clinical risk score was developed 
which ranged from 0-55 points. Children with a score <10 points had 3% risk, whereas 
children with a score ≥30 points had 42% risk of asthma at 8 years.
We concluded that the asthma prediction score could serve as a useful tool for clini-
cians when preschool children present with asthma symptoms, especially in primary 
care.
In chapter 8 we investigated whether the objective tests FeNO, Rint, and specifi c IgE 
could be used in children with respiratory symptoms at the age of 4 years to predict 
asthma symptoms until the age of 8 years. Thereby we assessed whether these tests 
had any added predictive value over the information from a standard clinical history, 
which is readily available. We found that FeNO and specifi c IgE measured at 4 years 
were signifi cantly associated with wheezing and the use of inhaled steroids at 8 years. 
Moreover, specifi c IgE was also associated with a doctors’ diagnosis of asthma at 8 
years. Both tests remained signifi cantly associated with these outcomes at 8 years, 
even after mutual adjustment, and after adjustment for a clinical history at 4 years. Rint 
measured at 4 years was signifi cantly associated with wheezing at age 6, but no longer 
at 7 and 8 years.
From these fi ndings we concluded that it may be useful to measure both FeNO and 
specifi c IgE at 4 years in children with symptoms suggestive for asthma. The informa-
tion from these tests can help to identify those children who will develop persistent 
asthma symptoms, even after a clinical history is taken into account.
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In dit proefschrift hebben we onderzocht welke pre- en perinatale factoren geasso-
cieerd zijn met de ontwikkeling van astma en allergie op de kinderleeftijd, en welke 
factoren gebruikt zouden kunnen worden voor de preventie van astma. Ten tweede 
hebben we onderzocht of het mogelijk is om astma te diagnosticeren in jonge kinderen, 
op het moment dat zij voor het eerst klachten rapporteren. Daarvoor hebben we de 
voorspellende waarde bepaald van informatie uit de anamnese, en van drie additionele 
testen die uitgevoerd kunnen worden bij kinderen onder de 5 jaar, namelijk: 1) meting 
van de concentratie van stikstof monoxide in uitademingslucht (afgekort als FeNO); 2) 
meting van de luchtwegweerstand met behulp van de ‘interrupter resistance’ techniek 
(afgekort als Rint); en 3) meting van specifi ek immunoglobuline E in het bloed (afgekort 
als specifi ek IgE). 
Hoofdstuk 1 is een algemene introductie in de verschillende aspecten van astma op 
de kinderleeftijd, die onderzocht werden in dit proefschrift. Hier worden bovendien de 
doelen van de uitgevoerde studies en de verdere opzet van het proefschrift beschreven.
Hoofdstuk 2 beschrijft een studie naar de associatie tussen geboortegewicht en de 
ontwikkeling van luchtweg symptomen en astma in de eerste 7 levensjaren. A term 
geboren kinderen in de PIAMA studie (n = 3628) werden gevolgd gedurende 7 jaar en 
klachten van de luchtwegen werden jaarlijks geregistreerd. We hebben aangetoond, dat 
een lager geboortegewicht geassocieerd was met meer luchtwegklachten tussen de 
leeftijd van 1 tot 7 jaar. De associatie nam echter af met de leeftijd en was niet meer 
signifi cant op de leeftijd van 7 jaar. Het effect van geboortegewicht op luchtwegklachten 
was signifi cant groter onder de kinderen die waren blootgesteld aan sigarettenrook, in 
vergelijking met de kinderen die daar niet aan waren blootgesteld.
We concludeerden dat een lager geboortegewicht in a term geboren kinderen geas-
socieerd is met een tijdelijk toegenomen risico op luchtwegklachten. Dit effect wordt 
versterkt door blootstelling aan sigarettenrook.
Hoofdstuk 3 beschrijft een studie naar de associatie tussen kinderdagopvang op jonge 
leeftijd, de aanwezigheid van een oudere broer of zus, en de ontwikkeling van astma 
en allergie in de eerste 8 levensjaar. Eerdere studies hebben laten zien dat zowel 
kinderdagverblijf als de aanwezigheid van een oudere broer of zus ertoe leiden dat 
kinderen op jonge leeftijd meer luchtweginfecties doormaken. Volgens de ‘hygiëne 
hypothese’ kunnen deze vroege infecties de kans op de ontwikkeling van astma en 
allergie verkleinen. In het PIAMA geboorte cohort (n = 3963) werden luchtwegklachten 
jaarlijks geregistreerd, op de leeftijd van 8 jaar werden bovendien allergische sensiti-
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satie (specifi ek IgE) en bronchiale hyperreactiviteit bepaald. We zagen dat de kinderen 
die vóór de leeftijd van twee jaar naar kinderdagverblijf gingen, meer luchtweginfecties 
en symptomen hadden in de eerste levensjaren. Ze hadden daarentegen minder lucht-
weginfecties en symptomen tussen de leeftijd van 4 en 8 jaar. Op de leeftijd van 8 jaar 
bleek kinderdagverblijf niet beschermend te zijn voor astma symptomen, allergische 
sensitisatie of bronchiale hyperreactiviteit.
Wij concludeerden dat kinderdagverblijf op jonge leeftijd geassocieerd is met meer 
luchtwegsymptomen vóór de leeftijd van 4 jaar, maar geen blijvende bescherming biedt 
tegen astma of allergie.
Hoofdstuk 4 beschrijft de resultaten van een analyse van de associatie tussen een 
breed scala aan perinatale factoren en de ontwikkeling van verschillende longitudinale 
patronen van piepende ademhaling (piepende fenotypen). Vijf longitudinale piepende 
fenotypen werden in een eerder onderzoek gedefi nieerd, met behulp van de statisti-
sche methode ‘longitudinal latent class analysis’; 1) kinderen die nooit/zelden piepende 
ademhaling hadden (‘never/infrequent wheeze’, n = 2047); 2) kinderen met piepende 
ademhaling uitsluitend in de eerste 3 levensjaar (‘transient early wheeze’, n = 455); 3) 
kinderen waarbij piepende ademhaling begon na de leeftijd van 2 jaar (‘intermediate 
onset wheeze’, n = 98); 4) kinderen die op alle leeftijden van 0-8 piepende ademhaling 
hadden (‘persistent wheeze’, n = 83); en 5) kinderen waarbij het piepen begon na de 
leeftijd van 4 jaar (‘late onset wheeze’, n = 45). We vonden de volgende onafhankelijke 
risicofactoren voor ‘transient early wheeze’: mannelijk geslacht, allergie van vader of 
moeder, lage leeftijd van moeder, hoge body mass index van moeder, korte zwanger-
schapsduur, roken tijdens de zwangerschap, aanwezigheid van oudere broer/zus, en 
kinderdagverblijf in het 1e jaar. Risicofactoren voor ‘persistent wheeze’ waren mannelijk 
geslacht, allergie van vader of moeder, en het geven van borstvoeding gedurende 
minder dan 12 weken. ‘Intermediate onset wheeze’ was geassocieerd met een laag 
geboortegewicht en allergie van moeder.
We concludeerden dat de 5 piepende fenotypen verschillende associaties hadden 
met de onderzochte perinatale risico factoren. Sommige risicofactoren waren met 
slechts één van deze fenotypen geassocieerd. Dit zou kunnen betekenen dat de 
piepende fenotypen in feite verschillende ziektes zijn, met ieder een andere onderlig-
gende pathofysiologie. Aangezien sommige risicofactoren beïnvloedbaar zijn, zouden 
ze mogelijk gebruikt kunnen worden als aangrijppunt in astma preventieprogramma’s.
In hoofdstuk 5 hebben we de waarden van FeNO, een biomarker voor eosinofi ele 
luchtwegontsteking, vergeleken tussen de verschillende longitudinale piepende feno-
typen. In vergelijking met het fenotype van ‘never/infrequent wheeze’, was FeNO op 4 
jaar signifi cant hoger in het fenotype ‘intermediate onset wheeze’, al was het verschil 
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relatief klein. Op de leeftijd van 8 jaar was FeNO signifi cant hoger in de fenotypen 
‘persistent’, ‘intermediate onset’ en ‘late onset wheeze’, in vergelijking met ‘never/
infrequent wheeze’. Gestratifi ceerde analyses toonden aan, dat de hogere FeNO waar-
den op 8 jaar in de fenotypen ‘persistent’, ‘intermediate onset’ en ‘late onset wheeze’ 
uitsluitend aanwezig waren bij kinderen met allergische sensitisatie.
We concludeerden daarom dat FeNO op 8 jaar geassocieerd is met specifi eke 
piepende fenotypen, maar alleen in atopische kinderen. We speculeerden dat de pa-
thofysiologie van de piepende fenotypen verschilt tussen atopische en non-atopische 
kinderen; eosinofi ele ontsteking speelt mogelijk uitsluitend een rol in de ontwikkeling 
van piepende ademhaling bij atopische kinderen.
Hoofdstuk 6 presenteert een studie naar de overeenstemming tussen voorgeschreven 
astma medicatie aan de ene kant en astma diagnose en symptomen aan de andere 
kant, in kinderen van 2-8 jaar oud. We zagen dat ongeveer een derde van de kinderen 
met piepende ademhaling geen inhalatiemedicatie gebruikten, in het jaar dat ze de 
symptomen hadden. Zelfs onder de kinderen die op de leeftijd van 8 jaar ernstige 
astmatische klachten hadden rapporteerde 30% dat ze geen inhalatiecorticosteroï-
den gebruikten, terwijl dat de eerste keus behandeling is voor persisterend astma. 
Tegelijkertijd rapporteerde ongeveer de helft van alle kinderen die ten minste 2 jaar 
inhalatiecorticosteroïden gebruikten, dat ze gedurende die 2 jaar geen enkele keer last 
hadden gehad van een piepende ademhaling.
We concludeerden hieruit dat onder- en overbehandeling van astmasymptomen 
een veel voorkomend probleem lijkt te zijn in kinderen van 2-8 jaar. De prevalentie van 
overbehandeling nam met de leeftijd toe, hetgeen impliceert dat regelmatige follow-up 
in kinderen met astmamedicatie belangrijk blijft.
In hoofdstuk 7 werd een klinische voorspelregel ontworpen om astma te diagnostice-
ren. De regel kan gebruikt worden bij kinderen onder de 5 jaar, die voor de eerste keer 
symptomen hebben die bij astma zouden kunnen passen. In de PIAMA studie werden 
alle kinderen met astmatische symptomen (piepende ademhaling en/of nachtelijk 
hoesten) onder de 5 jaar geselecteerd (n = 2171). In de kinderen werden mogelijke 
prognostische variabelen voor de ontwikkeling van astma bepaald, op de leeftijd dat 
ze de symptomen voor het eerst hadden. Wij vonden dat astma op de leeftijd van 8 
jaar voorspeld kon worden met 8 onafhankelijke klinische parameters. Een klinische 
risico score werd ontwikkeld, met een range van 0-55 punten. Kinderen met een score 
van <10 punten hadden 3% risico op het ontwikkelen van astma op 8 jaar, terwijl bij 
kinderen met een score van ≥30 punten dit risico 42% was.
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We concludeerden dat deze klinische astma voorspelregel een handig hulpmiddel kan 
zijn voor artsen, wanneer jonge kinderen zich presenteren met astma symptomen, met 
name in de eerstelijnszorg.
In hoofdstuk 8 hebben we onderzocht of de objectieve testen FeNO, Rint en specifi ek 
IgE nuttig zijn, om in kinderen met luchtweg symptomen op de leeftijd van 4 jaar te 
voorspellen of deze symptomen op 8 jaar nog steeds aanwezig zullen zijn. Daarbij 
hebben we bovendien bepaald, of deze testen een additionele voorspellende waarde 
hadden, boven de informatie die standaard in een klinische anamnese gevraagd wordt. 
We hebben gevonden dat de testen FeNO en specifi ek IgE gemeten op de leeftijd 
van 4 jaar, signifi cant geassocieerd waren met piepende ademhaling en het gebruik 
van inhalatiecorticosteroïden op 8 jaar. Specifi ek IgE was bovendien geassocieerd met 
dokters diagnose van astma op de leeftijd van 8 jaar. Ook na correctie voor elkaar en 
voor de klinische anamnese op 4 jaar, bleven beide testen signifi cant geassocieerd met 
de uitkomstmaten op 8 jaar. Rint op 4 jaar was signifi cant geassocieerd met piepende 
ademhaling op 6 jaar, maar op 7 en 8 jaar niet meer.
We concludeerden hieruit dat het nuttig kan zijn om FeNO en specifi ek IgE te meten 
op de leeftijd van 4 jaar, in kinderen met symptomen suggestief voor astma. Ook nadat 
de klinische anamnese bekend is, kan de informatie van beide testen helpen bij het 
identifi ceren van de kinderen die persisterende astma symptomen ontwikkelen.
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De afgelopen jaren heb ik met veel plezier gewerkt aan dit proefschrift. Toch is het een 
heerlijk gevoel dat het nu helemaal klaar is. Dit is een mooi moment om eens even 
stil te staan en terug denken aan alle mensen die mij deze jaren zo enorm geholpen 
hebben. Dankzij hen was het een leerzame en ontzettend leuke tijd. Graag wil ik een 
aantal van hen persoonlijk bedanken.
Allereerst mijn co-promotor, Dr. A.H. Wijga, en mijn twee promotoren, Prof.dr. H.A. 
Smit en Prof.dr. J.C. de Jongste.
Beste Alet, vanaf de eerste dag kon ik met al mijn problemen bij jou binnenlopen. Je 
snelle hulp en goede adviezen hebben me een vliegende start bezorgd binnen PIAMA. 
Vanuit Rotterdam kon ik niet meer zo makkelijk op je deur kloppen, maar de uitgebreide 
gesprekken die wij hadden over elk artikel gaven mij enorm veel inzicht en steeds weer 
het vertrouwen dat het iets moois zou worden.
Beste Jet, veel dank voor je enthousiaste begeleiding en waardevolle adviezen de 
afgelopen jaren. Je hebt me de ruimte gegeven om zelf keuzes te maken en toch altijd 
gezorgd dat mijn promotietraject een logische lijn bleef volgen. Je steeds weer frisse 
kijk op onze artikelen heeft vaak geholpen om daarin de boodschap op een heldere en 
overtuigende manier over te brengen. Geweldig dat je in deze jaren professor bent 
geworden en nu mijn promotor bent.
Beste Johan, bedankt voor het vertrouwen dat jij vanaf het begin in mij had, zowel 
in de kliniek als in het onderzoek. Je hebt me veel vrijheid gegeven, maar stond voor 
me klaar wanneer dat nodig was. Ik zag altijd uit naar onze gesprekken, die maakten 
dat ik iedere keer weer vol goede moed en vol nieuwe ideeën vooruit kon. Je snelle 
en uitgebreide commentaren op mijn manuscripten waren natuurlijk van ongekende 
waarde. Zeer veel dank voor dat alles.
Prof.dr. B. Brunekreef wil ik graag bedanken voor zijn goede begeleiding en het bie-
den van de kans om te werken met de data van dit prachtige cohort. 
Prof.dr. A.J. van der Heijden, Prof.dr. A. Hofman, Prof.dr. C.K. van der Ent wil ik be-
danken voor hun bereidheid zitting te nemen in de kleine Promotie Commissie en het 
beoordelen van mijn proefschrift. Prof. Hofman wil ik met name bedanken voor zijn 
steun en vertrouwen, waardoor ik aan het eind van mijn studie alsnog mee kon doen 
aan de MSc Clinical Epidemiology; het was een geweldig jaar en bovendien van zeer 
grote waarde bij de totstandkoming van dit proefschrift.
Het PIAMA onderzoek zou nooit mogelijk geweest zijn zonder de inzet van alle kinde-
ren en hun ouders die al jarenlang aan de studie hebben deelgenomen. Ik wil hen daar 
heel hartelijk voor danken. Ook wil ik graag Damon, Emi en Lieve bedanken dat zij als 
“fotomodel” wilden fi gureren in dit proefschrift!
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Graag wil ik alle collega’s van PIAMA van harte bedanken voor al het werk dat zij ver-
richt hebben. Ada, voor haar eindeloze inspanningen om alle PIAMA datasets op orde 
te houden en voor haar frequente en goede hulp. Alle co-auteurs voor hun zorgvuldige 
correcties en suggesties op de manuscripten. De aanpassingen kostten soms veel tijd, 
maar ze waren zeer waardevol en altijd de moeite waard. Alle PIAMA promovendi voor 
hun steun, advies en de leuke tijd wanneer we elkaar zagen; helaas liggen Rotterdam, 
Utrecht en Groningen niet naast elkaar. Jessica Brussee, die al was vertrokken toen 
ik begon, van wiens vele werk ik dankbaar gebruik heb gemaakt. Olga Savenije, voor 
onze samenwerking bij de stukken over astma fenotypen en haar waardevolle analyses 
in samenwerking met Bristol. Ulrike Gehring en Maarten Schipper voor hun heldere 
statische adviezen. 
Het hele ‘pulmoteam’ wil ik graag bedanken voor de gezelligheid en hun hulp en 
advies tijdens de research vergaderingen: Harm Tiddens, Mariëlle Pijnenburg, Hettie 
Janssens, Iris Groothuis, Noor Rikkers, Els van der Wiel, Eveline Nieuwhof, Lianne van 
der Giessen, Carmelo Gabriele, Sandra Lever, Edith van Duyn, Sabine Maurits. Irma 
Stok voor haar bereidheid om altijd weer te helpen en mee te denken bij de meest 
uiteenlopende problemen.
Mijn collega onderzoekers wil ik graag bedanken voor de mooie tijd de afgelopen 
jaren. Ruben, Marije en Martine, pulmo-collega’s, dankzij jullie voelde ik me vanaf de 
eerste dag welkom. Veel succes en geluk met de kleintjes thuis, en Martine met de 
kleine op komst bovendien. Ralf, veel dank voor de leuke en goede samenwerking, 
eerst als student maar al snel als collega. Ik ben jaloers op al je mooie projecten, en 
New Orleans was fantastisch. Ook de nieuwe collega’s Sandra, Esther en Leonie, 
bedankt voor de leuke tijd en heel veel succes.
Tijdens mijn onderzoek heb ik heel wat werkplekken versleten. De eerste offi ciële 
plek werd ‘Het Chalet’, waar wij op elkaar waren aangewezen, Marjolein, Gerthe en 
Emile. Misschien geen adequate huisvesting, maar wel gezellig! De ijskoffi e bij Doppio, 
het eindeloze geouwehoer, de paprikakwekerij en onze mooie feestjes maakten de 
verzengende hitte, de bouwherrie en de zandstormen in en om ‘Het Chalet’ meer dan 
goed. Vervolgens naar de 4e verdieping, met veel nieuwe collega’s. Nienke D, Sjoerd, 
Sandra, Nienke V, Alexandra, fantastisch om ook met jullie een kamer te delen, wat 
hebben we een boel gelachen! Maar ik wil ook alle andere collega’s bedanken voor 
de gezelligheid bij lunches, VOBS, weekendjes, Dizzy, Coenen, enzovoort: Lizet, San-
dra, Judith, Saskia, Charlotte, Suzanne, Denise, Hester, Jeroen, Ruben, Ralph, Eefje, 
Femke, Ruud, Marieke, Mirjam, Emiel, Annemieke, Elbrich… en natuurlijk alle anderen. 
Lieve vrienden, jullie wil ik graag bedanken voor jullie interesse en steun. Onze week-
endjes weg en vakanties waren super, met name natuurlijk de grote reis naar Colombia. 
Hans, veel dank voor onze mooie vriendschap, geweldig dat je mij als paranimf terzijde 
wilt staan. Uzor, we’ve known each other since the MSc program and followed the 
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same path for these last years. How symbolic that we can end this fantastic period as 
each other’s paranimf.
Lieve familie, pap en mam, Bram en Lot. Bedankt voor al jullie liefde en onvoorwaar-
delijke steun. Pap en mam, jullie hebben mij onbegrensde mogelijkheden gegeven en 
zijn altijd betrokken geweest, niet alleen deze laatste jaren. Veel dank voor alles.
Lieve Steph, boven alles waren de afgelopen drie jaren toch vooral ònze jaren. De 
eerste week van mijn promotietijd waren we samen in New York, vandaag precies drie 
jaar geleden. Als gevolg daarvan zeiden we anderhalf jaar geleden ‘ja’ tegen elkaar in 
Colombia, met al onze vrienden en familie erbij. Nu met zijn tweetjes in Rotterdam, wie 
weet waar onze reis samen eindigt… Het was een geweldige tijd, en het wordt alleen 
maar mooier. Bedankt voor je onvoorwaardelijke liefde, geduld, steun, begrip en hulp. 
Te amo.
Daan BW 7.indd   219 28-10-10   13:06
Daan BW 7.indd   220 28-10-10   13:06
Curriculum vitae
Daan BW 7.indd   221 28-10-10   13:06
Daan BW 7.indd   222 28-10-10   13:06
223
C
V
CURRICULUM VITAE
Daan Caudri was born in Eindhoven on January 22nd, 1981. In 1999 he passed his sec-
ondary school exam (VWO) at the “Collegium Marianum” in Venlo. In the same year 
he started his medical training at the Medical Faculty of the Erasmus University of 
Rotterdam. In the years 2001-2002 he was treasurer of the STOLA foundation (Stichting 
Stages in Ontwikkelingslanden). In 2003 he performed a research project together with 
S.F van den Heuvel on ‘tuberculosis and HIV’ in a rural hospital in Manyemen, Cameroon 
(supervisors: Dr. J.L. Nouwen, Dr. C. Timah ). In 2005 he started a masters in Clinical 
Epidemiology at the Netherlands Institute for Health Sciences (Nihes) in Rotterdam, for 
which he attended two courses at the Harvard school of Public Health in Boston, USA. 
In 2006 he obtained his Master of Science degree in Clinical Epidemiology and received 
the Nihes Award 2006 for fi rst author of the best research paper (supervisor: Prof.dr. 
J.C. de Jongste). After obtaining his medical degree (cum laude) in 2007, he worked for 
8 months as a resident (ANIOS) pediatrics at the Erasmus MC – Sophia Children’s Hos-
pital in Rotterdam. In November 2007 he enrolled in the residency program in pediatrics 
at the Erasmus MC – Sophia Children’s Hospital in Rotterdam (head pediatrics Prof.dr. 
A.J. van der Heijden, Dr. M. de Hoog). He combined his clinical training with a research 
fellowship (AGIKO) at the department of Pediatric Pulmonology, under supervision of 
Prof.dr. J.C. de Jongste. His research project was funded by the Netherlands Organisa-
tion for Scientifi c Research (NWO) ‘Toptalent scholarship’, which he received in 2007. 
The research performed during this period is presented in this thesis.
In may 2009 he married Stephanie Fijten, who is a medical doctor. Together they live 
in Rotterdam.
CURRICULUM VITAE
Daan BW 7.indd   223 28-10-10   13:06
Daan BW 7.indd   224 28-10-10   13:06
List of publications
Daan BW 7.indd   225 28-10-10   13:06
Daan BW 7.indd   226 28-10-10   13:06
227
P
U
B
LI
C
A
T
IO
N
S
LIST OF PUBLICATIONS
Caudri D, Wijga A, Gehring U, Smit HA, Brunekreef B, Kerkhof M, Hoekstra MO, Gerrit-
sen J, de Jongste JC. Respiratory symptoms in the fi rst 7 years of life and birth weight 
at term: the PIAMA Birth Cohort. Am J Respir Crit Care Med 2007;175(10):1078-85
Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caudri D, Picelli 
G, Sen EF, Giaquinto C, Cantarutti L, Baiardi P, Felisi MG, Ceci A, Wong IC; TEDDY Eu-
ropean Network of Excellence. Drug use in children: cohort study in three European 
countries. BMJ 2008;337:a2245
Caudri D, Wijga A, Scholtens S, Kerkhof M, Gerritsen J, Ruskamp JM, Brunekreef 
B, Smit HA, de Jongste JC. Early daycare is associated with an increase in airway 
symptoms in early childhood but is no protection against asthma or atopy at 8 years. 
Am J Respir Crit Care Med 2009;180(6):491-8
Caudri D, Wijga A, Schipper CMA, Hoekstra MO, Postma DS, Koppelman GH, 
Brunekreef B, Smit HA, de Jongste JC. Predicting the long-term prognosis of chil-
dren with symptoms suggestive of asthma at preschool age. J Allergy Clin Immunol 
2009;124(5):903-10
Caudri D, Wijga A, Hoekstra MO, Kerkhof M, Koppelman GH, Brunekreef B, Smit HA, 
de Jongste JC. Prediction of asthma in symptomatic preschool children using exhaled 
Nitric Oxide, Rint and specifi c IgE. Thorax 2010;65:801-807
Savenije* OE, Granell* R, Caudri D, Koppelman GH, Smit HA, Wijga A, de Jongste JC, 
Brunekreef B, Sterne JA, Postma DS, Henderson J, Kerkhof M. Comparison of child-
hood wheezing phenotypes in two birth cohorts: PIAMA and ALSPAC. *both authors 
contributed equally. J Allergy Clin Immunol 2010; revision.
Caudri D, Wijga AH, Smit HA, Koppelman GH, Kerkhof M, Hoekstra MO, Brunekreef B, 
de Jongste JC. Asthma symptoms and medication in the PIAMA birth cohort: evidence 
for under- and overtreatment. Submitted
Caudri D*, van der Valk RJP*, Savenije OEM, Koppelman GH, Smit HA, Wijga AH, Postma 
DS, Kerkhof M, Brunekreef B, de Jongste JC. Childhood wheezing phenotypes are associ-
ated with FeNO in atopic children at age 8. *both authors contributed equally. Submitted.
Caudri D, de Jongste JC. Exhaled nitric oxide and childhood asthma
J Pediatr 2010 Mar;156(3):514 (letter)
LIST OF PUBLICATIONS
Daan BW 7.indd   227 28-10-10   13:06
Daan BW 7.indd   228 28-10-10   13:06
PhD Portfolio
Daan BW 7.indd   229 28-10-10   13:06
Daan BW 7.indd   230 28-10-10   13:06
231
P
O
R
T
FO
LI
O
PhD PORTFOLIO: 
SUMMARY OF PhD TRAINING AND TEACHING
PhD PORTFOLIO
Erasmus MC Department: General Paediatrics – Paediatric Pulmonology
Research School: Nihes
PhD period: 1 December 2007 – 3 December 2010
Master of Science Clinical Epidemiology 2005 – 2006
Promotors: Prof.dr. J.C. De Jongste, Prof.dr. H.A. Smit
Co-promotor: Dr. A.H. Wijga
General academic courses Year
Workload 
(ECTS)
Biomedical English Writing and Communication 2009 4.0
Research skills
Master of Science Clinical Epidemiology, Nihes 2005-2006 40
including elective/in depth courses:
· Repeated measurements in clinical studies
· Missing values in clinical research
· Paediatric clinical epidemiology
· Prognostic research
· Ethical basis in health care delivery
· Decision analysis in clinical research
Weekly research meeting, department Paediatric Pulmonology Erasmus MC - Sophia 2007-2010 2.0
Weekly radiology meeting, department Paediatric Pulmonology Erasmus MC - Sophia 2007-2010 1.0
Lectures on longitudinal data analysis, department Statistics Erasmus MC 2009-2010 0.5
Seminars and workshops
TULIPS Workshop ‘Grant writing & Successful Team Building’ 2010 1.4
Dag voor de jonge onderzoekers, NVK, Veldhoven 2008, 2009 0.6
Generation R symposium (oral presentation) 2009 1.0
Netherlands Respiratory Society (NRS) symposium 2008, 2009 0.6
Jaarsymposium Astma Fonds (poster presentation) 2008, 2009 1.0
Symposium 60-jarig bestaan Nederlandse Vereninging voor Allergologie (oral presentation) 2008 1.0
(Inter)national conferences
‘Werkgroep Epidemiologisch Onderzoek Nederland’ congress (WEON), Groningen, 
Netherlands (oral presentation)
2008 1.4
18th European Respiratory Society, Berlin, Germany (oral presentation: awarded ‘Paediatric 
Respiratory Epidemiology Abstract Award’)
2008 1.4
‘Werkgroep Epidemiologisch Onderzoek Nederland’ congress, Amsterdam, Netherlands 
(2 poster presentations)
2009 1.0
15th European Union for School and University Health and Medicine (EUSUHM) congress 
2009, Leiden, Netherlands (oral presentation)
2009 1.4
19th European Respiratory Society, Vienna, Austria (oral presentation) 2009 1.4
American Thoracic Society, San Diego, USA (poster presentation) 2010 0.5
American Thoracic Society, New Orleans, USA (2 poster presentation & oral presentation: 
awarded ‘ATS Travel Award’)
2010 2.0
20th European Respiratory Society, Barcelona, Spain (invited speaker symposium ‘Early 
Origins of Adult Lung Disease – Early Origin of Asthma’)
2010 2.0
Daan BW 7.indd   231 28-10-10   13:06
232
PhD PORTFOLIO
Teaching activities
Supervising medical students practical 2007-2010 0.5
Supervising Master’s theses (1 student) 2009-2010 3.0
Statistical advice/consultations 2010 3.0
Other
Peer review of articles for scientifi c journals 2009-2010 1.4
Clinical work Paediatric Pulmonology, outpatient clinic 2007-2010 2.0
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